Pathogenicity studies on verocytotoxin-producing Escherichia coli : bacterial adhesion, toxin expression and uptake by Colby, Susan Mary
A Thesis Submitted for the Degree of PhD at the University of Warwick
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/135303 
Copyright and reuse:
This thesis is made available online and is protected by original copyright.
Please scroll down to view the document itself.
Please refer to the repository record for this item for information to help you to cite it. 
Our policy information is available from the repository home page.
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk
warwick.ac.uk/lib-publications
Pathogenicity Studies on Verocytotoxin-producing Escherichia c o l i : 
Bacterial adhesion, Toxin Expression and Uptake.
by
Susan Mary Colby
BSc. (Hons) Warwick
Sv  ttc -f ¿cf \
This thesis is presented for the Degree of Doctor of Philosophy, in the 
Department of Biological Sciences, University of Warwick.

I declare that this thesis has been composed by myself and has not been used 
in any previous application for a degree. The results presented here were 
obtained by myself with the exception of immunogold labelling which was 
carried out by Nicholas Powell at the MRC Clinical Research Centre, Harrow. 
All work was carried out at the University of Warwick under the supervision 
of Dr C S Dow apart from studies on the cellular uptake of Verotoxin which 
were carried out at the MRC Clinical Research Centre, Harrow, under the 
supervision of Dr S P Borriello.
All sources of information have been specifically acknowledged by means of 
reference.
Declaration
ii
Acknowledgments
I would like to thank my supervisor, Dr C S Dow, for all his 
encouragement and support, especially in the latter stages. Also I wish to 
acknowledge the technical assistance of Vicky Cooper especially in raising 
antisera and to everyone at Warwick who gave me advice and help. Sue 
Cardy, Sian Fox, Ifti Urabi and Hazel Spenceley deserve a special thank-you 
for putting up with me and making life in the lab more enjoyable.
I wish to thank Dr S P Borriello for useful discussions, and allowing me 
to carry out the toxin internalization work in his lab at the MRC Clinical 
Research Centre, Harrow. Whilst at the CRC, I was greatly helped by Mala 
Krishna, and by Nicholas Powell, who carried out the immunogold labelling 
studies.
I acknowledge the financial support of the Department of Biological 
Sciences, University of Warwick. I spent two months at the CRC, Harrow, 
which was supported by the Nuffield Foundation and the SGM President's 
Fund.
Table of Contents
Page
Chapter 1 Introduction 1
1.1 Pathogenic Escherichia coli 1
1.1.1 Enterotoxigenic E.coli (ETEC) 1
1.1.2 Enteroinvasive E.coli (EIEC) 2
1.1.3 Enteropathogenic E.coli (EPEC) 2
1.1.4 Enterohaemorrhagic E.coli (EHEC) 3
1.2 History of Isolation of VTEC 5
1.3 Animal Reservoir for VTEC 6
1.4 Clinical Manifestations of VTEC Infections 9
1.4.1 Haemorrhagic colitis 9
1.4.2 Haemolytic Uraemic Syndrome 10
1.4.3 Oedema Disease of Swine 11
1.5 Diagnosis of VTEC Infections 12
1.5.1 Detection of Verotoxins 12
1.5.2 Isolation of VTEC 13
1.5.3 Detection of Neutralizing Antibodies 15
1.5.4 The Use of DNA Probes in Diagnosis 15
1.6 Adherence of VTEC 16
1.7 Verotoxins - General Introduction 18
iv
1.8 Binding of Verotoxins to Eukaryotic cells 21
1.9 Mechanism of Action of Verotoxins 24
1.10 Verotoxin-Converting Phages 25
1.11 Genetics of Verotoxin Production 27
1.11.1 Transcription of Verotoxin Genes 28
1.11.2 Translation of Verotoxin Subunits 29
1.12 Other VT-Producers 30
1.13 The Role of the Bacterial Cell Envelope in Pathogenicity 31
1.13.1 The Gram-Negative Cell Envelope 31
1.13.2 Bacterial Lipopolysaccharide 33
1.13.3 Outer Membrane Proteins 34
1.13.4 Flagella 36
1.14 Cellular Internalization of Toxins 37
1.15 The Role of Calcium Uptake in Toxin Internalization 40
Chapter 2 Materials and Methods 42
2.1 Bacterial strains 42
Page
v
Page
2.2 Monoclonal antibodies 42
2.3 Cytotoxicity Assay 44
2.3.1 Tissue Culture 44
2.3.2 Vero Cell Assay 44
2.4 Latex Agglutination Assay 45
2.4.1 Coating Latex Particles 45
2.4.2 Stabilising Coated Latex Particles 45
2.4.3 Preparation of the Antigen Filtrate 46
2.4.4 Latex Agglutination Test 46
2.5 Colony ELISA 47
2.6 DAB/Nickel Development System 47
2.7 Phage Induction 48
2.8 Preparation of crude toxin for SDS-PAGE analysis 48
2.8.1 Mitomycin C Treatment 48
2.8.2 Ammonium sulphate precipitation 49
2.8.3 Hydroxyapatite column chromatography 49
2.9 Polyacrylamide Gel Electrophoresis (PAGE) 50
2.9.1 SDS-PAGE 50
2.9.2 4-15% Non-Denaturing PAGE 52
vi
Page
2.10 Silver nitrate staining of polyacrylamide gels 53
2.10.1 Protein staining 53
2.10.2 LPS staining 53
2.11 Protein Assay 54
2.12 Plate ELISA 55
2.13 Chemical Mutagenesis 56
2.14 Small-scale preparation of plasmid DNA 57
2.14.1 Isolation of plasmids 57
2.14.2 Agarose gel electrophoresis 58
2.15 Api 20E Tests 58
2.16 Saline Extraction of Heat-Stable Antigens 59
2.17 Passive Haemagglutination Assay 59
2.18 Oxoid 0157 Latex Agglutination test 60
2.19 Western Blotting 60
2.191 Preparation of Whole Cell Antisera 60
2.19.2 Immunoblotting 61
2.19.3 Chloronaphthol development system 62
vii
2.20 Outer Membrane Preparation 62
2.21 Neutral Sugar Analysis 63
2.21.1 Phenol Extraction of Lipopolysaccharide 63
2.21.2 Thin Layer Chromatography 64
2.22 Hydrophobicity studies 65
2.22.1 Microbial Adhesion to Hydrocarbons (MATH) 65
2.22.2 Salt Aggregation Test (SAT) 65
2.22.3 Hydrophobic Interaction Chromatography (HIC) 66
2.23 Attachment Studies 66
2.23.1 Attachment of Bacteria to Mucus 66
2.23.2 Attachment of Bacteria to HeLa cells 67
2.23.3 Staining Tissue Culture Cells 68
2.24 Immunogold Labelling 68
Chapter 3 The Development of Toxin Assays and the Effect of
Mitomycin C on Verotoxin Production 69
3.1 The Development of Assay Systems 69
3.1.1 Cytotoxicity Assay 70
3.1.1.1 Introduction 70
3.1.1.2 Results and Discussion 70
Page
viii
3.1.2 Latex Agglutination Assay 71
3.1.2.1 Introduction 71
3.1.2.2 Results and Discussion 74
3.1.3 Colony EUSA 75
3.1.3.1 Introduction 75
3.1.3.2 Results and Discussion 78
3.2 The Effect of Mitomycin C on Verotoxin Production 81
3.2.1 Introduction 81
3.2.2 Results and Discussion 83
3.2.2.1 Lysis of Cells 83
3.2.2.2 Analysis of Extracellular Proteins 86
3.2.2.3 Total Protein Concentration 90
3.2.2.4 Toxin Production 93
3.2.2.5 Specific Activity 95
3.2.2.6 Tissue Culture Assays 95
Chapter 4 The Production and Characterization of Mutants of
E.coli 0157:H7 100
4.1 Introduction 100
4.2 Results and Discussion 101
4.2.1 Plasmid Profiles 101
4.2.2 Biochemical Profiles 103
Page
ix
4.2.3 Passive Haemagglutination Assay 105
4.2.4 Oxoid Latex Agglutination Assay 108
4.2.5 SDS-PAGE Analysis of Saline-extracted antigens 110
4.2.6 Immunoblotting of Saline-extracted antigens 112
4.2.7 Neutral Sugar Analysis 117
4.2.8 Hydrophobicity Studies 121
4.2.9 Attachment of Bacteria to Mucus and HeLa cells 127
4.2.9.1 Attachment to Mucus 127
4.2.9.2 Attachment to HeLa Cells 129
4.2.10 Toxin Production 137
4.2.10.1 Colony ELISA 137
4.2.10.2 Vero Cell Assays 139
4.2.10.3 Plate ELISA 140
4.2.10.4 Immunogold Labelling 143
Chapter 5 Mechanism of Internalization and Intracellular
Processing of Verotoxins 151
5.1 Receptor-Mediated Endocytosis 151
5.1.1 Introduction 151
5.1.2 Results and Discussion 154
5.1.2.1 The Effect of Metabolic Inhibitors 154
5.1.2.2 The Effect of preventing Fusion between Endosomes and
Lysosomes 156
5.1.2.3 The Effect of Lysosomotropic Agents 159
Page
x
5.1.2.4 The Effect of Monensin 160
5.2 The Role of Calcium Uptake in Cellular Internalization of VT1
and VT2 163
5.2.1 Introduction 163
5.2.2 Results and Discussion 163
5.2.2.1 The Effect of Calcium Channel Blockers 164
5.2.2.2 The Effect of Inhibitors of the Secretory Mechanism of Cells 165
5.2.2.3 The Effect of Inhibition of the Calcium-Calmodulin Complex 167
5.2.2.4 The Significance of Extracellular Calcium Levels 168
Chapter 6 Overall Conclusions 170
Chapter 7 References 173
Page
xi
List of Figures
Figure Page
1.1 Structure of Gt>3 and Gb4 22
1.2 Diagrammatic representation of the Gram-negative bacterial 32 
cell envelope
1.3 Schematic structure of LPS from Salmonella typhimurium 35
1.4 Schematic representation of receptor-mediated endocytosis 39
1.5 The calcium pathway in mammalian cells 41
3.1 Vero cell assay. The effect of Verotoxins on Vero cells 72
3.2 Latex agglutination assay. VT1 MAb reacted with 0157:H7 and 76
026:H11
3.3 Latex agglutination assay. VT1 and VT2 MAb reacted with a 77
VTl-producer
3.4 Colony ELISA 80
3.5 The effect of mitomycin C on growth of E.coli 0157:H7 84
3.6 Induction of bacteriophage in E.coli 0157:H7 85
3.7 SDS-PAGE analysis of extracellular proteins from a mitomycin 87 
C-treated culture of E.coli 0157:H7
3.8 SDS-PAGE analysis of extracellular proteins from a mitomycin 88 
C-treated culture of E.coli 026:H11
3.9 SDS-PAGE analysis of ammonium sulphate-precipitated 91 
0157:H7 extracellular proteins after hydroxylapatite column 
chromatography
3.10 The effect of mitomycin C on distribution of intracellular and 92 
extracellular protein
3.11 The effect of mitomycin C on % distribution of VT1 and VT2 94
xii
3.12 Intracellular and extracellular specific activity of VT1 and VT2 96
4.1 Plasmid profiles of 0157:H7 and putative mutants 102
4.2 Passive haemagglutination assay 106
4.3 SDS-PAGE analysis of saline-extracted antigens 111
4.4 Immunoblotting of SDS-PAGE gel (11 % acrylamide) of saline- 114 
extracted antigens with anti-0157:H7
4.5 Immunoblots of SDS-PAGE gels (11% acrylamide) of saline- 115 
extracted antigens with 1) anti-0157:H7 & 2) anti-026:Hll
4.6 Neutral sugar analysis 119
4.7 Biosynthesis of sugar residues 120
4.8 Attachment to mucus 130
4.9 Attachment of 0157:H7 to HeLa cells in the presence and 134
absence of 0157:H7 antiserum
4.10 Immunoblotting of outer membrane preparations with 136
anti-0157:H7
4.11 Colony ELISA of 0157:H7 and donesl-6 138
4.12 Plate ELISA to determine distribution of VT1 and VT2 of 142
0157:H7 and clones 1,5 and 6
4.13 Immunogold labelling of VT1 144
5.1 Schematic representation of receptor-mediated endocytosis 152 
- points of action of inhibitors
5.2 The calcium-calmodulin pathway - the points of action of 166
inhibitors
Figure Page
xiii
List of Tables
1.1 Enterovirulent E.coli 4
1.2 Number of isolates of E.coli 0157:H7 in Canada from 1978-1987 7
1.3 Physicochemical properties of Verotoxins 20
2.1 Bacterial strains 43
2.2 Monoclonal antibodies 42
3.1 Cytotoxicity assay 73
3.2 Vero cell assay 97
4.1 Api 20E biochemical profiles 104
4.2 The Oxoid latex agglutination assay 109
4.3 Microbial adhesion to hydrocarbons 124
4.4 Salt aggregation test 125
4.5 Hydrophobic interaction chromatography 126
4.6 Attachment of 0157:H7 and clones 5 & 6 to HeLa cells 132
4.7 Attachment of 0157:H7 and clones 5 & 6 to HeLa cells in the 133 
presence of 0157:H7 antiserum
4.8 Vero cell assay 141
5.1 Endpoint effect of metabolic inhibitors on cytotoxicity 155
of VT1 and VT2
5.2 Endpoint effect of prevention of fusion between endosomes and 158 
lysosomes on the cytotoxicity of VT1 and VT2
5.3 Endpoint effect of lysosomotropic agents and trifluoperazine 161 
on cytotoxicity of VT1 and VT2
5.4 Endpoint effect of inhibitors of the calcium pathway on the 169 
toxicity of VT1 and VT2 on Vero cells
Table Page
xiv
Abbreviations
AE Attaching-effadng
DMSO Dimethylsulphoxide
DNA Deoxyribonudeic acid
EDTA Diaminoethane tetraacetic acid
EHEC Enterohaemorrhagic Escherichia coli
EIEC Enterinvasive Escherichia coli
EPEC Enteropathogenic Escherichia coli
ETEC Enterotoxigenic Escherichia coli
EVEC Enterovirulent Escherichia coli
ELISA Enzyme-linked immunosorbent
assay
FVT Free Vero toxin
g Gramme
GBS Glycine buffered saline
Gb3 Globotriaosylceramide
Gb4 Globotetraosylceramide
HUS Haemolytic uraemic syndrome
KDa KiloDalton
LPS Lipopolysaccharide
LT Heat-labile toxin (ETEC)
MAb Monoclonal antibody
MDa MegaDalton
M Molar
mg Microgram
mg Milligram
mM Millimolar
xv
OD Optical density
PAGE Polyacrylamide gel electrophoresis
RME Receptor -mediated endocytosis
SDS Sodium dodecyl sulphate
ST Heat-stable toxin (ETEC)
TEMED N/N/N,/N'-
tetramethylethylenediamine
Tris Tris-hydroxymethylaminomethane
TTP Thrombotic thrombocytopenia
purpura
Tween 20 Polyoxyethylenesorbitan
monolaurate
VTEC Verotoxin-producing Escherichia coli
VT Verotoxin (s)
VT1 Verotoxin 1
VT2 Verotoxin 2
VT2vh Verotoxin 2 human variant
VT2vp Verotoxin 2 porcine variant
v/v Volume by volume
w/v Weight by volume
xvi
Aims of This Study
The putative pathogenic mechanisms of VTEC are: cytotoxin production, 
adherence to epithelial cells in an attaching-effacing manner, and in most 
cases, possession of a 60-MDa plasmid. The aims of this study were to 
investigate toxin production and cellular internalization, and, through the 
production of mutants, to attempt to study the pathogenicity of the organism 
as a whole. A preliminary step was therefore to develop biological and 
immunological assays to detect the toxins.
VT1 and VT2 are encoded by lysogenic phages, so it was proposed that 
a chemical known to induce phages might affect toxin production. The effect 
of mitomycin C on a VTEC strain, 0157:H7 (ATCC 35150), was therefore 
studied through analysis of extracellular proteins and both intracellular and 
extracellular toxin levels.
It is likely that in vivo it is the cumulative effects of the pathogenic 
mechanisms described above which bring about the clinical manifestations of 
a VTEC infection. Many studies have focused on one potential virulence 
determinant. This study aimed at producing mutants through chemical 
mutagenesis, in an attempt to investigate the organism as a whole. The 
mutants were to be characterised with respect to plasmid content, toxin 
production, and attachment to epithelial cells and mucus.
Although VT1 and VT2 are known to be N-glycosidases, the entry of 
these toxins into mammalian cells has not been elucidated. Through the use of 
various conditions and inhibitors, this study aimed to show the mechanism of 
entry and possible intracellular processing of these toxins. The potential role 
of the calcium uptake system, in VT internalization was also investigated.
xvii
Summary
Verotoxin-producing Escherichia coli (VTEC) are a group of medically 
important bacteria which have been implicated in cases of haemorrhagic 
colitis and haemolytic uraemic syndrome. They are characterised by the 
ability to produce Verotoxins (VT), potent exotoxins which kill mammalian 
cells by inhibiting protein synthesis. Two distinct VT are known, Verotoxin 1 
(VT1) and Verotoxin 2 (VT2), and variants of VT2 have been described.
VTEC adhere to intestinal cells via an attaching-effacing mechanism 
and many strains carry a 60-MDa plasmid which was thought to be involved 
in adhesion. Attachment of VTEC is thought to be an important pathogenic 
mechanism since it allows colonisation to occur, and facilitates delivery of 
toxin. The exact mechanisms of VTEC infection, however, especially the 
variation in severity of disease have not been established.
This study aimed to investigate the putative virulence attributes of 
VTEC, namely toxin production and bacterial attachment. In order to study 
the toxins, it was first necessary to develop a reliable method of assay, and for 
this, two assays were chosen; a Vero cell assay which measured biological 
activity, and a colony ELISA, which detected the presence of toxin antigens.
Since VT are produced by lysogenic phages, the effect of a phage 
inducer, mitomycin C, on VT production, was investigated. Increased levels 
of VT appeared to be detected and SDS-PAGE analysis of extracellular 
proteins revealed that the amount of toxin, and other phage proteins 
increased in the presence of mitomycin C, whilst bacterial protein levels 
remained constant. This effect was not seen when a non-VTEC strain was 
tested. The specific activity of VT increased inside the cell, where bacterial 
protein synthesis had ceased, but decreased extracellularly due to cell lysis. 
Extracellular phage particles were demonstrated by plaque assay.
Mutants of 0157:H7 strain ATCC 35150, were produced by chemical 
mutagenesis. They did not possess the 60-MDa plasmid, found in the parent 
strain, and had an altered biochemical profile. Immunological assays revealed 
that they were altered in the O side chain of the LPS and it was shown by 
immunoblotting, that only the major outer membrane proteins reacted with 
anti-0157:H7 although they were not rough mutants. Analysis of the LPS 
neutral sugars showed that the mutants contained rhamnose, instead of 
fucose which was present in the parent strain. Despite these changes, 
however, the hydrophobicity of the mutants, or their ability to attach to 
colonic mucus or HeLa cells was unaffected, indicating that the 60-MDa 
plasmid is not significant in attachment. The mutants appeared to produce 
toxin with little activity, which was also biologically unstable. Secretion of the 
toxin appeared to be reduced, possibly as a result of the LPS mutations.
The internalisation and intracellular processing of VT1 and VT2 was 
studied, and it was shown that the toxins were internalised by receptor- 
mediated endocytosis, but could probably by-pass this pathway. There was 
no requirement for exposure to an acidic environment, although fusion of 
endosomes with lysosomes was essential. It was also necessary for cells to 
possess physiologically functioning calcium channels for intoxication to 
occur.
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Chapter 1 Introduction
1.1 Pathogenic Escherichia coli
Escherichia coli is the predominant species among the facultative 
anaerobic normal flora of the human intestine. Certain members of this 
species however, are associated with intestinal infections and have been 
termed enterovirulent E.coli (EVEC) (Lupski & Feigin 1988). EVEC fall 
into four main categories : enterotoxigenic E.coli (ETEC), enteroinvasive 
E.coli (EIEC), enteropathogenic E.coli (EPEC), and enterohaemorrhagic 
E.coli (EHEC). A fifth group, enteroadherent E.coli (EAEC) is less well 
defined, and will not be discussed further. EVEC are categorised according 
to the distinct clinical syndromes they induce. Within each grouping, 
strains tend to fall into characteristic 0 :H  serotypes (Table 1.1). (E.coli are 
serotyped according to the O (somatic) and H (flagellar) antigens they 
possess.)
1.1.1 Enterotoxigenic E.coli (ETEC)
ETEC are a major cause of traveller's diarrhoea and infant diarrhoea in 
less-developed countries. They cause disease by colonization of the 
mucosal surface of the small intestine, and by production of heat-labile 
(LT) and/or heat-stable (ST) enterotoxins, that cause fluid secretion, 
resulting in diarrhoea. Attachment of the bacteria to the intestinal wall is 
mediated by fimbriae. The clinical features of ETEC infection are watery 
diarrhoea, nausea, abdominal cramps and low-grade fever.
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1.1.2 Enteroinvasive E.coli (EIEC)
EIEC cause a dysenteric form of diarrhoeal illness, by invasion and 
proliferation within epithelial cells, predominantly in the colon, resulting 
in cell death. The ability of these bacteria to invade epithelial cells is due to 
possession of a 140-MDa plasmid which codes for production of several 
outer membrane proteins, which are involved in invasiveness. The 
resulting illness is characterized by fever, severe abdominal cramps, 
toxaemia, and watery diarrhoea followed by gross dysentry consisting of 
scanty stools of blood and mucus.
1.1.3 Enteropathogenic E.coli (EPEC)
EPEC are an important cause of infantile diarrhoea in many developing 
countries. They lack specific virulence determinants characteristic of other 
diarrhoeagenic E.coli strains, namely invasiveness or toxin production, 
and are thought to cause disease by an attaching and effacing adherence to 
intestinal mucosal epithelial cells. There is no invasion of these cells, but 
disruption of cytoskeletal elements is followed by loss of the microvillous 
border, resulting in characteristic attaching and effacing (AE) lesions. EPEC 
illness tends to be clinically more severe than other diarrhoeal infections 
in infants, and is characterized by fever, malaise, vomiting, and diarrhoea 
containing little blood, but large amounts of mucus.
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1.1.4 Enterohaemorrhagic E.coli (EHEC)
It is the fourth EVEC category, EHEC, which is the subject of this study. 
This group is defined by the ability to produce exotoxins known as 
Verotoxins (VT). These bacteria are also known as Verotoxin-producing 
E.coli (VTEC) and this is the preferred terminology in this thesis. In 
addition to VT production, VTEC adhere to epithelial cells by an attaching 
and effacing mechanism characteristic of EPEC (Levine 1987), and many 
strains carry a 60-MDa plasmid thought to be involved in attachment 
(Karch et al 1987). Although several serotypes have been classified as 
VTEC (Table 1.1), most human strains belong to the 0157 serogroup, and 
of these a high percentage possess the H7 flagellar antigen (0157:H7), 
although some are non-motile. Two distinct VTs are known, Verotoxin 1 
(VT1), which is immunologically identical to Shiga toxin, produced by 
Shigella dysenteriae type 1, and Verotoxin 2 (VT2) which is antigenically 
distinct from Shiga toxin and VT1. Variants of VT2, VT2vp and VT2vh, 
from animal (Marques et al 1987) and human (Oku et al 1989) origin 
respectively have also been described. VTEC cause disease ranging from 
mild diarrhoea, which may be bloody, through to haemorrhagic colitis or 
the haemolytic uraemic syndrome (HUS). Haemorrhagic colitis consists of 
bloody diarrhoea, abdominal pain, and low grade or no fever. These 
symptoms also describe the prodromal phase of HUS, where acute renal 
failure, thrombocytopenia, haemolytic anaemia and even death may 
result.
The relationship between VT and Shiga toxin led to an alternative 
nomenclature system of Shiga-like toxins (SLT) (Strockbine et al 1986). It is 
common therefore to find reference to SLT1 and SLT11 instead of VT1 and
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Table 1.1 Enterovirulent E.coli
Pathogenic E.coli can be divided into four main groups 
according to the clinical symptoms they induce. Within each 
grouping, strains tend to fall into characteristic 0:H  serotypes.
Group
Enterotoxigenic E.coli ETEC
Enteroinvasive E.coli EIEC
Enteropathogenic EPEC
E.coli
Most common 
serotypes
06,08,015,020,025, 
027,063,078,080, 
085,0115,0128ac, 
0139,0148,0153, 
0159,0167.
028ac,029,0124, 
0136,0143,0144, 
0152,0164.
055,0111,0119,012701 
42.
Enterohaemorrhagic EHEC 0157,(0111,026)
E.coli
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VT2. In this report however, the original nomenclature of VT1 and VT2 
will be adhered to.
1.2 History of Isolation of VTEC
Verotoxins (VT) were first described in 1977 by Konowalchuk et al (1977), 
after an observation that culture filtrates of certain strains of E.coli, from 
various sources, contained a heat-labile toxic substance which was lethal to 
Vero (African Green Monkey kidney) cells. This cytopathic activity 
contrasted with the cytotonic effect on Vero cells of the heat-labile toxin 
(LT) produced by ETEC, and in addition, antisera to LT did not neutralize 
the effect of VT. Further investigation of one of these E.coli strains, 
O26:H30, showed the presence of two toxins, with isoelectric points of 7.2 
and 6.8 (Konowalchuk et al 1978). Since seven of the ten strains producing 
VT were isolated from infants with diarrhoea, it seemed possible that VT 
were involved in diarrhoeal disease. A clinical study by Wade et al (1979), 
in which VT-producing E.coli (serogroup 026) was isolated from three 
children with bloody diarrhoea, supported this hypothesis.
It was in the early 1980’s that the link between VTEC and diarrhoeal 
disease became established, with reports of VTEC isolation from cases of 
haemorrhagic colitis (Karmali et al 1983), and HUS (Riley et al 1983), 
conditions of previously unknown aetiology. E.coli 0157:H7, until then 
thought of as a 'rare' E.coli serotype was isolated more frequently (Wells 
et al 1983). This serotype is now acknowledged as the most common VTEC 
isolate. In one survey, E.coli 0157:H 7 was found to be the third most 
frequently isolated enteric bacterial pathogen following Campylobacter 
jejuni and Salmonella species (Cahoon & Thompson 1987). Prior to 1982 
this serotype was rarely isolated from humans or animals, for example
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only one strain was detected at the Center for Disease Control in Atlanta, 
in >3000 isolates serotyped between 1973-1982 (Riley et al 1983). Since 1982, 
0157:H 7 strains have frequently been recovered from patients with 
haemorrhagic colitis and HUS (Table 1.2). Studies indicate that E.coli 
isolates of serotype 0157:H7 are members of a single clone widely 
distributed throughout North America (Whittam et al 1988). This study 
also showed that 0157:H7 strains are no more closely related to other 
VTEC serotypes than are randomly selected clonal genotypes from the 
E.coli population as a whole.
It is important to note that other VTEC serotypes are becoming 
increasingly isolated, and in a recent study in Thailand, none of the strains 
possessing VT genes were 0157:H7 (Seriwatana et al 1988). It is becoming 
apparent that a great variety of E.coli serotypes can obtain the genes coding 
for VT, although it is the level of expression of these genes which is 
ultimately important in the role of these strains in clinical disease.
1.3 Animal Reservoir for VTEC
The main reservoir of VTEC is the intestinal tract of animals, 
predominantly cattle. E.coli 0157:H7 has been isolated from cattle after 
cases of both haemorrhagic colitis and HUS were associated with the 
ingestion of raw milk (Borczyk et al 1987). This serotype was also isolated 
when contaminated ground beef was implicated in an outbreak of 
haemorrhagic colitis and HUS (Wells et al 1983). Hence, it has been 
deduced that the route of transmission of these pathogens is primarily 
zoonotic in nature. Person-to-person spread has been reported (Karmali et 
al 1988), indicating that a relatively small dose of the infectious agent may
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Table 1.2 Number of isolates of E.coli 0157:H7 in Canada
from 1978-1987
Year Number of isolates
1978-81 5
1982 25
1983 59
1984 163
1985 294
1986 750
1987 1342
(From Hockin et al 1988)
There is only one reported case of isolation of 0157:H7 from a sick 
cow (Orskov et al 1987), however, in a survey in North America this 
serotype was isolated from >3% of retail fresh meats and poultry, 
indicating that it is not a rare contaminant of these products (Doyle & 
Schoeni 1987). Cattle have also been implicated as a source of VTEC in 
England, approximately 1% of cattle at an abattoir were found to carry this 
serogroup in their faeces (Chapman et al 1989). As cattle appear to be the 
main reservoir for 0157:H7, there is some speculation that this VTEC 
serotype has evolved from the normal flora of these animals (Whittam et 
al 1988).
VTEC serogroups other than 0157 are frequently isolated from 
cattle with diarrhoea (Mohammed et al 1986) and weaned pigs with 
diarrhoea and oedema disease (Dobrescu 1983). The VTEC serogroups 
associated with diarrhoea and oedema disease in pigs are 045, 0138, 0139, 
and 0141, but there are no reports of these strains being implicated in 
human disease. Around 10% of healthy cattle were found to carry VTEC 
(Montenegro et al 1990) including serogroups implicated in human 
infections, but they appear to form part of the normal flora of these 
animals. This figure correlates with that of Read et al (1990), who detected 
VTEC in 10.4% of beef samples from meat processing plants, although it 
must be stressed that not all of these VTEC serogroups have been 
implicated in human disease.
be sufficient to initiate disease, but this is a less common mode of
transmission.
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1.4 Clinical Manifestations of VTEC Infections
The disease produced as a result of VTEC infection ranges from mild 
uncomplicated diarrhoea, through haemorrhagic colitis to HUS. Infection 
usually results in a self-limiting diarrhoeal illness, and asymptomatic 
infection has been reported (Cleary 1988). In some patient groups, 
however, there is a progression to more serious symptoms, and one of the 
predisposing factors towards these groups is age, with the very young and 
the elderly being most at risk. The reason for this is not clear, but in any 
one outbreak of VTEC infection a wide spectrum of illness may be 
reported. Diarrhoea due to VTEC, which may or may not be bloody, 
develops 3-4 days after infection as a result of reduced absorption in the 
gut, and loss of fluid, electrolytes and plasma proteins is secondary to 
severe mucosal damage in the large bowel. The more severe 
manifestations of human VTEC infection, haemorrhagic colitis and HUS, 
as well as oedema disease of swine, will be described in more detail to 
emphasize the importance of studying VTEC as pathogens.
1.4.1 Haemorrhagic colitis
Haemorrhagic colitis is usually a self-limited, acute, afebrile illness that is 
characterized by abdominal cramps and watery diarrhoea which becomes 
bloody, resembling lower gastrointestinal bleeding. The young and elderly 
are prone to complications and in one severe outbreak a 31% fatality rate 
was reported among nursing home residents (Krishnan et al 1987).
Since the syndrome was first linked to VTEC (Riley et al 1983), both 
sporadic cases (Pai et al 1984) and outbreaks of VTEC-associated 
haemorrhagic colitis have been reported (Johnson et al 1983, Wells et al
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1983). Most cases have been associated with contaminated meat products, 
and haemorrhagic colitis was at one stage referred to as the "hamburger 
disease". Whilst 0157:H7 is the most common VTEC isolate from cases of 
haemorrhagic colitis (Kleanthous et al 1988) other serotypes have been 
reported, as well as atypical 0157 strains (Bopp et al 1987). The use of 
antibiotics to treat VT-associated haemorrhagic colitis is not beneficial, and 
the early use of antimotility agents to control the diarrhoea may increase 
the duration of the colitis (Robson et al 1990).
1.4.2 Haemolytic Uraemic Syndrome
HUS is the leading cause of acute renal failure in children, with the 
highest incidence occuring in late summer/early autumn, either in small 
outbreaks or as sporadic cases. Around 8% of children with 0157:H7 
infections will develop HUS (Rowe et al 1991) and in North America the 
mortality rate is about 5% (Stavric & Spears 1989). HUS is not a common 
disease of adults, although a few cases have been reported (Neill et al 1985, 
Crosse & Naylor 1990). As mentioned previously the elderly are 
particularly susceptible to VTEC infections, and in one nursing home 
outbreak 30% of infected residents died of HUS (Karmali 1987).
HUS patients characteristically display a triad of features : acute 
renal failure, microangiopathic anaemia and thrombocytopenia. The most 
common variety of HUS, the idiopathic form, is typically preceded by a 
prodromal phase which resembles haemorrhagic colitis. The pathogenesis 
of HUS has not been established although an observation that most sera 
from acute HUS cases contained antibodies that lysed human umbilical 
vein endothelial cells suggests that autoimmunity may play a role in the 
disease (Leung et al 1988).
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It is possible to link the incidence of HUS to the frequency of 
isolation of VTEC. The highest reported frequency of HUS is in Argentina 
(250 cases/year) where VTEC levels are high, although 0157:H7 is not the 
most common isolate (Lopez et al 1989). Conversely a low incidence of 
both HUS and VT-associated diarrhoea is seen in Thailand (Seriwatana et 
al 1988). It should be noted that although the link between HUS and VTEC 
is clear, HUS is still a relatively uncommon complication of VTEC 
infection.
Thrombotic thrombocytopenia purpura (TTP) has also been linked 
to 0157:H 7 where symptoms resemble those of HUS, but with 
neurological manifestations which are only rarely linked to HUS (Ramsey 
& Neill 1986). Studies have been carried out to investigate a link between 
genotype and disease produced by VTEC, and in patients with HUS or TTP, 
0157:H7 strains producing VT2 only, were the most likely isolates (Ostroff 
et al 1989). VTEC containing more than one copy of VT2 and VT2vh 
genes have been isolated (Schmitt et al 1991, Ito et al 1990), although 
multiple copies of VT1 genes have not been reported. Since VT2 has been 
associated with the more serious manifestations of VTEC infections, there 
is speculation that multiple gene copies could play a role in the 
pathogenesis of these infections.
1.4.3 Oedema Disease of Swine
VT2vp is associated with oedema disease of swine which affects mainly 
weaning pigs, and can result in serious economic losses. It is a 
neurological disease which begins with staggering gait and limb paralysis 
and progresses to convulsions, coma, and finally death. The disorder is 
characterized by oedema which is restricted mainly to the stomach wall 
and colonic mesentery, and profound vascular damage. The pathology of
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oedema disease can be induced in weaning pigs by administration of 
<10ng purified VT2vp per kg of body weight, so it appears that the toxin 
alone is responsible for the majority of the symptoms of this infection 
(Gordon et al 1992). This means that a vaccine currently under 
development to protect against the action of VT2vp, based on a toxoid 
preparation should protect against oedema disease(MacLeod & Gyles 
1991).
1.5 Diagnosis of VTEC infections
VTEC infections can be diagnosed on the basis of isolation of the 
organism, detection of VT, or the presence of neutralising antibodies in 
the patient's serum. VT can be detected as free toxin (FVT), usually in 
stool filtrates, or it can be released from cells by use of compounds which 
alter the permeability of the cell envelope, such as polymyxin B, and 
subsequently assayed. It is well recognized however that the most 
important and sensitive investigation in diagnosis of VTEC infection is 
the detection of FVT (Karmali ef al 1985).
1.5.1 Detection of Verotoxins
The detection of FVT is the most important factor in diagnosis of VTEC 
infections, especially as many VTEC-negative patients are positive for FVT 
as organisms are often present in numbers too low to detect. FVT is 
usually assayed from stool filtrates in tissue culture assays where the toxin 
is titrated across monolayers of Vero (African Green Monkey kidney) cells, 
although the use of Vero cell suspensions may be a more rapid method of 
detecting VT (Maniar et al 1990). The presence of VT can be confirmed by a 
neutralization test with appropriate antiserum. A less expensive and more
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rapid method of detecting VT from supernatants or cell extracts is an 
enzyme linked immunosorbent assay (ELISA), which can detect ng toxin 
m l'l , although this is far less sensitive than tissue culture assays where pg 
toxin m l'l can be measured (Kongmuang et al 1987). Colony ELISA using 
monoclonal antibodies against VT1 (Strockbine et al 1988) and VT2 (Perera 
et al 1988) detect moderate- to high-level producers of VT and have 
proved useful for epidemiological screening.
Although tissue culture techniques are expensive and time 
consuming, most other methods fail to detect such low levels of toxin.
1.5.2 Isolation of VTEC
The initial diagnostic procedure in most laboratories is the isolation of the 
causative organism, and 0157:H7 is routinely investigated by use of 
selective medium. The selection is based on the fact that this serotype, 
unlike 95% of E.coli strains, does not ferment sorbitol in 24 hours. A 
modified MacConkey agar containing sorbitol instead of lactose (SMAC 
agar) is used to select for non-sorbitol fermenters such as E.coli 0157:H7. 
However, many other bacteria do not ferment sorbitol, and even when 
present, 0157:H7 may constitute only a small percentage of non-sorbitol 
fermenters, so further tests are necessary to confirm the presence of the 
organism. This is usually done by serotyping the isolate with 0157 
antiserum (Kleanthous et al 1988) although for identification, it is 
preferable to demonstrate that organisms are able to decarboxylate lysine 
and ornithine, as cross-reaction of other serotypes with 0157 antiserum 
has been reported (Haldane et al 1986).
Several groups have incorporated a further selective step to 
identify 0157:H7. Farmer & Davis (1985) added H7 antiserum to a sorbitol 
medium, which reacted with the flagella of 0157:H7 resulting in loss of
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motility. It is also possible to differentiate between 0157:H7 and other non­
sorbitol fermenters, which are mostly Proteus species and other E.coli 
serotypes, by addition of rhamnose and cefixime to SMAC agar. Proteus 
species are inhibited by cefixime, and the E.coli strains will ferment 
rhamnose, while 0157:H7 is unable to do this (Chapman et al 1991).
These routine screening procedures are clearly limited in that VTEC 
other than 0157:H7, all of which are able to ferment sorbitol, will not be 
detected. It has been estimated, for example, that in HUS infections 30% 
VTEC can be attributed to non-0157 serogroups (Kleanthous et al 1988). 
Thus, although 0157 is the most commonly isolated VTEC serogroup, this 
is in part due to the fact that other serogroups are not looked for. More 
VTEC infections would therefore be diagnosed if the production of VT was 
investigated. One solution to this problem is to screen colony sweeps for 
VT production by releasing the toxin with polymyxin B. This method 
allows VT detection even if VTEC numbers are low, and although less 
sensitive than demonstration of FVT, it ensures that all VTEC can be 
detected not just 0157:H7. VT released in this manner has been assayed by 
standard Vero cell assays (Karmali et al 1985), or, more rapidly by an ELISA 
based on the VT cell receptor, globotriosylceramide ( Ashkenazi & Cleary 
1990).
In addition to the problem of detecting relatively low numbers of 
VTEC in a mixed flora, it is necessary to test faeces within four days of 
onset of symptoms, as VTEC are rapidly cleared from stools of patients. 
Often, by the time HUS develops, characteristically one week after onset of 
symptoms, the organism is no longer present in faeces.
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1.5.3 Detection of Neutralizing Antibodies
Chart et al (1991a) have suggested that serological testing of patients with 
HUS for antibodies to the lipopolysaccharide (LPS) of 0157 provides 
evidence of infection with 0157 when faecal bacteria or VT cannot be 
detected, since healthy controls failed to demonstrate these antibodies. 73% 
of children with HUS were serum-positive in an ELISA compared to 23% 
which gave positive results for bacteriology or toxin testing alone. Similar 
findings were reported by Bitzan & Karch (1992) using an indirect 
haemagglutination assay. A diagnosis based on seropositivity alone 
should be interpreted cautiously, however, as cross-reaction has been 
reported between the LPS of 0157:H7 and Brucella abortus, B.melitensis, 
E.hermannii (Perry & Bundle 1990) and Yersinia enterocolitica 0 9  (Chart 
et al 1991b). This is because the LPS of these organisms share common 
sequences.
Rather than detect antibodies to 0157:H7, it is possible to look for 
neutralizing antibodies to VT using a modification of the receptor 
enzyme linked immunosorbent assay (the NeutRELISA). This method 
measures the ability of antibodies in patients' sera to inhibit the binding of 
a known concentration of VT to the VT receptor, globotrioasylceramide, 
Gb3 (Boulanger et al 1990). A positive result would confirm a VT 
infection, and would allow detection of VTEC other than 0157:H7.
1.5.4 The Use of DNA Probes in Diagnosis
DNA probes have been used to detect the presence of genes coding for VT, 
and for the lysogenic phages which carry these genes ( Seriwatana et al 
1988, Bettelheim et al 1990), and whilst this is an effective method of 
screening for epidemiological studies, it is not a routine diagnostic
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procedure due to expense and the need for specialized equipment. 
Screening for the presence of VT genes gives no indication of expression 
of the toxins, although it does indicate the incidence of the genes in the 
E.coli population.
1.6 Adherence of VTEC
Attachment of VTEC is an important pathogenic mechanism, allowing 
colonization to occur, which in turn facilitates toxin delivery. VTEC 
adhere to the intestine of infected animals, in the attaching and effacing 
(AE) manner which is characteristic of EPEC isolates (Moon et al 1983, 
Sherman et al 1988b). EPEC and VTEC can be distinguished, however, 
because VTEC colonize and adhere to the caecum and colon, whereas 
EPEC primarily colonize the duodenum and upper small bowel (Karmali 
1989). This mode of adherence is characterized by the close attachment of 
the organism to the enterocyte, effacement of the microvilli, and 
disruption of the cytoskeleton at the site of attachment. The cell 
membrane is commonly seen "cupping" around the bacterium, and there 
is an accumulation of actin beneath the attachment site. This characteristic 
has been exploited in the detection of bacteria which attach in the AE 
manner (Knutton et al 1989).
Early studies indicated that VTEC adhered to epithelial cells via 
fimbriae which were encoded by a 60-MDa plasmid (Karch et al 1987). 
However, Ashkenazi et al (1992) have since demonstrated that some non- 
fimbriate VTEC strains hybridise with a probe derived from the 60-MDa 
plasmid (Levine et al 1987). In addition, some non-fimbriate E.coli 
0157:H7 have been shown to adhere to epithelial cells in vitro (Sherman 
et al 1987), therefore there is much controversy over the role of the 60- 
MDa plasmid in VTEC adherence.
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The results of the present study support the hypothesis that 
possession of the 60-MDa plasmid is not a major factor in VTEC 
attachment. 0157:H7 (ATCC 35150) was investigated and found to be non- 
fimbriated (personal communication, I. Urabi) although it did possess a 
large plasmid of ~60-MDa. Mutants of this strain, which had lost the 
plasmid, were able to adhere to HeLa cells to the same extent as the parent 
strain. Tzipori et al (1987) failed to find an association between possession 
of a 60-MDa plasmid, and virulence of 0157:H7 strains in gnotobiotic 
piglets. Thus there are strong indications that the 60-MDa plasmid is not 
in itself responsible for adherence of VTEC.
Analysis of genes which hybridised with the plasmid-derived probe 
indicated that the ability to produce AE lesions was not plasmid-encoded 
(Hall et al 1990). Studies using plasmid-cured strains suggest that the 
plasmid is involved in initial adherence to the brush border, but is not 
required for AE activity (Tzipori et al 1989). Adherence of VTEC in vivo 
and the formation of AE lesions is probably mediated by a 94-kDa 
membrane protein. In EPEC strains AE activity is dependent upon a 94- 
kDa membrane protein encoded by the chromosomal eae gene (Jerse & 
Kaper 1991). Homologous sequences found in VTEC strains indicate that a 
chromosomal gene could be responsible for VTEC AE adherence (Jerse et 
al 1991). This evidence is supported by the finding that a 94-kDa outer 
membrane protein competitively inhibits adherence of 0157:H7 (Sherman 
et al 1991). Antiserum to the Eae protein of EPEC recognized a 
corresponding protein in 026:H11 strains, but not in 0157:H7 strains (Jerse 
& Kaper 1991). Thus, it is proposed that these proteins serve similar 
functions, but are antigenically distinct, emphasizing that 026:H11 is more 
closely related to EPEC strains than it is to 0157:H7 (Whittam et al 1988). 
Regulation of AE attachment in EPEC strains is positively regulated by a 
60-MDa plasmid (which unlike the VTEC plasmid does not encode
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fimbriae), possession of which is related to increased virulence (Jerse & 
Kaper 1991). It is speculated that the 60-MDa plasmid in VTEC may play a 
similar role in VTEC pathogenicity, since at least in some cases, there is 
correlation between adherence and possession of fimbriae (Winsor et al 
1992). In addition, the plasmid-encoded adhesins may be involved in 
tissue specificity of VTEC.
1.7 Verotoxins- General Introduction
VT are bipartite toxins, composed of a single A subunit which becomes 
enzymatically active, and a pentamer of smaller B subunits which bind to 
specific cell-surface receptors. The association between the A and B 
subunits is non-covalent. Two antigenically distinct VT are known, 
Verotoxin 1 (VT1) and Verotoxin 2 (VT2), and variants of VT2; VT2vh 
and VT2vp, have been described from human (Oku et al 1989), and 
animal origin (Marques et al 1987). The relative sizes of the subunits of 
VT1, VT2 and VT2vp are shown in Table 1.3.
All VT are cytotoxins, and VT1, VT2 and VT2vh are enterotoxins as 
defined by the ability to cause fluid accumulation in the rabbit ileal loop 
test. VT2vp does not show enterotoxic activity (Tzipori et al 1987). With 
the exception of VT2vp which appears to be the product of a chromosomal 
gene (Pollard et al 1990), VT are produced by lysogenic phage, which at 
least in some cases are lambdoid in nature (Huang et al 1987). Around half 
of 0157:H7 strains are lysogenized by VT1- and VT2-encoding phages, and 
produce both toxins (Newland & Neill 1988).
VT1 is closely related to Shiga toxin, which is produced by Shigella 
dysenteriae type 1. Antibodies to Shiga toxin will neutralize the activity of 
VT1 but not VT2, and at the amino acid level VT1 and Shiga toxin differ 
by only a single amino acid residue in the A subunit (Strockbine et al
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1988). Expression of Shiga toxin and VT1 is repressed by high levels of 
iron (van Heyningen & Gladstone 1953, Calderwood & Mekalanos 1987), 
although VT2 production is not iron-regulated (Weinstein et al 1988a).
VT2 is antigenically distinct from VT1, and the toxins share 58% 
homology at the amino acid level (Jackson et al 1987a). The activity of VT1 
and VT2 is identical however, and they both inhibit protein synthesis by 
inactivation of the 60s ribosomal subunit (Igarashi et al 1987). VT2 
variants include VT2vp which has been isolated from cases of porcine 
oedema disease, and VT2vh which more closely resembles VT2. They are 
classified as variants because although they are neutralized by antibodies 
to VT2 and not VT1, and share >90% nucleotide sequence homology with 
VT2, they are less cytotoxic for HeLa cells than VT2. This has been shown 
to be due to differences in receptor binding in the case of VT2vp, but not 
VT2vh, which differs only slightly from VT2. VT1, VT2 and VT2vh bind 
to Gb3  (globotriaosylceramide) while VT2vp binds very weakly to this 
receptor but strongly to Gb4  (globotetraosylceramide), which is not 
recognized by the other VT (DeGrandis et al 1989).
The toxins are heat-labile to varying degrees, with VT1, which is 
unaffected by heating to 60°C being the most heat-stable, whereas >75% of 
VT2 activity is lost at this temperature (Head et al 1988). VT1 must be held 
at 80°C for at least 20 minutes or boiled for 2 minutes to be inactivated 
(Petrie et al 1987). VT2vp is more heat-labile than either VT1 or VT2, and 
activity is completely lost at 65°C after 30 minutes (MacLeod et al 1991).
Production of VT by certain EPEC strains suggests a putative role for 
these toxins in the pathogenesis of EPEC infections. Some 026:H11 strains 
not only produced VT but appeared to possess the 60-MDa plasmid 
associated with VTEC adherence, and these strains have been 
recategorized as VTEC (Scotland et al 1990). VT production has not been 
associated with EIEC strains (Cleary & Murray 1988).
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Table 1.3 Physicochemical Properties of Verotoxins
Subunit Toxin Mol.
weight
A VT1 32,211
VT2 33,135
VT2vp 33,050
B VT1 7,690
VT2 7,817
VT2vp 7,565
No. of No. of Pi
Nucleo­ Amino
tides acid
Residues
879 293 11.1
888 296 9.8
891 297 8.7
207 69 5.9
210 70 5.4
204 68 10.2
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1.8 Binding of Verotoxins to Eukaryotic Cells
VT exhibit extreme toxicity towards certain cultured cell lines, but most 
cell types tested are not susceptible to toxin action in vitro. The nature of 
this selectivity is not clear, although it is likely that cells resistant to VT do 
not contain measurable amounts of toxin receptors. This was found to be 
the explanation for resistance of certain cells to cytotoxin produced by 
Shigella shigae (Eiklid & Olsnes 1980). Since insertion of the VT receptor 
into the membrane of resistant cells renders these cells sensitive to VT, 
this may also explain the cell selectivity of VT (Tyrrell et al 1992).
Studies on VT suggest that the holotoxin binds to cells via the B 
subunits, with the A subunit directed away from the membrane. The cell 
surface receptor-binding site probably lies in a cleft between adjacent 
subunits of the B pentamer (Stein et al 1992). Cytotoxic activity is lost if the 
last four amino acids from the carboxy terminus of the 70 amino acid VT2 
B subunit are deleted but not if the terminal two amino acids only are lost 
suggesting that the critical amino acid residues are phenylalanine 67 and 
asparagine 68 (Perera et al 1991b).
The functional receptor for both VT1 and VT2 on HeLa and Vero 
cells is a neutral glycolipid, globotriaosylceramide (Gb3 )(Figure 1.1) 
(Lingwood et al 1987, Waddell et al 1987). Shiga toxin binds several Gal 
al-4Gal-containing glycolipids (Jacewicz et al 1986), but it appears that Gb3  
is the high-affinity receptor (Jacewicz et al 1989).
The major difference between VT2 and VT2vp is the cytotoxicity 
towards cultured cell lines. VT2 is cytotoxic towards Vero and HeLa cells, 
whereas VT2vp has little effect on HeLa cells (Marques et al 1987). This is 
because, despite the fact that VT2 and VT2vp share >90% nucleotide
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homology (Weinstein et al 1988b), they do not bind to the same receptor 
glycolipid (DeGrandis et al 1989). This difference is reflected in the 
isoelectric points of the B subunits of VT1, VT2 and VT2vp (Table 1.3). 
VT2vp binds to globotetraosylceramide (Gb4 ), and binds only weakly to
Gb3.
VT1 and VT2 do not recognize Gb4 , indicating that a terminal Gal 
al-4Gal sequence is essential to binding (Figure 1.1). Vero cells have equal 
amounts of Gb3 and Gb4  therefore are equally sensitive to VT2 and 
VT2vp. HeLa cells presumably lack Gb4 , and so VT2vp, which binds to Gb3 
very weakly, has HeLa cell activity only when the toxin is present in high 
concentrations. Like VT2, VT2vh binds to terminal Gal al-4Gal sequences 
in Gb3 (Samuel et al 1990). The difference in receptor binding may result 
from minor changes in the amino acid sequence since a single change 
(Asp-18 to Asn) in the B subunit of VT1 changed the binding phenotype to 
that of VT2vp (Tyrrell et al 1992).
The difference in glycolipid binding specificity between VT2 and 
VT2vp may give some insight into the differences in clinical symptoms 
seen between VT2 and VT2vp infections. Both purified VT2 and VT2vp 
are lethal for weaning pigs, but VT2 does not produce the clinical 
symptoms of oedema disease seen when VT2vp is administered (Samuel 
et al 1990). This suggests that differences in receptor specificity can 
determine the type of disease seen in animals.
Human Burkitt lymphoma cells (Daudi cells) possess many 
receptors for VT (Gb3 & Gb4 ) and so bind large amounts of the toxins. 
Mutant Daudi cells were produced by Cohen et al (1987) which had lost 
the ability to bind VT and were cross-resistant to inhibition of growth by a- 
interferon. This suggests that an additional role for these glycolipids in
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vivo is in the modulation of the affinity of a-interferon for its membrane 
protein receptors.
1.9 Mechanism of Action of Verotoxins
After binding to the eukaryotic cell, toxin entry is thought to occur via 
receptor-mediated endocytosis (personal observation, this study). In the 
process of intracellular translocation, the A subunit undergoes proteolytic 
cleavage at a trypsin-sensitive site near the amino terminus, to produce 
the active A’ fragment. This inhibits eukaryotic protein synthesis by 
cleavage of the N-glycosidic bond at adenosine 4324 (A4324) in the 28S 
rRNA of rat liver 60S ribosomal subunits. This results in the blocking of 
elongation-factor-1-dependent binding of aminoacyl-tRNA to ribosomes, 
although non-enzymatic binding of aminoacyl-tRNA, peptide bond 
formation and translocation are not inhibited (Igarashi et al 1987). Shiga 
toxin, which differs from VT1 in only one amino acid residue, has an 
identical mode of action, and inactivation has been shown to occur at a 
rate of at least 40 ribosomes per minute (Reisbig et al 1981). This N- 
glycosidase activity has been demonstrated in vitro on isolated ribosomes, 
but also occurs in living cells since microinjection into Xenopus oocytes 
has the same effect (Saxena et al 1989). The sequence in which A4324 lies, 
is well-conserved in rat, yeast and E.coli ribosomes and is likely to be very 
important since hydrolysis of a single bond or removal of one base leads to 
total inactivation of ribosomes (Endo et al 1988).
This mode of inactivation may be a general mechanism for 
ribosome-inactivating cytotoxins since ricin, a higher plant toxin, has the 
same activity (Endo et al 1987). The relatedness of ricin and VT extends 
not only to the mode of action but also to nucleotide sequence homology. 
Homology exists between the enzymatically active units of VT and ricin,
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namely the A subunit of VT and the A chain of ricin (Calderwood et al 
1987). The crystal structure of ricin has been determined, and a cleft in the 
A chain is thought to correspond to the active-site. The conserved residues 
between ricin and VT were plotted on the ricin A chain crystal structure, 
and 7 amino acids of VT were shown to lie in the proposed active site. 
From this data site-directed mutagenesis was used to determine that 
glutamic acid 167 is an active-site residue in VT1 and is critical for enzymic 
activity of the toxin (Hovde et al 1988). Mutation of the corresponding 
amino acid residue in VT2vp led to reduction of enzymic activity by 
approximately 1,500-fold. In vivo this mutant toxin failed to affect 
pathological changes in pigs, but did induce production of neutralising 
antibodies to VT2vp, therefore this is a possible vaccine candidate (Gordon 
et al 1992). The corresponding glutamic acid residue at position 166 of the 
A subunit is essential for full toxic activity of VT2 (Jackson et al 1990). A 
second region vital to the cytotoxicity of VT is between amino acid 
residues 202 and 213 of the A subunit (Jackson et al 1990).
1.10 Verotoxin-Converting Phages
VT1 and VT2 are produced by lysogenic phage, which at least in some 
cases are lambdoid in nature, homology existing with the J gene which 
codes for the lambda tail fibre, and with the genes which code for DNA 
replication and integration functions (Huang et al 1987). The existence of 
this relationship is supported by the fact that E.coli K12 produces high 
levels of VT if lysogenized with a VT-converting phage, but this does not 
occur if the K12 strain is a lambda lysogen (Smith et al 1983). VT2vp- 
encoding phage have not been isolated, and it now appears that the genes 
encoding this toxin are chromosomally located (Pollard et al 1990).
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Most of the studies on VT-converting phages, concentrate on the 
VT-encoding genes, rather than biology of the phages. However, since 
these are lambdoid phages, it is likely that they share similar 
characteristics to phage lambda. In a cell lysogenic for lambda, none of the 
viral genes needed for productive infection are transcribed, and very little 
viral mRNA is detectable. Six regulatory genes are responsible for ten 
regulatory proteins which maintain the lysogenic state (Luria et al 1978). 
The repressor protein, coded by the cl gene, prevents transcription of the 
rest of the viral genome, and any conditions which result in breakdown of 
this protein, cause the phage to enter the lytic cycle. VT-converting phages 
can be induced by UV light or mitomycin C (O'Brien et al 1984, Head et al 
1988), because these conditions induce the SOS response in the host cells. 
This involves activation of the RecA protein, which is able to break down 
the phage repressor causing the phage to enter the lytic cycle (Walker 
1987).
VTEC strains which produce both VT1 and VT2 are lysogenized by 
two distinct phage. 0157:H7 strain 933 for example, contains two toxin­
converting phages, 933J which produces VT1, and 933W which carries VT2 
genes (Strockbine et al 1986). The VT1- and VT2-encoding phage of 
0157:H 7 are morphologically indistinguishable, consisting of regular 
hexagonal heads (74 x 74nm) and short contractile tails (28 x llnm ). This 
morphology differs from that of VT1-encoding phage HI 9, isolated from 
026:H11, where the hexagonal phage head is more elongated (117 x 67nm) 
and the longer flexible tail is non-contractile (177 x 12nm). The VT1 region 
cloned from H19 and 933J is identical however, and was unrelated to the 
VT2 region from 933W when restriction sites over 2kb were analysed 
(Willshaw et al 1987). VTl-encoding phage isolated from a bovine strain of 
026:H11 was similar in morphology to that from a human strain (Rietra et
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al 1989), so the morphology of the phage seems to be a property of the 
serotype.
In contrast to other toxin-converting phage eg Corynebacterium  
diphtheriae, the tox genes map away from the phage attachment genes. 
Thus VT-converting phage genes were not picked up by simple imprecise 
prophage excision. It is interesting that despite the almost identical 
sequence between VT1 and Shiga toxin, Shiga toxin is the product of a 
chromosomal gene (Sekizaki et al 1987). This difference has been exploited 
to differentiate between VT1 and Shiga toxin by the polymerase chain 
reaction (PCR) as oligonucleotide primers based on a common region of 
VT1 and Shiga toxin will identify both genes, but if a unique sequence in 
the promoter region of the VT1 gene ie phage DNA is used, Shiga toxin is 
not recognized (Pollard et al 1990).
A study by Brown et al (1989) suggested that VT-converting phages 
in 0157:H7 are present in many nontoxigenic E.coli isolated from children 
in Thailand. They proposed that although VTEC are isolated with low 
frequency this is not due to the absence of phages capable of carrying the 
genes for VT. This view is not supported by a study in the United States 
where results suggested that the occurrence of silent or poorly expressed 
VT genes is low (Newland & Neill 1988).
Phage typing has been postulated as a means, in addition to other 
studies, to monitor the epidemiology of outbreaks of VT1 and VT2 
(Ahmed et al 1987).
1.11 Genetics of Verotoxin Production
Nucleotide sequencing has given greater insight into the relatedness 
between VT, and their relationship with, other toxins. The nucleotide 
sequence of VT1 is identical to that of Shiga toxin, apart from three
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nucleotides in the A subunit which results in a single amino acid 
difference (Strockbine et al 1988). By contrast, VT1 genes share only 57 to 
60% nucleotide sequence homology and 55 to 57% deduced amino acid 
sequence homology with those of VT2 (Jackson et al 1987a). The VT2 
variants are closely related to VT2, with 91% overall sequence homology 
between VT2 and VT2vp, and >95% homology between VT2 and VT2vh 
(Ito et al 1990). There is no significant homology between VT and other 
bacterial toxins with intracellular targets, eg diphtheria toxin, 
Pseudomonas exotoxin A, and cholera toxin, although homology with the 
plant toxin ricin has been reported (Calderwood et al 1987).
1.11.1 Transcription of Verotoxin Genes
The genes encoding the A and B subunits of VT constitute an operon with 
12 nucleotides separating the coding regions of VT1 (Calderwood et al 
1987) and 14 nucleotides separating the A and B subunit genes of VT2 
(Jackson et al 1987a). The intergenic space between the A and B subunit 
genes of VT2vh and VT2vp is 14 and 15 nucleotides respectively (Ito et al 
1990, Weinstein et al 1988b). A VTEC isolate has been described that 
contained two VT2vh operons which were almost identical (Ito et al 1990). 
Similarly Schmitt et al (1991) detected two copies of VT2 genes in an 
isolate of 0157, although there are no reports of multiple gene copies in 
VT1-producers.
The A and B subunit genes are transcribed into a polycistronic 
mRNA from a promoter upstream from the A subunit. If this promoter is 
blocked, VT1 B subunits can be transcribed from a promoter 5' to the B 
gene, within the C-terminus of the A subunit reading frame (Jackson et al 
1987b). VT2 B subunits cannot be transcribed independently (Sung et al 
1990).
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VT1 production is repressed at the level of transcription by high 
levels of iron in the medium. This control requires the product of the 
chromosomal fur gene, a 17-KDa protein which combines with iron to 
form a repressor which binds to a site within the VT1 promoter, inhibiting 
transcription (Calderwood & Mekalanos 1987). A 21bp region of dyad 
symmetry overlapping the proposed promoter region of VT1, is absent 
from the promoter regions of VT2 and VT2 variants, and these toxins are 
not iron-regulated (Sung et al 1990, Ito et al 1990). Unlike the VT1 
promoter, the nucleotide sequence of the VT2 promoter is not highly 
homologous to known E.coli promoters and may be a less efficient 
transcription start signal, which is reflected in lower observed levels of 
VT2 compared to VT1 (Strockbine et al 1986).
1.11.2 Translation of Verotoxin Subunits
VT are composed of a single A subunit and 5 B subunits, a stoichiometry 
which results from independent translation of the A and B subunits. 
Putative ribosome-binding sites identified upstream of both A and B 
subunit genes are identical in all VT operons (Ito et al 1990). The subunit 
genes of VT1 and VT2vp are separated by 12 and 15 nucleotides 
respectively (Calderwood et al 1987, Weinstein et al 1988b) so they are 
translated in the same reading frame. In contrast, the A and B subunit 
genes of VT2 and VT2vh are separated by 14 nucleotides so must be 
translated in different reading frames (Jackson et al 1987a, Ito et al 1990). 
Both the A and B subunit genes are translated with N-terminal signal 
sequences of around 20 nucleotides, which do not form part of the mature 
toxin (DeGrandis et al 1987, Jackson et al 1987a, Gyles et al 1988).
The A subunit of VT1 is three amino acids shorter and is more basic 
than that of VT2, although the B subunits of the two toxins differ by only
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one amino acid in length and share a similiar isoelectric point (Table 1.3). 
VT2 and VT2 variants are closely related at the amino acid level, although 
within this sub-group of toxins, the A subunits are more highly conserved 
than the B subunits (Ito et al 1990). The A subunits of VT2 and VT2vp for 
example are 94% homologous, whereas there is only 84% nucleotide 
homology between the B subunits (Gyles et al 1988).
1.12 Other VT-Producers
All strains of S.dysenteriae type 1 appear to produce VT1 but not VT2, 
when tested by either genetic or immunological methods (Smith et al 
1987). This is because Shiga toxin, which these strains actually produce, is 
identical antigenically to VT1 and differs by only one amino acid. Strains 
of S.flexneri, S.boydii, S.sonnei and other serotypes of S.dysenteriae also 
produce a cytotoxin, but neutralization by anti-Shiga toxin (equivalent to 
anti-VTl) is either non-existent, or only partial (Prado et al 1986). Thus it 
appears that toxins of the VT family are not common in other Shigella 
species.
In contrast, cytotoxin produced by some isolates of Vibrio cholerae 
and V.parahaemolyticus are neutralizable by anti-Shiga toxin but not by 
anti-cholera toxin as might be expected. These strains were reported to be 
Shiga-like toxin producers (O'Brien et al 1984a) . However unlike VT, the 
toxic activity was completely cell-associated, and more significantly was 
heat-stable. So it appears that this toxin is antigenically cross-reactive with 
Shiga toxin (and hence to VT1), but is probably not part of this family of 
toxins. It therefore appears that despite the fact that these toxins are phage- 
encoded, the host range of these lysogenic phage, as determined by the 
ability of organisms to produce VT, seems to be very narrow.
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1.13 The Role of the Bacterial Cell Envelope in 
Pathogenicity
In order to be a successful pathogen, an organism must be able to gain 
entry into the host, and survive and multiply whilst resisting host defence 
mechanisms. Most bacteria, except the Mycoplasma, possess an additional 
layer, external to the cytoplasmic membrane, referred to as the cell wall. 
This is essential to prevent cell lysis, as the cytoplasmic membrane alone 
could not withstand the osmotic pressure inside the cell caused by the 
high internal concentration of metabolites. Since the cell wall is the 
outermost part of the bacterial cell, it is essential that this part of the cell 
has adapted to aid the survival of the pathogen in the host. In general, 
bacteria can be classified as either Gram-positive or Gram-negative 
according to the reaction of the cell wall in the Gram stain. E.coli are 
Gram-negative organisms, so the structure of the Gram-negative cell 
envelope will be briefly described below.
1.13.1 The Gram-Negative Cell Envelope
The cell envelope of Gram-negative bacteria is much more complex than 
that of Gram-positive organisms. The cytoplasmic membrane of Gram­
positive bacteria is surrounded by a thick cell wall composed of 
peptidoglycan and teichoic acid. In the case of Gram-negative bacteria 
however a periplasmic space, containing a narrow layer of peptidoglycan, 
separates the cytoplasmic membrane from an outer membrane consisting 
of phospholipids, proteins and lipopolysaccharides (Figure 1.2).
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Figure 1.2 Diagrammatic representation of the Gram-Negative Bacterial 
Cell Envelope
The three main layers of the cell envelope are shown: 
outer membrane (OM), inner membrane (IM) and peptidoglycan (PG). 
Individual components shown are: the cell wall (CW), periplasmic space 
(PS), lipoprotein (LP), outer membrane protein (OMP), inner membrane 
protein (IMP), periplasmic protein (PP), lipopolysaccharide (LPS) and 
phospholipid (PL).
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Gram-negative bacteria are more resistant than Gram­
positive species to a variety of host defence mechanisms due to the 
presence of the outer membrane. This protection is physical, biochemical 
and/or immunological in nature. Physically the outer membrane protects 
cells from the detergent action of bile salts and degradation by digestive 
enzymes. This property is especially important in enteric bacteria such as 
E.coli. The outer membrane endows the bacterial surface with strong 
hydrophilicity which is important in evading phagocytosis, and provides a 
strong permeability barrier to many antibiotics. The lipopolysaccharide 
(LPS) component is especially important in pathogenicity, allowing an 
organism to alter the surface antigen constitution and so evade host 
defences.
1.13.2 Bacterial Lipopolysaccharide
LPS is found exclusively in Gram-negative organisms and is composed of 
three components: a core polysaccharide common to many Gram-negative 
bacteria, an O-specific polysaccharide which confers virulence and 
serological specificity, and a lipid A component mainly responsible for 
toxicity. The schematic structure of the best characterized LPS, Salmonella 
typhimurium, is shown in Figure 1.3.
The lipid A moiety is hydrophobic and contains six saturated 
fatty acid chains linked to two glucosamine residues. These fatty acyl 
chains constitute about half of the outer leaflet of the outer membrane, but 
are absent from the inner leaflet, which instead contains phospholipids. 
Lipid A is responsible for the toxic properties and potent biological effects 
associated with LPS. Mutants incapable of synthesizing lipid A cannot be 
isolated as loss of this component is lethal to the cell.
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Linked to the lipid A is the core oligosaccharide region. This is 
formed of 10 sugar units which project outward, and join to the O side 
chain, which is made up of many repeating tetrasaccharide units. Both the 
core oligosaccharide and the O chain are highly hydrophilic, and contain 
several sugars rarely found elsewhere in nature. These include an eight- 
carbon sugar, 2-keto-3-deoxyochonate (KDO); heptose, a seven-carbon 
sugar; and L-rhamnose and abequose, six carbon sugars. Studies with 
mutants of S.typhimurium  defective in LPS have shown that loss of O 
antigens appear to increase sensitivity to antibodies and complement.
LPSs are synthesized in the plasma membrane and then transferred 
to the outer membrane. Lipid A is synthesized first and then core 
oligosaccharide is formed by addition of sugars from activated donors such 
as UDP-glucose and UDP-galactose. The tetrasaccharide units of the O 
chain are synthesized on carrier lipids, and assembled by transfer from one 
carrier to a growing chain on another carrier molecule. The completed O 
side chain is then added to the core oligosaccharide.
1.13.3 Outer Membrane Proteins
The outer membrane has a characteristic protein composition which 
differs from that of the cytoplasmic membrane. Outer membrane proteins 
perform a variety of functions for the cell. Some form diffusion pores or 
specific transport systems, others are involved in maintaining the 
structural integrity of the outer membrane, while a few have enzymatic 
function. A feature of outer membrane proteins is that their profile is 
dependent on strain,and physiological conditions.
The porins, OmpF, OmpC and PhoE, make up almost 2% of the 
total cell protein of E.coli. Their function is to allow passage of small
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Figure 1.3. Schematic structure of LPS from Salmonella typhimurium 
Adapted from Luderitz et al 1982
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hydrophilic molecules across the outer membrane. The relative 
proportions of OmpC and OmpF vary depending on growth conditions, 
although the sum of their quantities tends to remain constant (Puente et 
al 1991). Under conditions of high osmolarity, synthesis of OmpF is 
repressed whereas OmpC expression is derepressed. PhoE is produced only 
under conditions of phosphate starvation. OmpA has a similiar molecular 
weight to (35-36KDa) , and is almost as abundant as, porins. Although 
OmpA may be involved with transport across the membrane, it is 
unlikely by itself to form pores. The function of this protein may be to 
stabilise the membrane, possibly in conjunction with lipoprotein.
Other proteins may be present in the outer membrane in large copy 
numbers under certain physiological conditions. The LamB protein for 
example, which is involved in maltose uptake may be present in 
comparable amounts to porins when fully induced.
Outer membrane proteins are important in disease as antibodies 
are commonly raised against them. Antibodies against Salm onella  
typhimurium outer membrane proteins for example, confer protection 
against infection by this organism (Udhayakumari & Muthukkaruppan 
1987). Attachment of VTEC is also thought to be mediated by outer 
membrane proteins (Sherman et al 1991).
1.13.4 Flagella
Many bacteria possess appendages, such as flagella, which increase motility 
of the organism. Colonization and penetration of the surface mucous layer 
which overlies the lining of the gastrointestinal tract is an important 
aspect of the pathogenesis of enteric bacteria, and flagella may aid this 
process. Flagella may also function as bacterial attachment factors to 
promote binding to receptors on enterocytes or colonocytes. Expression of
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flagella appears to be an important virulence factor for Vibrio cholerae and 
Campylobacter jejuni (Yancy et al 1978, Morooka et al 1985), and as most 
clinically isolated strains of 0157 possess H7 flagella, they may be 
important in pathogenesis. Attachment of 0157:H7 is not competitively 
inhibited by H7 flagella, so clearly any role flagella have in pathogenesis is 
not at the actual level of attachment (Sherman et al 1988a).
1.14 Cellular Internalization of Toxins
In general, bacterial toxins can be classified according to whether they 
damage the cell membrane, or act intracellularly. VT inhibit protein 
synthesis by acting on the 60S ribosomal subunit (Endo et al 1988), 
therefore they fall into the category of intracellularly acting toxins. Several 
other toxins have been shown to act on intracellular targets, including 
diphtheria toxin, Pseudomonas exotoxin A, Shiga toxin, and E .coli 
enterotoxins (Middlebrook & Dorland 1984). They all appear to share a 
common mechanism of action whereby binding to specific receptors on 
the target cell, is followed by internalization and subsequent interaction 
with the intracellular target.
It is known that several toxins with intracellular targets are able to 
enter cells via receptor-mediated endocytosis (RME) (Figure 1.4) 
(Willingham & Pastan 1984). This process begins with the binding of the 
toxin to a specific receptor on the target cell. The toxin-receptor complexes 
rapidly migrate to specialized regions of the cell membrane known as 
coated pits. Most animal cells possess these areas (500-1500 per cell) which 
are rich in the protein clathrin. This clustering, which is thought to be 
mediated by the enzyme transglutaminase (Middlebrook & Dorland 1984), 
seems to be temperature-dependent as, in the case of Shiga toxin, it occurs 
at 37°C but at 0°C the binding sites are randomly distributed (Sandvig et al
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1989). The toxin is internalized by invagination of the plasma membrane 
to form coated vesicles, which, upon loss of the clathrin coat are known as 
endosomes. Some of the toxin is then transported to the trans-Golgi 
region, and 30-60 minutes after entry, fuse with primary lysosomes or the 
trans-reticular Golgi apparatus. During this transit the intravesicular pH 
falls to about pH5, approaching that of lysosomes, and some toxins require 
this acidic environment to maintain their activity. The remainder of the 
endocytosed toxin is routed back to the cell surface and released in an 
intact form, as only a few toxin molecules are actually transported to the 
cytoplasm (Olsnes & Sandvig 1983).
In the case of diphtheria toxin, once the endosomal pH has fallen to 
5.3, a hydrophobic domain is inserted into the endosomal membrane, 
allowing the active fragment of the toxin to enter the cytosol via 
transmembrane channels. Other toxins must pass from the endosome to 
the cytosol via lysosomes, which may indicate a requirement for further 
processing by lysosomal enzymes which are not present in endosomes. 
The mechanism of translocation to the cytosol is not fully understood, 
although diphtheria toxin, which normally passes to the cytosol directly 
from the endosome, can enter cells directly across the plasma membrane, 
if the external pH is low. Translocation is clearly in this case triggered by 
acidic conditions, and, as lysosomal pH is also low, it is assumed that this 
is one of the requirements for entry of toxins to the cytosol.
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Figure 1.4
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Since the outcome of toxin internalization is cell death, it is unlikely that 
mammalian cells have a specific uptake mechanism for toxins. It is, 
however, probable that existing transport pathways are involved in the 
uptake of these proteins. Calcium plays a regulatory role in all living 
organisms, and it is known that the activity of bacterial toxins such as 
Shiga toxin (Sandvig & Brown 1987) and C.difficile toxin B (Caspar et al 
1987), and the plant toxins abrin and modeccin (Sandvig & Olsnes 1982a) 
are affected in the presence of drugs which block calcium transport across 
membranes. Calmodulin is a calcium-binding protein required to facilitate 
calcium transport in mammalian cells, and this pathway is represented in 
Figure 1.5. It appears that a calcium flux through naturally occurring 
channels is necessary for toxin uptake, but must be controlled, since 
calcium ionophores, which cause a strong influx of calcium ions, and thus 
upset the calcium gradient across the membrane, protect rather than 
sensitise cells against Shiga toxin (Sandvig & Brown 1987), abrin and 
modeccin (Sandvig & Olsnes 1982a). The protection afforded, is at the level 
of toxin entry since addition of calcium channel blockers such as 
verapamil is only effective before internalization of the toxins.
1.15 The Role of Calcium Uptake in Toxin Internalization
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Fig 1.5 The Calcium Pathway in Mammalian cells
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Chapter 2 Materials and Methods
2.1 Bacterial strains
The bacterial strains used in this study are listed in Table 2.1.
2.2 Monoclonal Antibodies
Monoclonal antibodies were provided by N Strockbine as detailed in Table
2.2.
Table 2.2 Monoclonal Antibodies
MAb Source Reference
MAb 13C4 (ascites) N Strockbine Strockbine el al 1985
MAb BC5 BB12 (ascites) N Strockbine Downes et al 1988
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Table 2.1 Bacterial Strains
Strain
E.coli 0157.H7 
E.coli 026:H11
E.coli 0157 
Clinical isolate 
E.coli K12
E.coli 026:H11 
(E3787/H19) 
E.coli 0157:H- 
(E32511)
E.coli 
C600 (933J) 
E.coli
C600 (933W) 
E.coli DH1
E.coli Econl
S.dysenleriae 
type 1
Genotype
F*, recAl, end A l, 
gyrA96, thi-1, 
hsdR17, (rkMk), 
supE44,1"
Source
ATCC 35150
NCTC 8781
Warwick
Hospital
University of 
Warwick
S. Scotland
S. Scotland
T. Meyer 
T. Meyer 
P. Reeves
Northwick Park 
Hospital 
NCTC 4837
Reference
Wells (1983)
PHLS
Manchester
Willshaw et al 
(1987)
Willshaw et al 
(1987)
Meyer et al 
(1989)
Meyer et al 
(1989)
Hanahan (1983)
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2.3 Cytotoxicity Assay
2.3.1 Tissue Culture
Vero cells were grown in 75ml flasks in growth medium consisting of 
Medium 199 (Flow) supplemented with 10% foetal calf serum (FCS), 
lOmM L-glutamine, penicillin (50Uml'l) and streptomycin (50mgml"l). 
Confluent monolayers were removed with trypsin-EDTA and 
resuspended at 4x10^ cells ml'* in growth medium. A 100 pi volume of 
diluted cells was added to each well of a 96-well microtitre plate. The cells 
were allowed to reach confluency by overnight incubation at 37°C in an 
atmosphere of 5% CO2 . The growth medium was then replaced with 
maintenance medium, which was the same as growth medium except that 
it contained only 2% FCS. The monolayers were then ready to be used in 
the Vero cell assay, although were stable in maintenance medium for up 
to two days.
2.3.2 Vero Cell Assay
Bacterial cultures were grown, with shaking, in 10ml of Penassay broth at 
37°C for 18 hours. Cells were harvested by centrifugation at 10,000g for 10 
minutes and the supernatant was passed through a 0 .2 2 pm membrane 
filter. The filtrate was then diluted two-fold across a microtitre plate and 
lOOpl aliquots of each dilution were transferred to the Vero cell 
monolayers using a multichannel pipette. The plates were incubated at 
37°C for 24-48 hours in 5% C02- Toxin titres were assessed as the dilution 
of the sample that killed 50% (CD5 0 ) of the Vero cell monolayer. Negative 
controls, containing uninoculated broth, were included in each 
experiment. Where it was necessary to confirm the presence of VT, 
antitoxin (at 1 :1 0 0 0 ) was added to each well with the toxin.
44
2.4 Latex Agglutination Assay
2.4.1 Coating Latex Particles
The method of Bernard & Lauwerys (1983) was used to coat latex particles 
as follows.
50pl antibody (MAb 13C4 or MAb BC5 BB12) and 4ml freshly 
prepared, 0.22pm-filtered, GBS (10X stock contained: 1M glycine, 1.7M 
NaCl & 76mM NaN3  adjusted to pH9 with NaOH) were mixed in a plastic 
universal tube. 0.5ml latex particles (0.73pm, 2.5% solids) were added and 
incubated for 60 minutes at room temperature with continuous agitation. 
After centrifugation at 25,000g for 10 minutes at 25°C, the particles were 
washed twice in 10ml of a solution containing 0.1M NaCl and 15mM 
NaN3 . Particles were resuspended in 10ml of this solution and stored at
4°C for up to 6  months.
2.4.2 Stabilising Coated Latex Particles
Before use of coated latex particles in an agglutination assay, stabilization 
was necessary to prevent non-specific aggregation between particles. The 
antibody-coated particles from stock were resuspended by vortexing, and 
0.5ml of 1.1% bovine serum albumin (BSA) was added to 3.6ml of latex 
particle suspension. The BSA was necessary to overcome non-specific 
protein-protein interactions. After vigorous vortexing for 5 minutes, 
0.4ml GBS pH 10.1, was added and the suspension was homogenized by 
further vortexing.
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2.4.3 Preparation of the Antigen Filtrate
A modification of the method of Karmali et al (1985) was used to extract 
VT.
lOOpl of an overnight Penassay (Difco Antibiotic medium no.3) 
broth culture was inoculated into 2 0 ml of fresh broth, and incubated with 
shaking at 37°C for 5 hours. Cells were harvested by centrifugation at 
10,000g for 10 minutes in glass centrifuge tubes. The cell pellets were 
washed twice in PBS and suspended in 1ml of a polymyxin B solution 
(2mgml‘ l in PBS) which alters the permeability of the cell envelope and 
releases intracellular toxin. After 10 minutes incubation at 37°C, the 
suspension was centrifuged at 10,000g for 10 minutes. The pellet was 
discarded, and the supernatant (antigen) was passed through a 0 .2 2 pm 
membrane filter.
2.4.4 Latex Agglutination Test
The polymyxin B-treated culture filtrate (antigen) was diluted 1:100 in GBS 
pH9 containing 0.1% BSA. 50pl of stabilized coated latex particles were 
added to 20pl of diluted sample and vortexed rapidly. This mixture was 
incubated for 30 minutes at 37°C in a shaking water bath, and the reaction 
was stopped by adding 5ml of GBS containing 0.1% Tween 20 (0.45pm 
filtered).
Latex agglutination was stable for up to 12 hours at 25°C or 24-48 
hours at 4°C. To detect latex agglutination, 50pl of sample was added to 
20ml Isoton (Coulter) in an accuvette. The particles were counted 
according to size using a Coulter Counter II fitted with a 30/80 orifice.
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2.5 Colony ELISA
Bacterial colonies were inoculated onto Penassay agar plates and incubated 
at 37°C for 16-20 hours. The surface of the agar was then overlaid with dry 
nitrocellulose membrane (Hybond-C, Amersham pic) ensuring that no air 
bubbles were trapped. 2ml polymyxin B (2mgml"l in PBS) was added and 
then incubated at 37°C for 60 minutes. This allowed the polymyxin B to 
permeate the cell envelope and release intracellular toxin. After 
incubation the membrane was gently peeled off the agar and thoroughly 
washed in PBS to remove bacterial debris. To prevent non-specific binding 
of the antibody, the membrane, in a glass Petri dish, was blocked by 
addition of 10ml TBS (150mM sodium chloride, 50mM Tris-HCl pH 7.5) 
containing 2% Marvel. After shaking at room temperature for 10 minutes, 
the TBS-2% Marvel was poured off and replaced by an identical fresh 
solution, to which lOpl 1° antibody (MAb 13C4 or MAb BC5 BB12 ) was 
added (to give a 1:1000 dilution). This was left shaking at room 
temperature overnight. Unbound 1° antibody was then removed by three 
10 minute washes in TBS containing 0.1% Tween 20. 10ml of fresh TBS- 
0.1% Tween 20 was then added containing lOpl 2° antibody ( Anti-mouse 
peroxidase conjugate, Sigma). After 1-2 hours incubation with shaking, at 
room temperature, the membrane was washed twice in TBS-0.1% Tween 
20 (10 minutes per wash) and twice more in TBS only. The membrane was 
then developed using the DAB/nickel method.
2.6 DAB/Nickel Development System
6 mg DAB (3' 3' diaminobenzidene tetrachloride) was dissolved in 9ml of 
0.05M Tris pH 7.6. To this, 1ml of a 0.3% w/v stock solution of nickel 
chloride in water, was added, followed by 0.1ml of a 3% solution of 
hydrogen peroxide in water. This solution was applied to the membrane,
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which developed in 1-20 minutes. The membrane was washed in water 
before the reaction was complete as development continued for 1 0  
minutes after washing.
2.7 Phage Induction
Plaque assays were carried out to demonstrate the presence of phages in 
culture filtrate from E.coli 0157:H7 which had been grown in the presence 
of l.Opgml'l mitomycin C. Ten-fold dilutions of the filtrate were made in 
modified LB broth (lOg tryptone, 5g yeast extract, 5g sodium chloride per 
litre, + lOmM calcium chloride & 0.001% thiamine). Each dilution was 
allowed to adsorb onto indicator cells, E.coli DH1 ( grown to an OD600 of 
0.5), for 20 minutes at 37°C. lOOpl samples from the absorption mixture 
were mixed with 3ml modified LB soft agar (0.7%). This was immediately 
poured into Petri dishes containing modified LB agar (1.5%). Plates were 
examined for the presence of plaques in the bacterial lawn after overnight 
incubation at 37°C.
2.8 Preparation of crude toxin for SDS-PAGE analysis.
2.8.1 Mitomycin C treatment
A single bacterial colony (0157:H7 ATCC 35150) was inoculated into 10ml 
Penassay broth (Difco Antibiotic medium No. 3) and incubated at 37°C 
overnight. 2.5ml of this culture was inoculated into llitre of fresh broth 
and incubated at 37°C until the bacterial suspension reached an OD600 
-0.5. At this stage, O.lpgml'l of mitomycin C was added to each flask. 
Seven flasks were set up in this way, so that one flask could be harvested 
every hour after addition of the drug. After harvesting the cells at 10,000g 
for 1 0  minutes, the supernatant was reduced in volume by differential 
ammonium sulphate precipitation.
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2.8.2 Ammonium sulphate precipitation
Solid ammonium sulphate was added to the supernatant at 4°C to 40% 
saturation, and after 30 minutes incubation at 4°C, with agitation, the 
precipitate was removed by centrifugation at 1 0 ,0 0 0 g for 1 0  minutes, and 
discarded. Further ammonium sulphate was added to the supernatant to 
60% saturation. The second precipitate containing the toxin was recovered 
by centrifugation as before. The pellet was resuspended in 10ml of 0.01 M 
phosphate buffer and dialysed overnight against 2  litres of this buffer, with 
3 changes of buffer. The crude toxin was then analysed by SDS-PAGE or 
further purified by hydroxylapatite column chromatography.
2.8.3 Hydroxylapatite column chromatography
The dialysed crude toxin preparation was applied to a 15 x 150mm 
hydroxylapatite column (Biorad) equilibrated with 0.01M sodium 
phosphate buffer, pH 7.2. After washing with two column volumes of this 
buffer, the crude toxin was eluted with 0.2M sodium phosphate buffer pH 
7.2. Protein levels were monitored at 280nm during elution, using a 
Pharmacia UV detector. 1ml fractions were collected, and fractions 
containing the protein peak were pooled and dialysed against 0.01 M 
sodium phosphate buffer overnight, with 3 changes of buffer. The 
dialysate was analysed by SDS-PAGE analysis.
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2.9 Polyacrylamide Gel Electrophoresis (PAGE)
2.9.1 SDS-PAGE
The following stock solutions were prepared:
Buffer A Buffer B
0.75M Tris-HCl pH 8 . 8  
0.2% SDS
0.25M Tris-HCl pH 6 . 8  
0.2% SDS
Acrylamide stock (1 0 0 ml)
44g acrylamide 
0 .8 g bisacrylamide
Samples were analysed on 11% resolving gels with 4.5% stacking 
gels. Gel plates were assembled according to the manufacturers 
instructions (LKB Biotechnology Inc.). The resolving gel was made up as 
shown below and poured using a 1 0 ml pipette immediately after addition 
of the ammonium persulphate and TEMED, so that the top of the gel was 
approximately 40mm below the top of the plate. After pouring, the gel was 
overlaid with water-saturated butanol and allowed to set for 30 minutes. 
The butanol was poured off, and 10ml Buffer B was poured onto the top of 
the gel, then thoroughly removed along with traces of butanol. The 
stacking gel was poured to the top of the gel plate and allowed to set 
around a comb, which on removal produced wells for sample loading. 
The gel was placed into the electrophoresis tank and running buffer 
(0.025M Tris, 0.129M glycine, 0.1% SDS) was added to the upper and lower 
reservoirs.
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Resolving gel (11%) Stacking gel (4.5%)
Buffer A 27ml Buffer B 1 0 ml
Acrylamide stock 13.6ml Acrylamide stock 3ml
Distilled water 1 2 ml Distilled water 7ml
Ammonium persulphate (10%) Ammonium persulphate
1.9ml 0.5ml
TEMED 130pl TEMED 40pl
Prior to loading, samples were boiled for 5 minutes in an equal 
volume of sample buffer which contained, per 40ml, 10ml 0.025M Tris- 
HC1 pH 6 .8 , 0.8g SDS, 4ml glycerol, 2ml 2-mercaptoethanol and 0.025g 
bromophenol blue. Sample buffer was made up in advance and stored at 
4°C. Denatured samples were then loaded onto the gel using a Hamilton 
syringe. Molecular weight standards (Pharmacia) were included on each 
gel.
Samples were run at 20mA through the stacking gel and 40mA 
through the resolving gel. When the dye front reached the lower edge of 
the gel, the power was switched off, and the gel removed from the 
apparatus. The samples were then stained by the silver nitrate method or 
transferred to nitrocellulose prior to immunoblotting.
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2.9.2 4-15% Non-Denaturing PAGE
The following stock solutions were prepared:
25% (w/v) acrylamide (100ml) 30% (w/v) acrylamide (100ml)
acrylamide 25g acrylamide 30g
bisacrylamide 1.25g bisacrylamide 0.15g
Lower gel buffer (100ml)
Tris 36.6g (pH 8 . 8  with HC1)
From these solutions, 4% and 15% gel solutions were made up.
4% (w/v) acrylamide solution 15% (w/v) acrylamide solution
25% (w/v) acrylamide 9.2ml 30% (w/v) acrylamide 10ml
lower gel buffer 7.5ml lower gel buffer 2 .6 ml
distilled water 40.8ml 30% (v/v) glycerol 7.4ml
TEMED 1 2 .2 pl TEMED 2 .6 pl
* ammonium persulphate 104.25pl * ammonium persulphate 26pl
* 1 0 % ammonium persulphate was made up immediately before use.
The 4% and 15% acrylamide solutions were placed into separate 
compartments of a gradient maker. The gel was then poured so that the 
acrylamide concentration ranged from 15% at the bottom of the gel to 4% 
at the top. The gel was placed in the electrophoresis tank containing 
running buffer (0.025M Tris, 0.129M glycine), and prerun for 1 hour at 
18mA. Samples were then loaded in a buffer containing 75% (v/v) glycerol
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and 0.1% (w/v) bromophenol blue. Gels were run at 18mA until the dye 
front reached the bottom of the gel.
After removal from the gel tank the samples were transferred to 
nitrocellulose.
2.10 Silver nitrate staining of polyacrylamide gels.
Samples which had been separated by PAGE were stained by the silver 
nitrate method of Wray et al (1981). A modification of this method was 
used to stain LPS.
2.10.1 Protein staining
After PAGE the gel was soaked in 50% methanol, in a sandwich box, for at 
least 8  hours, with three changes of wash. 2.5ml ammonia was added to 
42ml 0.36% (w/v) sodium hydroxide in a measuring cylinder. To this, 
silver nitrate (1 .6 g dissolved in 8 ml distilled water) was added with 
shaking, until the solution was transparent. Distilled water was then 
added to a total volume of 200ml. The gel was stained in this solution for 
15 minutes, with shaking. After thoroughly washing out the box, the gel 
was washed twice for 5 minutes in distilled water. The stain was 
developed in 500ml of a solution containing 2.5ml of 1% (w/v) citric acid 
and 0.4ml formaldehyde solution.
To stop the stain, 500ml of a solution containing 225ml methanol 
and 50ml acetic acid was added. The stained gel was then photographed on 
a light box.
2.10.2 LPS staining
After PAGE, the gel was fixed overnight in 200ml of a solution containing 
25% (v/v) isopropanol in 7% (v/v) acetic acid. The gel was then soaked for 
5 minutes in an oxidising solution (150ml distilled water containing 1.05g
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periodic acid and 4ml 25% (v/v) isopropanol in 7% (v/v) acetic acid) 
which was made up just before use.
After eight 20 minute washes in distilled water, the gel was stained 
for 10 minutes in : 0.1M sodium hydroxide (28ml), concentrated ammonia 
(lml), 20% (w/v) silver nitrate (5ml), and water 115ml. This solution was 
used immediately after preparation. Excess stain was removed by four 10 
minute washes in water.
A developing solution was made up containing 50mg citric acid and 
0.5ml of 37% formaldehyde per litre. It was essential to keep this solution 
at 25°C as at higher temperatures, staining of protein as well as LPS occurs. 
The stain was developed in this solution for 10-20 minutes until bands 
appeared. To stop the developer, the gel was placed in 200ml distilled 
water containing 10ml of 7% (v/v) acetic acid for 1 hour. The stained gel 
was then washed and stored in distilled water prior to photography.
2.11 Protein Assay
Protein concentrations were determined by the method of Lowry et al 
(1951).
Reagents: A 5% sodium carbonate 
B (i) 1% C uS04.5H 20
(ii) 2 % sodium potassium tartrate 
C 50ml reagent A + lml B (i) + lml B (ii)
- used immediately.
Each sample was diluted as appropriate, and 0.5ml were added to 
two boiling tubes. To each tube, 0.5ml 1M sodium hydroxide was added, 
followed by 2.5ml of reagent C. After 10 minutes incubation at room 
temperature, 0.5ml of 50% (v/v) Folin-Ciocalteu reagent in water, was 
added to each tube, and thoroughly vortexed. Tubes were then incubated
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at room temperature for 30 minutes to allow the development of a colour 
reaction. The optical density of each tube was read at 650nm. To assess 
protein levels, a series of protein solutions (bovine serum albumin) of 
known concentrations (0-lmg protein) were tested in parallel. The optical 
densities of the standard solutions were used to draw a calibration curve 
from which the protein concentrations of unknown solutions were 
extrapolated.
2.12 Plate ELISA
100pl MAb to either VT1 or VT2 diluted 1:1000 in coupling buffer (sodium 
carbonate 0.795g, sodium hydrogen carbonate 1.465g in 500ml distilled 
water, pH 9.6) was added to each well of a 96-well ELISA plate. The plate 
was sealed with plastic film and incubated overnight at 4°C. The MAb 
acted as capture antibodies to concentrate the antigen.
Unattached antibodies were removed by washing the plate 3 times 
in ELISA wash, a saline solution containing 0.1% (v/v) Tween 20. To 
prevent non-specific binding of antigen, each well was blocked for 1 hour 
at 37°C with lOOpl ELISA diluent (0.6g Tris, O.lg bovine serum albumin in 
100ml ELISA wash, adjusted to pH 7.4 with glacial acetic acid). The plate 
was washed 3 times in ELISA wash.
1 0 0 pl of a 1 : 1 0  dilution of antigen (culture filtrate) was added to each 
well and incubated at 37°C for 1 hour. lOOpl polyclonal rabbit anti-VT 
(1:100, antiserum was a gift from S. Scotland) was added to each well and 
incubated at 37°C for 1-2 hours, then washed 3 times to remove 
unattached antibodies. Anti-rabbit peroxidase conjugate (Sigma) diluted 
1:1000 in ELISA diluent was then added. After incubation at 37°C for 1 
hour, the plate was washed 3 times with ELISA wash.
TMB substrate was made up from 10ml substrate buffer (0.1M 
sodium acetate adjusted to pH 5.2 with glacial acetic acid), lOOpl TMB
55
(58mg tetramethylbenzidine dissolved in 10ml DMSO) and lpl hydrogen 
peroxide. lOOpl of this solution was added to each well and incubated at 
37°C for 10 minutes. The reaction was stopped by addition of 50pl 2M 
sulphuric acid, and the absorbance of each well was read at 450nm using a 
Biorad ELISA plate reader.
The following controls were included in each ELISA: 1. The antigen was 
omitted, and replaced by broth instead of culture supernatant, or PBS in 
place of sonicate. This ensured that the polyclonal antiserum did not bind 
non-specifically. 2. The primary antibody (anti-VT polyclonal) was omitted 
to ensure that the anti-rabbit serum was binding only to rabbit antigens 
(the MAb were of mouse origin).
No antigen was added to the first row of wells in each plate, as a blank for 
the plate reader.
2.13 Chemical mutagenesis
E.coli 0157:H7 was grown overnight at 37°C in Penassay broth (Difco 
Antibiotic medium no.3). 500pl was then harvested in a microfuge and 
resuspended in 10ml of fresh Penassay broth. After incubation at 37°C for 1 
hour, O.lpgml'l mitomycin C was added, before further incubation at 37°C 
for 2 hours. The bacterial suspension was then serially diluted and plated 
onto Penassay agar plates to obtain single colonies.
After overnight incubation, six of these clones were subcultured 
onto fresh agar. Plasmids were isolated from these clones and analysed by 
agarose gel electrophoresis.
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2.14 Small-scale preparation of plasmid DNA
2.14.1 Isolation of Plasmids
Plasmid DNA was extracted using an alkaline lysis method.
1.5ml of an overnight culture, in an Eppendorf tube, was 
centrifuged in a microfuge for 1 minute. The medium was removed by 
aspiration and the pellet was resuspended by vortexing in lOOpl of cell 
resuspension solution. After 5 minutes at room temperature, 200pl of a 
freshly prepared cell lysis solution was added, and mixed gently by 
inverting the tube 2 or 3 times. The tube was stored on ice for 5 minutes 
after which 150pl of ice-cold neutralisation solution was added and mixed 
by inversion of the tube several times. After 5 minutes on ice the 
preparation was centrifuged in a microfuge at 4°C. The supernatant was 
transferred to a fresh tube and an equal volume of phenol/chloroform 
was added and mixed by vortexing. After centrifugation for 2 minutes the 
supernatant was transferred to a fresh tube. 2  volumes of ice-cold 1 0 0 % 
ethanol were added and mixed by vortexing. After 2 minutes at room 
temperature, the tube was centrifuged for 5 minutes in a microfuge. The 
supernatant was removed by aspiration and the pellet, containing the 
plasmid DNA, was dried under vacuum for 5-10 minutes. The dried pellet 
was resuspended in 50pl TE (lOmM Tris-HCl pH 8.0, ImM EDTA) 
containing DNAse-free pancreatic RNAse (20pgml'l).
Plasmid DNA was analysed by agarose gel electrophoresis on 0.7% 
agarose gels.
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The following solutions were used in the preparation of plasmid DNA:
Cell resuspension Cell lysis solution Neutralization
solution solution
50mM Glucose 0.2M sodium 5M potassium acetate
hydroxide 60ml
lOmM EDTA 1% SDS Glacial acetic acid
11.5ml
25mM Tris-Cl pH 8.0 Distilled water 28.5ml
4mgml-l lysozyme *
* Powdered lysozyme was added to the solution just before use.
2.14.2 Agarose gel electrophoresis
Agarose gels were used to separate plasmid bands. 0.7g agarose was 
dissolved in 100ml lxTBE (lOx TBE contains 1 ) by boiling for several 
minutes. After cooling to -50°C, lOpl ethidium bromide (lOmgml'l) was 
added to the gel before pouring into a horizontal gel tank (Hybaid) 
containing a well-forming comb. After setting, the comb was removed, 
and buffer (lxTBE) was added to the tank so that the gel was just covered. 
DNA samples were added to 6 X loading buffer (40% sucrose + 0.25% 
bromophenol blue) before loading. Gels were run for 3-4 hours at 100V.
2.15 Api20E Tests
Api 20E tests were carried out according to the manufacturers instructions. 
A single bacterial colony was resuspended in distilled water, and dispensed 
into the cupules of an assay strip. Reactions which required an anaerobic 
environment were overlaid with mineral oil. The assay strips were
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incubated for 16-20 hours at 37°C, then developed using reagents supplied 
by the manufacturer, where necessary. The results were translated into a 7- 
digit figure and from this, using the Apilab software, the identity of the 
organism was deduced.
2.16 Saline Extraction of Heat-Stable Antigens
Confluent bacterial growth from four nutrient agar plates was transferred 
to 4ml of 0.9% (w/v) sodium chloride, and heated at 100°C for 60 minutes. 
Cells were pelleted by centrifugation at 10,000 rpm for 10 minutes and the 
supernatant, containing soluble antigens, was filtered through a 0 .2 2 pm 
membrane filter, and stored until use, at 4°C.
2.17 Passive Haemagglutination Assay
Saline-extracted antigens were diluted 1:10 in PBS (pH 7.0) and incubated 
for 60 minutes at 37°C with an equal volume of a 1 % suspension of sheep 
red blood cells (RBC), previously washed in PBS. The sensitized RBC were 
centrifuged, washed three times in PBS, and resuspended in PBS to give a 
0.5% RBC suspension.
Two-fold dilutions of antibody to 0157:H7 (previously diluted to 
1:40) were made in a 96-V-shaped well microtitre tray (25pl per well). 25pl 
sensitized RBC were added to each well, and the plates were shaken gently 
to mix the contents of each well. After incubation for 60 minutes at 37°C, 
haemagglutination was observed by eye. The titre was recorded as the 
highest dilution of antiserum to give agglutination of sensitized RBC. Pre- 
immune serum was used in negative control assays.
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2.18 Oxoid 0157 Latex Agglutination Test
This test was carried out according to the manufacturers instructions. 
Briefly, bacterial cells were mixed on a glass slide, with latex particles 
coated with 0157. Any bacteria able to agglutinate the latex particles were 
further tested with negative control latex particles. Agglutination of these 
particles was indicative of non-specific agglutination.
2.19 Western Blotting
2.19.1 Preparation of Whole Cell Antisera
Bacteria were grown up overnight at 37°C in 10ml Penassay broth (Difco 
Antibiotic Medium no.3), harvested by centrifugation, and washed twice 
in PBS (pH 7.0). Cells were further incubated at 37°C, overnight, in 1% 
Formalin (v/v). After centrifugation, the cells were washed six times in 
PBS to remove Formalin, then resuspended in 2ml PBS. lOOpl of this 
suspension was plated onto nutrient agar and incubated overnight at 37°C, 
to ensure that all bacteria were dead.
0.5ml of formalinised bacteria were injected intravenously into a 
New Zealand White rabbit. The procedure was repeated after two weeks 
and again after four weeks. After 10 weeks the rabbit was bled from an ear 
vein. 10ml of blood was collected at each bleeding. Blood was stored at 4°C 
for 24 hours before serum was removed using a Pasteur pipette and 
centrifuged at 1500g for 20 minutes to remove red blood cells. Serum was 
stored in 1ml aliquots at -20°C.
Preimmune serum was obtained by bleeding the rabbit in the same 
way, before immunization with formalinized bacteria.
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2.19.2 Immunoblotting
A modification of the method described by Towbin et al (1979) was used 
for the transfer of saline-extracted antigens from SDS-PAGE gels to 
nitrocellulose membranes.
A nitrocellulose membrane filter (Amersham pic) was cut to the 
size of the polyacrylamide gel, and soaked, with the gel, in Western 
transfer buffer (25mM Tris-HCl pH 8.3, 192mM glycine, 20% (v/v) 
methanol). The membrane was then placed on top of the gel, with the 
exclusion of air bubbles, and sandwiched between soaked Whatman no. 1 
paper cut to the same size. This was placed in the holder of a Biorad 
Transblot tank, and transfer of the proteins from the gel to the 
nitrocellulose was carried out according to the manufacturers instructions, 
at 300mA for 3 hours.
After transfer, the nitrocellulose filter was rinsed in distilled water 
to remove salt, from the buffer, and soaked in 100ml Ponceau S (0.5% 
(w/v) in 5% trichloroacetec acid). After rinsing briefly to remove excess 
dye, the positions of the molecular weight standards were marked on the 
membrane.
The nitrocellulose membrane was soaked briefly in 20ml TBS 
(150mM sodium chloride, 50mM Tris-HCl pH 8.0), in a sandwich box, 
until all traces of the dye were removed. Fresh TBS containing 2% dried 
skimmed mik (Marvel), which acted as a blocking agent, was added and 
incubated, with shaking, at room temperature. After 30 minutes this 
solution was poured off and a fresh TBS-Marvel solution was added, 
containing primary antibody (anti-0157:H7 or anti-026:H ll) at a final 
dilution of 1:500. This was incubated, with shaking, overnight at room 
temperature.
The solution containing primary antibody was discarded, and the 
nitrocellulose membrane was washed three times ( 1 0  minutes /wash) in
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TBS containing 0.1% Tween 20. A fresh solution of TBS-Tween 20 was 
added, containing a 1 : 1 0 0 0  dilution of secondary antibody (anti-rabbit 
peroxidase conjugate, Sigma). This was incubated on a shaker at room 
temperature for 1 - 2  hours, after which the filter was washed twice ( 1 0  
minutes /wash) in TBS-Tween 20 and twice in TBS only. The membrane 
was then developed using the chloronaphthol method.
2.19.3 Chloronaphthol development system
Solution A (1.5g sodium chloride, 1ml 1M Tris-HCl pH 7.5 made up to 
50ml with water) and solution B (50mg 4-chloronaphthol, 10ml methanol 
made up to 50ml with water) were prepared less than 1 hour before use. 
50pl of hydrogen peroxide were added to solution A, before solutions A 
and B were mixed. The mixture was added to the membrane, and shaken 
gently at room temperature until a colour reaction developed (5-30 
minutes). The membrane was removed from the solution before the 
reaction went to completion, and placed into distilled water. The water 
was changed 3 times over a 30 minute period, after which the 
nitrocellulose membrane was dried on filter paper and stored in the dark.
2.20 Outer Membrane Preparation
100ml LB broth (lOg tryptone, 5g yeast extract, lOg sodium chloride per litre 
pH 7.0) was inoculated with 1ml of an overnight bacterial culture and 
incubated with shaking at 37 °C for several hours to allow cells to reach 
mid-exponential phase (4x10® cells m l'l). After centrifugation at 10,000 
rpm for 10 minutes at 4°C, cells were resuspended in 10ml of lOmM Tris- 
C1 pH 8  and sonicated (3 x 30 second bursts). Unbroken cells were removed 
by centrifugation at 3000 rpm for 20 minutes at 4°C. The resulting 
supernatant was centrifuged at 20,000 rpm for 60 minutes at 4°C. The pellet
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containing the outer membrane was resuspended in 150ml distilled water 
and stored at -20°C.
The crude outer membrane preparation was thawed, and 50pl 
samples were extracted with 8  volumes of a detergent solution containing 
1.67% (w/v) Sarkosyl and ll.lm M  Tris-Cl pH 7.6 for 20 minutes at 20°C. 
The insoluble outer membranes were pelleted by centrifugation at 20,000 
rpm for 90 minutes at 20°C. The pellet was suspended in 50pl of SDS- 
PAGE sample buffer prior to analysis by SDS-polyacrylamide gel 
electrophoresis.
2.21 Neutral Sugar Analysis
2.21.1 Phenol Extraction of Lipopolysaccharide
2g of freeze-dried E.coli 0157:H7 cells, or mutant cells of this serotype, were 
resuspended in 100ml of distilled water at 67°C. 100ml of 91% phenol 
(w/v), preheated to 67°C, were added, and the mixture was stirred at 67°C 
for 20 minutes. The homogenate was cooled in iced water and was 
continuously stirred for 5 minutes before centrifugation at 3000g for 20 
minutes at 20°C. The upper aqueous phase was carefully removed and 
kept at room temperature, before the lower phenolic phase was reheated 
to 67°C. 75ml of distilled water, preheated to 67°C were added to the 
phenolic phase, and after mixing and centrifugation as before, the phases 
were separated. The aqueous phases were pooled, and alongside the 
remaining phenol phase, were dialysed against running water to remove 
the phenol. The combined aqueous phases were dialysed for 2-3 days 
whereas the phenol phase required 7 days. Cell debris was removed from 
the dialysed phenol phase by centrifugation at 2000g for 20 minutes. The 
volume of each phase was reduced to approximately 30ml by rotary 
evaporation at room temperature. The concentrated extracts were
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centrifuged at 105,000g for 4 hours at 4°C in a 60 Ti Beckmann rotor. The 
LPS pellet from each phase was resuspended in water with a glass 
homogeniser and recentrifuged twice as above. After the final 
centrifugation the pellets were freeze-dried.
2.21.2 Thin Layer Chromatography
The neutral LPS sugars were analysed by thin layer chromatography (TLC).
To lmg of freeze-dried LPS, 1 0 0 (0.1 of 0.5M H2 SO4  was added. After 
hydrolysis for 4 hours at 100°C, the mixture was neutralised with a 
saturated solution of barium hydroxide. Small samples were spotted onto 
indicator paper to test for neutralisation. The hydrolysis tubes were then 
spun at 3000g for 15 minutes to pellet barium sulphate formed during 
neutralisation. The supernatants were removed and then freeze-dried.
For analysis by TLC, hydrolysates were resuspended in 1 Ojol water. 
2|ol samples were then spotted onto cellulose-coated glass plates (Merck). 
Further samples were applied, with drying between each application. 3(il 
of sugar standards were also loaded, containing lOmgml'l of glucose, 
rhamnose, mannose, galactose, ribose and fucose.
Plates were placed in a tank containing a solvent system of n- 
butanol ¡pyridine:water in a ratio of 6:4:3 volumes. The solvent had been 
stored for 24 hours in the tank to allow the atmosphere to become 
saturated. The plates were left in the tank for several hours until the 
solvent front was approximately 1cm from the top. After removal from 
the tank the plates were allowed to air-dry. They were then returned to the 
tank and rerun in the same direction, as before. This allowed better 
separation of the sugars. After drying, the plates were developed by 
spraying with anilinium hydrogen phthalate (0.7ml aniline, 1.6g O- 
phthalic acid in 100ml n-butanol saturated with water). Sugars were 
visualised after baking at 100°C for 10-15 minutes.
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2.22 Hydrophobicity studies
2.22.1 Microbial Adhesion to Hydrocarbons (MATH)
This method was described by Rosenberg et al (1980).
Bacteria were grown in 10ml volumes, overnight at 37°C. Cells were 
harvested by centrifugation, washed twice, and resuspended in 1 .2 ml of 
PUM buffer (22.2g K2 H PO 4 .3 H 2 O, 7.26g KH2 P O 4 , 1.8g urea, 0.2g 
M gS0 4 .7 H2 0 , per litre distilled water, pH 7.1). The optical density at 
400nm was determined spectrophotometrically and adjusted, if necessary, 
to give a standard opacity for each bacterial suspension. A volume of n- 
hexadecane (0.1-0.4ml) was added, and after 10 minutes of incubation at 
30°C the contents of each tube were mixed uniformly in a vortex mixer for 
2 minutes. After allowing 15 minutes for the phases to separate, the OD4 0 0  
of the lower phase was measured, and compared to the initial reading. The 
fraction of adherent cells was taken as the percentage decrease in OD4 0 0  of 
the aqueous phase after mixing and phase separation, as compared with 
that of the original separation.
2.22.2 Salt Aggregation Test (SAT)
SAT was carried out as described by Lindahl et al (1981).
Ammonium sulphate concentrations in sodium phosphate buffer 
(pH 6.8, 0.02M) ranging from 4M to 0.02M, in 0.2 increments, were 
prepared. lOpI aliquots of bacterial suspensions were spotted onto an equal 
volume of each of the salt concentrations, on glass slides. The slides were 
rocked gently for 1-2 minutes until aggregation was observed. The last 
dilution at which aggregation occurred was recorded. Bacterial 
suspensions used were of standard opacity so that equivalent cell 
concentrations were used in each test.
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2.22.3 Hydrophobic Interaction Chromatography (HIC)
The method of Mozes & Rouxhet (1987) was used.
Glass Pasteur pipettes were plugged with glass wool and packed to a 
height of 20mm with octyl-Sepharose CL-4B (Sigma). The column was 
washed with 20 bed-volumes of sterile PBS. Bacterial strains of the same 
optical density, were suspended in 2ml of the same buffer and the optical 
density at 580nm was measured before loading onto the column. The 
absorbance reading of the eluent was measured at 580nm (the first 2ml 
from the column was discarded as void volume). The percentage 
hydrophobicity was calculated by the formula;
ODi - ODe x 100 = % hydrophobicity 
ODe
where ODi was the absorbance of the suspension before loading onto the 
column and ODe was the absorbance of the eluent.
2.23 Attachment Studies
2.23.1 Attachment of Bacteria to Mucus
Mouse colonic mucus, which had been isolated by colonic washing, was 
provided (M Krishna). Mucus was run out on a 4-15% native gel (Section 
2.9.2), and transferred to nitrocellulose overnight, using a Biorad Transblot 
apparatus. The membrane was then blocked in 3% Marvel in TBS (150mM 
sodium chloride, 50mM Tris-HCl pH8.0). After washing in TBS, the 
membrane was probed with 10ml of an overnight bacterial culture 
(>10^m l"l) for 2 hours. Unattached bacteria were removed by washing 
twice in TBS, and antiserum (anti-E.co/i, provided by M Krishna) was 
added in TBS at a dilution of 1:1000, for 1.5 hours. The membrane was 
washed thoroughly in TBS to remove unbound antibodies, after which
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secondary antibody (anti-rabbit peroxidase conjugate, Sigma) at 1:1000 in 
TBS was added for 1 hour. After washing several times with TBS, the 
membrane was developed using the chloronaphthol method.
A control was carried out, using nutrient broth instead of a bacterial 
culture, to check that the antibodies used did not bind directly to the 
mucus.
2.23.2 Attachment of Bacteria to HeLa cells
HeLa cells were inoculated into 12-well tissue culture dishes (4xlo5m l'l) 
in 199 medium (Flow), and allowed to form monolayers overnight in 5% 
CC>2 at 37°C. Cells were then washed 3 times in PBS (pH 7.0).
Bacteria (10**) were resuspended in 2ml 199 medium and added to 
the HeLa cells. The tissue culture dishes were incubated at 37°C for 3 hours 
to allow the bacteria to attach. The culture medium was then removed 
and the HeLa cells were washed 6 times in PBS to remove loosely attached 
organisms. The HeLa cells with adherent bacteria were removed from the 
plate with 0.5ml 0.25% trypsin, and HeLa cells were lysed with 0.5ml BSA 
(0.1% in water). After vortexing, lysates were serially diluted tenfold in 
sterile PBS, and plated out in duplicate to calculate the number of viable 
bacteria adherent to the HeLa cells.
Inhibition studies were also carried out, where whole cell 
antiserum (lOOpl), raised against 0157:H7 ATCC 35130, was added with the 
bacteria. Pre-immune serum controls were included and results were 
expressed as a percentage of bacteria adherent to cells in the presence of 
pre-immune serum.
HeLa cells were cultured as for Vero cells (section 2.3.1)
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2.23.3 Staining Tissue Culture Cells
The attachment of bacteria was viewed microscopically by staining the 
cells after the washing step which removed unattached bacteria.
Tissue culture cells which were to be stained were grown on 13mm 
round coverslips in 24-well plates. To stain cells, the coverslip was air- 
dried and then fixed for 5-10 minutes in a solution composed of 3 parts 
methanol to 1 part glacial acetic acid, which was made fresh and kept on 
ice. It was necessary to then wash the coverslip 3 times in 95-100% 
methanol to remove the acid which would prevent staining. Each wash 
lasted 5 minutes. After the final wash the coverslip was air-dried. The cells 
were then stained in 5% Gurr Giemsa stain in phosphate buffer for 5-10 
minutes. Excess stain was removed by washing with tap water. The slide 
was then air-dried, mounted and viewed by light microscope.
2.24 Immunogold labelling
Immunogold labelling was carried out by Nicholas Powell at the Clinical 
Research Centre, Northwick Park Hospital, Harrow.
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Chapter 3 The Development of Toxin Assays and the Effect of 
Mitomycin C on Verotoxin Production.
3.1 The Development of Assay Systems
In any study on toxins, it is essential to have a reliable assay system. The 
assay of choice will depend upon the aspect of toxin production which is of 
importance to the study. If toxin activity is investigated for example, an 
assay which detects this property would be chosen, such as a cytotoxicity 
assay using a susceptible cell line. Immunoassays using antibodies raised 
against the toxin will monitor the production of toxin, but will not 
confirm that the toxin is biologically active. Alternatively, it may be only 
the presence of the toxin gene which is of interest, in which case DNA 
hybridisation studies would suffice as an assay system. Such studies would 
probably be followed up by assaying for the toxin itself, to confirm that the 
gene was expressed.
In this study, both a cytotoxicity assay and an immunoassay were 
required. A Vero cell assay was chosen as a method of assessing toxin 
activity, and two immunoassays were compared to find a rapid method of 
detecting toxin production, and differentiating between VT1 and VT2. 
Through a combination of these assays it was possible to characterise the 
production of toxin by mutants of 0157:H7 ATCC 35150. The Vero cell 
assay was further used in a study of the internalisation mechanisms of 
VT1 and VT2.
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3.1.1 Cytotoxicity Assay
3.1.1.1 Introduction
VT were originally described after the cytotoxic effect of an E.coli culture 
filtrate on Vero cells was observed (Konowalchuk et al 1977); and a Vero 
cell cytotoxicity assay has remained an important method of identifying 
VT. When unknown samples are tested, it is important to incorporate a 
neutralization step with anti-VT serum to confirm that the cytotoxic 
action results from VT and is not due to an unrelated toxin or a result of 
non-specific cell death. Kongmuang et al (1988) have produced mutant 
Vero cells which have lost the VT receptor, Gb3 - VT are cytotoxic towards 
parent but not mutant cells, whereas other toxins, which attach to 
different receptors on the Vero cells, are either cytotoxic towards both cell 
types, or do not affect either cell type. Such a modification of Vero cells 
improves the specificity of the tissue culture assay, since although it is 
time-consuming and requires specialized equipment it remains one of the 
most sensitive assays for VT.
In the present study, the strains used were known to produce VT, 
and this was confirmed by cytotoxicity assays and neutralization tests. Two 
other E.coli strains, which do not produce VT, had no effect on the Vero 
cells.
3.1.1.2 Results and Discussion
Culture filtrates of several E.coli strains were titrated across 96-well 
microtitre plates. Filtrates containing VT were cytotoxic towards the cells 
as shown in Figure 3.1. Toxin titres (TC5 0 ) were calculated as the reciprocal 
dilution of culture filtrate to kill 50% of cells, as assessed microscopically.
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Four VTEC strains were tested: 026:H11 E3787 (a VT1-producer), 
0157:H- E32511 (a VT2-producer), 0157:H7 (reference strain ATCC 35150) 
and 0157 (clinical isolate). All strains were cytotoxic towards Vero cells 
(Table 3.1). To confirm that the CPE were caused by VT, neutralisation 
assays were carried out, whereby neutralising monoclonal antibodies 
against VT1 and VT2 were incorporated into the cytotoxicity assays. The 
antibodies reduced the TC5 0  of all strains confirming that the CPE on Vero 
cells were due to VT (Table 3.1). The 0157:H7 and 0157 strains produced 
both VT1 and VT2, so MAb against both toxins were used to produce the 
neutralisation titre. Neither of the non-VTEC E.coli strains tested, K12 and 
026:H11 (an EPEC strain) had any effect on Vero cells.
Strains E3787 and E32511 were used as positive controls to ensure 
that the Vero cells used were susceptible to both VT1 and VT2. The fact 
that the titre of VT1 was considerably lower than that of VT2 can be 
explained by the fact that VT1 is thought to be almost completely cell- 
associated whereas VT2 is more equally distributed between the interior of 
the cell and the surrounding medium (Strockbine et al 1986). Thus in a 
situation where no agents such as mitomycin C or polymyxin B are 
present to extract intracellular toxin, lower levels of VT1 compared to 
VT2, would be expected.
3.1.2 Latex Agglutination Assay
3.1.2.1 Introduction
Agglutination of antibody-coated latex particles has frequently been used 
to detect homologous antigens. Commercial latex agglutination tests are 
available to detect many medically important bacteria including E.coli 
0157. These tests generally depend upon assessment of agglutination by
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Table 3.1 Cytotoxicity Assay
E.coli strain TC5 0 Neut. titre
E3787 (VT1 producer) 128 32
E32511 (VT2 producer) 131,072 4096
0157:H7 (reference strain) 32 4
0157 (clinical isolate) 32 4
026:H11 (EPEC) No CPE
K12 No CPE
Culture filtrates were titrated across Vero cells grown in 96-well microtitre 
plates. TC5 0  represents the reciprocal filtrate dilution to kill 50% cells 
assessed microscopically after 20-24 hours incubation at 37°C in 5% CO2 . 
Incorporation of neutralising anti-VT MAb confirmed the identity of the 
toxins by a reduction in TC5 0  (Neut titre).
Results shown were reproducible in triplicate, and when carried out on 
different days.
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eye, compared to a negative, and sometimes a positive, control. With 
some of these kits, including the 0157 test, false positive identification has 
been reported (Borczyk et al 1990).
In this study, an alternative method of detecting agglutination of 
latex particles was employed, that of particle size counting using a Coulter 
counter. The latex particles were coated with monoclonal antibodies 
against either VT1 or VT2. Specific and non-specific agglutination was 
easily differentiated although attempts to distinguish between VT1 and 
VT2 production were unsuccessful.
3.1.2.2 Results and Discussion
Agglutination of latex particles coated with anti-VTl in the presence of an 
0157:H7 culture filtrate is demonstrated in Figure 3.2. The first peak 
represents single latex particles (volume 0.141mm3 = diameter 0.73pm) 
and the smaller peak (volume 0.226mm3= diameter 1.46pm), results from 
agglutination of these particles due to the formation of complexes between 
antigen in the culture filtrate and antibody adsorbed onto the latex particle. 
It was possible to convert the volume reading to a diameter using the 
Coulter counter. When a culture filtrate of 026:H11, a non-VT-producer, 
was used as a source of antigen no agglutination was seen, and the small 
peak corresponding to agglutinated latex particles results from non-specific 
agglutination only (Figure 3.2.). The ratio of the height of the peak 
representing single latex particles to that representing agglutinated 
particles is significantly smaller when the antigen is homologous to the 
antibody coating the particles. 0157:H7, which produces VT1, gave a ratio 
of 3:1 for single: multiple latex particles . This ratio was 10:1 when a non- 
VT-producer was used (Figure 3.2), therefore this method could be used to 
detect at least high-level VT-producers. Ratios of around 3:1 were
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obtained when known VT1- and VT2 -producers (E3787 and E32511) were 
reacted with latex particles coated with the homologous antibody, whilst a 
non VT-producer, E.coli K12, gave a ratio greater than 10:1 with both anti- 
VT1 and anti-VT2 coated particles.
This method was not suitable for differentiating between VT1 and 
VT2 as some cross-reaction occurred using these monoclonal antibodies. 
Working with the same MAb Downes et al (1988) reported similar cross­
reaction. Latex particles were coated with either anti-VTl or anti-VT2, and 
reacted with culture filtrate from E3787, a VTEC strain known to produce 
only VT1. The ratio of peak sizes was 2:1 for the homologous antigen- 
antibody system, but was 3:1 when anti-VT2 was used, indicating that 
significant agglutination had occurred. From the earlier experiment, it was 
assessed that a ratio of around 10:1 corresponded to a negative result. It 
was clear therefore that cross-reaction had occurred between VT2 and anti- 
VTl.
It would be appropriate to use this method for detection of VT, 
although with these MAb it would not be possible to assess the type of 
toxin produced. For maximum detection it may be appropriate to use a 
mixture of VT1 and VT2 antibodies in a latex agglutination assay.
3.1.3 Colony ELISA
3.1.3.1 Introduction
Since VT are produced during the late log growth phase of VTEC 
(MacLeod & Gyles 1989) , it is necessary to grow bacteria, usually 
overnight, to obtain detectable levels of toxin. In order to screen 
several strains comparatively, it is advantageous to grow all
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Figure 3.2. Latex agglutination assay.
Latex particles coated with MAb against VT1 were reacted with a 
culture filtrate of a) 0157:H7 and b) 026:H11
0.141pm3 and 0.226pm3 correspond to single latex particles and 
agglutinated latex particles respectively. The count and size are 
expressed in arbitrary units.
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Figure 3.3 Latex agglutination assay
Culture filtrate from a VTl-producer (E3787) was reacted with latex 
particles coated with MAb against a) VT1 and b) VT2.
The peaks at 0.141pm3 and 0.226pm3 correspond to single latex particles 
and agglutinated latex particles respectively. The count and size are 
expressed in arbitrary units.
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organisms on a single agar plate. This ensures that all strains have been 
subjected to the same conditions, and allows direct comparison of toxin 
levels. To satisfy these criteria, a colony ELISA was developed using 
monoclonal antibodies, which allowed detection of VT1 and VT2 within 
the cell. Colonies were transferred onto nitrocellulose membrane and 
then incubated in the presence of polymyxin B. This drug permeabilises 
the cell membrane allowing release of intracellular toxin without affecting 
normal levels of toxin production.
3.1.3.2 Results and Discussion
Figure 3.3 shows that the VT1 positive control (C600933J) reacted more 
strongly with the MAb against VT1 than did any of the test organisms 
apart from S.dysenteriae. type l.The strong reaction of S.dysenteriae type 1 
with anti-VTl emphasizes the antigenic relatedness of Shiga toxin to VT1. 
Of the test organisms only 0157:H7 (ATCC 35150) and the clinical isolate of 
0157 gave a positive reaction. This shows that the two E.coli strains 
026:H11 and K12 did not produce VT1. The VT2 positive control 
(C600933W) did not react with the anti-VTl MAb, so at least in this assay, 
cross-reaction does not occur and the two toxin types can be differentiated.
The colony ELISA using MAb to VT2 gave similar results, in that 
only the positive control and the two 0157 strains were positive. These 
reactions were not as strong as those for VT1, which apparently contradicts 
the results of the cytotoxicity assays where VT2 titres were consistently 
higher than those of VT1. Since VT1 is predominantly cell-associated 
however, polymyxin B treatment allows detection of intracellular toxin 
not released during Vero cell assays. Thus VT1 levels were considerably 
higher in the colony ELISA than in the cytotoxicity assay. It is possible that 
total VT2 levels are lower than those of VT1, as observed by Strockbine et
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al (1986), although using higher concentrations of antibody for the colony 
blots using anti-VT2 may have improved the intensity of the positive 
reactions. Significantly S.dysenteriae, type 1 which reacted most strongly 
with anti-VTl, did not react at all with anti-VT2, further proof that there is 
no cross-reaction between the MAbs in this assay. In a similar 
immunoassay, Perera et al (1988) found that low-level VT producers could 
not be detected, and these results indicate that this applies to this assay, 
even though a more sensitive developing system was used. From a 
clinical viewpoint, however, this is unlikely to be a problem since E.coli 
producing low levels of VT are not implicated in disease (Marques et al 
1986).
These results indicated that the strain of 026:H11 did not produce 
either VT1 or VT2. As some strains of this serotype are VT-producers, this 
strain is an ideal organism to use as a negative control. Further studies by 
S.Fox (personal communication) using DNA probes, confirmed that this 
026:H11 strain does not carry the genes for VT production.
The colony ELISA seemed to be a reliable assay for VT and there did 
not appear to be cross-reaction between VT1 and VT2, which was a 
problem with the latex agglutination assay (section 3.1.2). This may in part 
be due to the repeated washing involved in the colony ELISA which 
would remove cross-reacting antibodies, however, this discrepancy 
between the latex and colony blot tests cannot fully be explained. An 
immuno-dot-blot assay evaluated by Panigrahi et al (1987) for detection of 
S.typhim urium  toxin was also found to be more sensitive than latex 
agglutination tested in parallel. This assay was similar to the colony ELISA 
in the present study, except that instead of testing cell-bound toxin, 
extracted toxin was spotted onto membranes. This technique was also 
successfully tested in the present study using culture filtrates as the toxin
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Figure 3.4 Colony ELISA
Colonies were transferred to nitrocellulose and treated with polymyxin B. 
Toxin was detected using MAb against a) VT1 and b) VT2.
The DAB/nickel chloride development method was used.
Control organisms were: VT1 - C600933J, VT2 - C600933W
Test organisms were : 0157:H7 (ATCC 35150), 0157 -clinical isolate (Cl),
E.coli K12 , E.coli 026:H11 (EPEC strain), S.dysenteriae type 1 (SD),
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source. However, using colony ELISA it is possible to test many strains on 
a single agar plate rather than growing up each strain individually in 
liquid broth, therefore this was the assay of choice for subsequent 
characterisation of mutants of 0157:H7. Colony ELISA results were 
compared to Vero cell assays, to assess whether toxin was biologically 
active.
3.2 The Effect of Mitomycin C on Verotoxin Production
3.2.1 Introduction
Mitomycin C, an antibiotic produced by Streptomyces species, inhibits 
bacterial DNA synthesis. Its action as a bifunctional alkylating agent leads 
to the formation of covalent crosslinks between complimentary strands of 
DNA, so preventing the two DNA strands from separating during 
replication. Inhibition of RNA synthesis and protein synthesis seem to be 
non-specific manifestations of cell toxicity (Verweij & Pinedo 1990). The 
drug is also thought to be involved in the induction of lysogenic phage. 
This is because when E.coli is exposed to agents or conditions which 
damage DNA or interfere with DNA replication, a diverse set of 
physiological responses known as SOS responses, are induced. More than 
17 din  (damage-inducible) genes are induced in response to such 
conditions (Walker 1987). The SOS regulatory system is controlled in part 
by the interplay of two proteins, LexA and RecA. During normal growth, 
the LexA protein represses the din genes, but when DNA is damaged or 
DNA replication is inhibited, an inducing signal is generated, which 
activates the RecA protein. The activated RecA protein interacts with, and 
causes proteolytic cleavage of, LexA. Activated RecA is also capable of 
mediating the cleavage of phage X repressor, not necessarily by direct
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proteolytic activity, but possibly by altering the conformation of the 
protein and increasing the susceptibility of, for example, a specifically 
labile bond to hydrolysis (Walker 1987), or facilitating autodigestion (Little 
1984). That the RecA protein is involved in phage induction is clearly 
indicated by the evidence that RecA (def) (RecA-) mutants, which are 
defective in all activities of RecA protein, are defective in recombination, 
SOS induction and lambda induction (Walker 1987). Viral DNA 
replication is not affected by mitomycin C, although the mechanism of 
this resistance has not been elucidated (Gale et al 1972). It is possible that 
the viral DNA is modified and is thus resistant to the action of the drug. 
Mitomycin C is thus a valuable tool in the study of viral DNA in the 
absence of host cell DNA synthesis
VT1 and VT2 are produced by lysogenic phages (Strockbine et al 
1986), and E.coli K12 produce high levels of VT if lysogenised with VT- 
converting phages (Smith et al 1983). Mitomycin C should result in 
cessation of bacterial DNA synthesis and induction of the VT-converting 
phage(s), which may result in increased production of VT, since this is a 
phage product. It is already known that mitomycin C treatment of E.coli 
0157:H- strain E32511 results in elevated levels of extracellular VT2 (Head 
et al 1988), although the mechanism of this enhancement has not been 
established. It could simply be due to the fact that mitomycin C causes cell 
lysis which releases pre-formed toxin, or in addition to this, induction of 
the toxin-converting phage may result in de novo synthesis of toxin.
This study was carried out to demonstrate the effect of mitomycin C 
on synthesis and release of VT, and has shown that this drug is able to 
increase toxin production and the level of extracellular viral proteins 
while bacterial protein synthesis is inhibited. The specific activity of toxin 
inside the cells also increased in the presence of mitomycin C, although
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extracellular specific activity levels were lower in the mitomycin C-treated 
cells as a result of bacterial proteins released during cell lysis.
3.2.2 Results and Discussion
3.2.2.1 Lysis of Cells
To confirm whether mitomycin C caused cell lysis, the optical density 
(600nm) of an exponentially growing culture of 0157:H7, after addition of 
mitomycin C, was monitored (Figure 3.5).
5ml of an overnight culture of ATCC 35150 was added to a 250ml 
flask containing 100ml Difco Antibiotic Medium no.3. The culture was 
allowed to reach the exponential growth phase (3 hours), at which time 
the mitomycin C was added. The effect of the drug is very clear, in that a 
decrease in the optical density corresponding to cell lysis was apparent in 
the cultures containing the drug, after 5-6 hours, which was 2-3 hours after 
the drug was added. The control culture continued to increase in optical 
density throughout this experiment. Cell lysis in the mitomycin C-treated 
culture was confirmed by light microscopy.
After 24 hours, phage (2.5 xlO3 pfu m l1) could be demonstrated in 
the supernatant of the culture containing l.Opgml'l mitomycin C, by the 
formation of clear plaques in a lawn of E.coli DH1 (Figure 3.6). It was 
necessary to use a lambda-free strain, as VT-converting phages are 
lambdoid in nature, and will not infect a lambda lysogen. No plaques were 
seen when supernatant from a culture grown in the absence of mitomycin 
C, was used. VT-encoding phages from 0157:H 7 consist of regular, 
hexagonal heads and short contractile tails, but unfortunately electron 
microscopy of the phage-containing supernatants in this study, was 
unsuccessful. However production of viral plaques confirms the lysogenic
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Figure 3.5 The effect of mitomycin C on growth of E.coli 0157:H7. 
The drug, which was added after 3 hours, was tested at two 
concentrations, 0.4ngmH & l.O^gml'l 
No mitomycin C was added to the control culture.
control
0.4Mg/ml
1 .Ong/ml
84
Figure 3.6 Induction of bacteriophage in E.coli 0157:H7
5mm
A culture filtrate from cells grown in the presence of mitomycin C 
(l.Opgml-1) was added to E.coli DH1. Clear plaques in the lawn of DH1, 
corresponding to induced phage, were observed after 16 hours at 37°C.
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nature of VTEC, and also that viral DNA synthesis is not inhibited by this 
concentration of mitomycin C.
These observations tie in with published studies on the effect of 
mitomycin C on levels of Salmonella toxin, where a drastic decrease in 
viable cells was seen, and thought to be caused by the selective inhibition 
of non-toxin protein synthesis with concomitant lytic release of toxin 
(Houston et al 1981).
3.2.2.2 Analysis of Extracellular Proteins
In order to assess whether the inhibition of protein synthesis was 
selective, extracellular proteins were analysed by SDS-PAGE. Cells were 
harvested at hourly intervals, between 1 and 7 hours after addition of 
mitomycin C (O.lpgml‘ 1) to exponentially growing cells. The cell-free 
supernatants were then concentrated by ammonium sulphate 
precipitation and subsequently analysed by SDS-PAGE (Figure 3.7). It was 
shown by SDS-PAGE that some proteins were removed in the 40% 
ammonium sulphate precipitate, however, these were mainly non-toxin 
proteins. Petrie et al (1987), reported that at 40% saturation, 5% toxin 
activity was precipitated, while at 60% saturation, >90% of toxin was 
precipitated.
The appearance of protein bands after 2 hours, confirmed the cell 
lysis seen in Figure 3.5 where the optical density of cultures to which 
mitomycin C had been added, began to decrease 2-3 hours after addition of 
the drug. The concentration of toxin, and of some low molecular weight 
proteins, increased proportionally with the length of exposure to 
mitomycin C. The toxin band corresponds to the A subunit, as the samples 
had been denatured by treatment with SDS. The smaller B subunits are
86
Figure 3.7 SDS-PAGE analysis of extracellular proteins from a culture of
mitomycin C-treated 0157:H7.
Proteins were concentrated by ammonium sulphate precipitation.
Lane 1 contains molecular weight markers. Lanes 2-8 contain extracellular 
proteins from cells harvested between 1 and 7 hours after addition of 
mitomycin C to exponentially growing cells.
Proteins were visualised by silver nitrate staining.
2 3 4 5 6 7 8
67
-•— toxin
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Figure 3.8 SDS-PAGE analysis of extracellular proteins from a culture of
mitomycin C-treated 026:H11.
Lanes 1-7 contain ammonium sulphate concentrated supernatants from 
cells harvested at hourly intervals between 1 and 7 hours after addition of 
mitomycin C (O.lpgml‘ 1) to exponentially growing cells.
Proteins were visualised by silver nitrate staining.
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not shown, as for unknown reasons the B polypeptides of VT migrate as 
diffuse and heterogeneous bands during SDS-PAGE (Newland et al 
1985).The concentration of other non-toxin proteins increased only 
slightly throughout the experiment, corresponding to a gradual cessation 
of transcription and hence bacterial protein synthesis. The non-toxin 
proteins which significantly increased in concentration were thought to be 
other phage proteins, since it is known that mitomycin C inhibits bacterial 
protein synthesis (Verweij & Pinedo 1990). One of the most prominent of 
these proteins has a molecular weight of ~43kDa, and this corresponds in 
size to a VT-phage structural protein reported by O'Brien et al (1984b).
This experiment was repeated with an enteropathogenic E.coli 
(026:H11) which does not produce VT, and in which a lysogenic phage 
could not be demonstrated. With this organism, the concentration of all 
proteins appeared to increase at a similar rate, due to the release of 
intracellular proteins by cell lysis (Figure 3.8). There was no selective 
inhibition of protein synthesis, as these bacteria were not lysogens. This 
observation reinforces the hypothesis that the extracellular proteins of 
0157:H7, which increase in concentration with increasing exposure time 
to mitomycin C, including toxin, are phage products.
The ammonium sulphate precipitates were further analysed by 
hydroxylapatite column chromatography (Figure 3.9). The column eluate 
was monitored spectrophotometrically, and the first four samples (1-4 
hours incubation with mitomycin C) resulted in a single protein peak. 
This was analysed by SDS-PAGE, and the results of the samples taken at 1- 
3 hours, can be seen in Figure 3.9, lanes 1-3. After 5 hours incubation 
however, a second, smaller protein peak appeared, which at subsequent 
time intervals, became larger than the original peak. Lanes 4 and 5 of 
Figure 3.9, show analysis of the original peak, and the second protein peak,
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respectively. The two peaks which resulted from hydroxylapatite 
chromatography of the 6 hour sample, are similarly shown in, in lanes 6 
and 7. It is thought that the second peak represented assembly of the phage 
proteins seen in Figure 3.7.
For the purposes of purification, it is desirable to achieve a situation 
where there is the greatest ratio of toxin to non-toxin proteins, ie before 
other phage proteins begin to assemble. From this data an incubation 
period of 3-3.5 hours appeared to be optimal.
3.2.2.3 Total Protein Concentration
As cell lysis will result in release of toxin and many non-toxin proteins 
into the supernatant, the levels of intracellular (sonicate) and extracellular 
(supernatant) protein were compared in the presence and absence of 
mitomycin C.
The effect of mitomycin C was immediately obvious with respect to 
the increase of extracellular protein from 6% to 40% of the total protein 
(Figure 3.10). However these values give no indication of the amount of 
toxin involved, or whether any of the proteins released into the 
supernatant were synthesized as a result of phage induction.
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Figure 3.9 SDS-PAGE analysis of ammonium sulphate-precipitated
0157:H7 extracellular proteins after hydroxylapatite column 
chromatography.
1 2  3  4  5  6
Samples were taken between 1 and 6 hours after addition of mitomycin C 
to exponentially growing cells. Samples were subjected to ammonium 
sulphate precipitation followed by hydroxylapatite column 
chromatography. A single peak was eluted from the column for samples 
exposed to the drug for 1-3 hours. Two protein peaks were eluted from 
subsequent samples.
Lanes 1-3 contain peak 1 from samples taken at 1-3 hours.
Lanes 4 and 5 contain peaks 1 & 2 from the 5 hour sample.
Lanes 6 and 7 contain peaks 1 & 2 from the 6 hour sample.
91
To
ta
l P
ro
te
in
 (%
)
Figure 3.10 The effect of mitomycin C (O.lp.gml'1) on distribution 
of cell protein between the inside of the cell and its 
environment
■  Intracellular 
H  Extracellular
Mitomycin C- Control
treated cells cells
Figures are expressed as a percentage of the total cell protein.
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3.2.2.4 Toxin Production
To assess the levels of toxin in the supernatant, an enzyme-linked 
immunosorbent assay (ELISA) was used, and toxin was detected using 
monoclonal antibodies to VT1 and VT2. The results were expressed as a 
percentage of the total toxin detected in each culture (Figure 3.11).
The most obvious effect of mitomycin C was in the distribution of 
toxin within the culture. In both the VT1 and VT2 experiments, the 
amount of toxin in the supernatant, increased. This observation in itself, 
does not show that mitomycin C treatment results in synthesis of 
increased levels of toxin due to phage induction, since it has been shown 
that cell lysis occurs. The increased extracellular toxin levels could simply 
result from lytic release of pre-formed toxin. By analysing the actual 
figures from the ELISA experiment rather than considering percentage 
distributions for both VT1 and VT2, there is an increase in both 
intracellular and extracellular toxin levels in the cells treated with 
mitomycin C (Figure 3.11). If the increase in extracellular toxin was due to 
lytic release of pre-formed toxin, there would be a corresponding decrease 
in toxin inside the cell, in the presence of mitomycin C. Since this clearly 
was not the case it is proposed that mitomycin C causes an increase in VT 
levels by induction of toxin-converting phages and de novo synthesis of 
toxin.
Control experiments showed that non-specific binding of either antigen or 
primary antibody was not significant. Attempts to purify VT had been 
unsuccessful, so it was not possible to standardise the assay with serial 
dilutions of toxin. Despite the fact that the ELISA was only semi- 
quantitative, there is clear indication that the amount of intracellular and 
extracellular toxin increased due to mitomycin C action.
93
O
D
 4
50
 
%
 To
xin
Figure 3.11 The effect of mitomycin C (0.1 p.gmH) on % distribution of 
VT1 and VT2. Bacteria were grown with (+) and without (-) 
the antibiotic, and intracellular and extracellular toxin levels 
were determined by an ELISA.
V T 1 VT2
I  Intracellular + 
■  Extracellular + 
I  Intracellular - 
E  Extracellular -
VT1 VT2
I  Intracellular +
■  Extracellular +
■  Intracellular • 
0  Extracellular •
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3.2.2.5 Specific Activity
The specific activity was calculated as optical density units per mg protein. 
From Figure 3.12 it can be seen that despite the fact that extracellular toxin 
levels were much higher in mitomycin C-treated cultures, because of lytic 
release of many non-toxin proteins, the specific activity was lower than in 
control cultures. The reverse was true for intracellular values, where 
phage induction resulted in increased toxin production, but the synthesis 
of bacterial proteins was gradually inhibited. The net result of this is an 
increase in the specific activity of VT.
3.2.2.7 Tissue Culture Assays
It has been shown that incubation of 0157:H7 ATCC 35150 in the presence 
of mitomycin C results in increased VT production compared to control 
cells. This strain produces both VT1 and VT2, as shown by the ELISA 
results, where monoclonal antibodies to VT1 and VT2 both gave positive 
results (Figure 3.11). It is known however that there is some cross­
reactivity between these monoclonal antibodies (Downes et al 1988), 
therefore to determine whether production of both of these toxins is 
genuinely increased by mitomycin C, two other strains were examined , 
E3787 which produces VT1 only, and E32511, a VT2 producer.
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Figure 3.12 Intracellular and extracellular specific activity of VT1 and VT2.
VT1 VT2
■  Intracellular + 
H  Intracellular •
■  Extracellular+ 
□  Extracellular -
Specific activity is expressed as OD units per mg protein.
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Table 3.2 Vero cell assay
-mitomycin C + mitomycin C Increase in titre
VT1 32 512 16-fold
VT2 2,048 65,536 32-fold
Culture filtrate of E3787 (VT1) and E32511 (VT2) were titrated across Vero 
cell monolayers. Titre is a reciprocal of the dilution to cause 50% cell 
death.
Bacteria were grown in the presence (+) or absence (-) of mitomycin C. 
Results were reproducible on three separate days.
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Table 3.2 shows that levels of both VT1 and VT2 were increased by 
incubating VTEC in the presence of mitomycin C. This supports the 
results of the ELISA (Figure 3.11), where it is clear that the amount of 
extracellular VT antigen increased in the presence of the drug, The tissue 
culture assay showed an increase in the titre of VT1 of 16-fold, and that of 
VT2, 32-fold, although since a 2-fold dilution series was used, these 
differences were probably not significant. Head et al (1988) noted a 100-fold 
increase in VT2 production in the presence of mitomycin C, although this 
figure corresponded to polymyxin B-extracted toxin from the cell pellets. 
However, the increase in extracellular levels appears to be similar to that 
found in this study.
It is concluded from these studies that addition of mitomycin C to 
an exponentially growing culture results in a large increase of extracellular 
toxin due to induction of toxin-converting phage. This contrasts with the 
effect of this drug on production of heat-labile toxin (LT) by 
enterotoxigenic E.coli (Gemski et al 1978). The increase in extracellular 
levels of LT caused by the mitomycin C treatment reflected lytic release of 
cell-bound toxin only. The cells lysed due to phage induction, but LT is 
plasmid- rather than phage-encoded so synthesis of this toxin will cease as 
bacterial protein synthesis is eventually inhibited by the mitomycin C. 
Other studies on the effect of mitomycin C on toxin production, including 
that of Houston et al (1981) on Salmonella toxin found, as in this study, 
that addition of mitomycin C increased the amount of toxin and total 
protein in culture supernatants, and that, as a result of cell lysis, there was 
a decreased amount of protein in mitomycin C-treated sonic extracts. As 
with LT however, the increase in biological activity of Salmonella toxin in 
the supernatant was almost equal to that lost from the sonic extracts. This
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contrasts to the findings in this study, where increase in both extracellular
and intracellular toxin levels in the presence of mitomycin C further
confirms the phage-encoded nature of VT.
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Chapter 4 The Production and Characterization of Mutants of E.coli
0157:H7
4.1 Introduction
In order to determine the importance of various characteristics of E.coli 
0157:H 7 in pathogenesis, a general mutagenesis method was chosen. 
Exponentially growing bacteria (0157:H7 ATCC 35150) were incubated 
with mitomycin C, an antibiotic produced by Streptomyces spp., which is 
also used as a plasmid curing agent. The activity of mitomycin C is 
dependent upon its in vivo reduction to the highly reactive hydroquinone 
derivative, a process which involves an NADPH2 -dependent enzyme. 
Reduced mitomycin C behaves as a bifunctional alkylating agent which 
forms covalent cross-links between complementary strands of DNA, 
usually involving guanine residues (Verweij & Pinedo 1990). As a 
mutagen, it is thought that mitomycin C induces mispairing during DNA 
replication by alkylating certain bases at certain positions. Alkylation- 
induced mispairing specifically generates transitions (A-T—C-G) in vivo 
(Drake & Baltz 1976). The drug also acts as a curing agent by inhibiting 
replication of the plasmid, resulting in loss of the plasmid after one or two 
generations. Mitomycin C as used in this study, could therefore cause 
alterations in both the chromosomal and plasmid DNA. Since it is not 
clear whether chromosomal or plasmid elements are involved in 
pathogenesis, mutations in both forms of DNA could lead to greater 
understanding of disease caused by 0157:H7. Preliminary identification of 
mutants was made, based on alterations in plasmid profiles and 
biochemical reactions.
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Two putative virulence attributes were considered in the 
assessment of the mutants: attachment of the organisms, and toxin 
production. With respect to attachment, the outer membrane, and 
especially the LPS was investigated. Two mutants, clones 5 and 6, with 
altered LPS components, were identified using antibodies raised against 
0157:H7 and were further characterised by thin layer chromatography 
(TLC) of LPS neutral sugars. Studies on the hydrophobicity of mutants in 
which the LPS was altered, and their ability to attach to human epithelial 
cells and to intestinal mucus in vitro, were carried out. Immunological 
methods were used to screen toxin production by mutants. The amount of 
biologically active toxin produced, and the distribution of toxin between 
the inside and outside of the cell was then measured, and comparisons 
were made between the mutants and the parent strain. Clones 5 and 6 
were reduced in toxin activity, and secretion appeared to be impaired 
compared to the wild-type. It is likely that at least some of the virulence 
factors of 0157:H7 are common to all VTEC.
4.2 Results & Discussion
4.2.1 Plasmid Profiles
After incubating 0157:H7 ATCC 35150 in the presence of mitomycin C, 
cells were plated onto Penassay plates to obtain single colonies. Six clones 
were chosen for further investigation. Since mitomycin C is a plasmid 
curing agent, the plasmid profiles of the clones were investigated to give 
an indication that the drug had been effective.
The plasmid content of the parent strain was identical to that of 
clones 2 and 3, and consisted of three plasmids of ~2kb, ~4kb and >23kb . 
Clone 4 contained in addition, a plasmid of ~4.2kb (Figure 4.1). Clones 1, 5
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Figure 4.1 Plasmici Profile
Plasmid preparations from 0157:H7 and clones 1-6 were 
separated on a 0.7% agarose gel, and visualised by ethidium 
bromide staining.
Lanes : 1 - 0157:H7 (parent strain). 2 - clone 1 . 3 -  clone 2. 4 - clone 3.
5 - clone 4. 6 - clone 5. 7 - clone 6. 8 - X Hindlll markers.
* Chromosomal DNA
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and 6 did not possess any of these plasmid bands, and only the 
chromosomal DNA band was visualised on the agarose gel (Figure 4.1).
Since the largest marker used was 23kb, it was not possible to 
estimate the size of the large plasmid, however, it is thought that this was 
the ~60-MDa plasmid (equivalent to ~94kb) which is carried by most 
0157:H7 strains (Karch et al 1987). The identity of this plasmid could have 
been confirmed by hybridization studies using a 3.4kb probe, known as 
CVD419, which was derived from the ~60-MDa plasmid (Levine et al 
1987). It is also possible to detect proteins which are associated with 
possession of the ~60-MDa plasmid using a direct ELISA (Toth et al 1991). 
A plasmid of similar size (~98kb) was found in all isolates of 0157:H7 by 
Ostroff et al (1989), and 85% of these strains contained in addition, between 
one and four other plasmids, ranging from 2-87kb. It appeared therefore 
that the plasmid profile of the parent strain was not untypical of 0157:H7 
strains.
The nature of the smaller 0157:H7 plasmids is not known, although 
they are not essential, as some strains do not carry these plasmids. The 
~60-MDa plasmid appears to code for a novel fimbrial antigen (Karch et al 
1987), although the significance of this in attachment and hence 
pathogenesis is unclear. Since clones 1, 5 and 6 did not possess the 
plasmids present in the parent strain, they appeared to be most suitable for 
further studies.
4.2.2 Biochemical Profiles
Since it was likely that chromosomal mutations had also occurred, 
biochemical profiles of all six mutants and the wild-type were 
investigated. An EPEC strain, 026:H11 was included for comparison.
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Table 4.1 Api 20E Biochemical Profiles
Strain Numerical Profile Identification Atypical Reactions
0157:H7 (35150) 5144172 E.coli 90.5% Sorbitol 90%
Clone 2 5144372 E.coli 94.5% Sorbitol 90%
Clone 3 5144172 E.coli 90.5% Sorbitol 90%
Clone 4 5144172 E.coli 90.5% Sorbitol 90%
Clone 5 5154562 E.coli 97.4% Rhamnose 87%
Clone 6 5154562 E.coli 97.4% Rhamnose 87%
026:H11 5144562 E.coli 99.3% Rhamnose 87%
Api 20E- Results of 21 biochemical tests were processed to give a numerical 
profile. Through computer analysis, the percentage probability of an 
organism belonging to a particular species was calculated. The percentage 
values under 'Identification' refer to the probable identity of the organism 
as E.coli , and those under 'Atypical Reactions' refer to the percentage of 
E.coli which are able to utilise a certain sugar which the organism tested is 
unable to.
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To analyse biochemical reactions, an Api 20E test was chosen. This 
is a commercial test to identify members of the Enterobacteriaceae family. 
The results of 21 biochemical reactions are processed to give a 7-digit 
numerical profile which identifies the probability of an organism 
belonging to a particular species. Any reactions which are atypical of the 
probable organism are highlighted. The results of the Api 20E tests are 
shown in Table 4.1. Of interest, were the atypical reactions of these 
organisms. Unlike 90% of E.coli, 0157:H7 is unable to ferment sorbitol. 
This is a characteristic which is exploited in the isolation of this 
serogroup (Kleanthous et al 1988). The metabolism of clones 5 and 6 had 
clearly been altered as they were able to ferment sorbitol, but, in common 
with 026:H11, were unable to ferment rhamnose. Clones 3 and 4 have 
identical profiles to the wild-type, and although clone 2 has an altered 
biochemical profile, further studies were concentrated on clones 5 and 6. 
Attempts to produce a biochemical profile for clone 1 were unsuccessful as 
the organism failed to grow in the test kit. The implication of this is that 
major changes in the metabolism of this organism had occurred as a result 
of mutagenesis, which meant that the organism required a richer, more 
complex medium than is available in the Api test strip.
4.2.3 Passive Haemagglutination Assay
Red blood cells (RBC) coated with protein or polysaccharide antigens will 
agglutinate in the presence of the appropriate antibody. In this study, 
RBC were coated with heat-stable saline-extracted antigens from the 
reference strain of 0157:H7 and clones 2, 3, 4, 5 and 6. The sensitised RBC 
were then reacted with antibodies raised against the reference strain of 
0157:H7. The aim was to demonstrate any changes in the antigenic
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Figure 4.2 Passive haemagglutination assay
A
B
C
D
E
F
G
H
0157 = H7
clone 3
clone 5
clone 6
Antiserum raised against 0157:H7 was titrated across rows A, C, E & G. 
Preimmune serum was titrated across rows B, D, F &H. Sheep RBC coated 
with heat-stable antigens from 0157:H7 and clones 3, 5 & 6 were added to 
the titrated antisera as indicated. Titres are represented as reciprocals of 
the last antiserum dilution at which agglutination was seen.
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determinants by comparing the passive haemagglutination titre with 
that of the parent strain. The antigen was extracted by heating bacteria 
resuspended in saline, at 100°C for 60 minutes. Although the exact 
composition of the antigen was not known, in a similar study, Penner & 
Hennessy (1980) observed that antigens extracted in this way from 
Campylobacter species possessed characteristics of O antigens. These 
included stability at 100°C and the ability to readily adsorb to RBC. In 
addition, the antigens elicited production of specific antibodies in rabbits.
The results of the passive haemagglutination assay of clones 3, 5 
and 6, are shown in Figure 4.2 alongside the parent strain. The wild-type 
and clone 3 had passive HA titres of 1280. This was the highest dilution of 
antiserum at which there was clear agglutination. The antigenic 
determinants of clone 3 clearly had not been altered significantly. Clones 2 
and 4 were also tested, and gave a passive HA titre of 1280 (not shown). 
Clones 5 and 6, however, failed to react with anti-0157:H7, indicating 
major changes in the antigenicity of these strains compared to the wild 
type. No haemagglutination was observed when sensitised RBC were 
reacted with pre-immune serum. This confirmed that aggregation of RBC 
resulted from specific antigen-antibody interactions. Clone 1 could not be 
tested because attempts to extract heat-stable antigens by saline treatment 
were unsuccessful. There was a possibility at this stage that the putative 
mutants were in fact contaminants, but subsequent colony ELISA and 
tissue culture assays showed that they were still able to produce toxin, so 
the possibility of these clones not being mutants was very low.
It was noted that in the first well, containing the highest 
concentration of antiserum, there was often no agglutination. This is 
known as the 'prozone phenomenon' and is thought to be due to the 
effect of high protein concentrations causing an increase in the net charge 
of the coated RBC. This increases the electrostatic repulsion between
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individual particles, which opposes the action of the antibody molecules 
to link the erythrocytes together (Cruickshank et al 1975). Once the 
protein concentration was reduced by dilution, the antibodies were able to 
aggregate the RBC and bring about agglutination.
4.2.4 Oxoid Latex Agglutination Assay
The Oxoid latex agglutination assay is a commercially available test, 
which detects the presence of 0157 antigens. The saline-extracted antigens 
of the 0157:H7 clones 5 and 6 had failed to react with antiserum raised 
against whole cells of 0157:H7 in a passive haemagglutination assay. 
These antigens were thought to consist predominantly of LPS, part of 
which is the O side chain, which is responsible for the O antigenicity of 
Gram-negative organisms. The Oxoid latex agglutination test, which 
consists of latex particles coated with antibodies to 0157, would give a 
negative result with clones 5 and 6 if the O side chain was significantly 
altered.
0157:H7 clones 3, 5 and 6 were tested alongside the parent strain, the 
0157 clinical isolate and, as a negative control, E.coli 026:H11. The results 
of the assays are shown in Table 4.2. Clones 5 and 6 failed to agglutinate 
latex particles coated with anti-0157, confirming that these strains were 
antigenically distinct from the wild-type strain. Both the 0157:H7 parent 
strain and the 0157 clinical isolate gave a positive reaction in this assay. 
To confirm that this agglutination was specific, these strains were further 
reacted with control latex particles, with which they gave a negative 
reaction. As expected, 026:H11 failed to agglutinate the test particles in 
this assay (Table 4.2).
This latex agglutination assay confirmed that the O side chains of 
clones 5 and 6 had been altered by the mutagenesis procedure.
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Table 4.2 The Oxoid latex agglutination assay
Organism Test latex particles Control latex particles
Clone 3 Positive Negative
Clone 5 Negative nt
Clone 6 Negative nt
0157:H7 ref strain Positive Negative
0157 clinical isolate Positive Negative
026:H11 Negative nt
Bacterial cells were mixed with test latex particles coated with anti-0157. 
Organisms able to agglutinate these particles were reacted with control 
latex particles to confirm that the initial agglutination was specific, 
nt - not tested
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4.2.5 SDS-PAGE Analysis of Saline-extracted Antigens
It was clear from the results of the passive haemagglutination and latex 
agglutination assays that the O side chains of clones 5 and 6 had been 
altered as a result of mutagenesis. The saline-extracted antigens were 
therefore separated by SDS-PAGE, and visualised by silver nitrate staining 
under conditions which visualise LPS rather than proteins.
The results of the SDS-PAGE analysis are shown in Figure 4.3 . This 
shows an apparent reduction in the amount of LPS in clones 5 and 6 
compared to the parent strain. The LPS of clones 2, 3 and 4 is comparable 
to that of the wild-type. Clone 1 could not be investigated since all 
attempts to extract heat-stable antigens were unsuccessful.
It was expected that the distinctive ladder-like pattern of LPS would 
be visualised by this staining method. This did not occur however, and 
only those portions of the LPS which did not comigrate with proteins 
were stained, giving all strains the appearance of rough LPS which 
consists of only lipid A and core oligosaccharides. It was subsequently 
discovered that if the samples had been treated with proteinase K the 
entire LPS would have been visualised (Hitchcock & Brown 1983), 
however, due to time limitations, this was not attempted. Compression 
of LPS by the proteins probably explains why the banding is well-defined. 
Hitchcock & Brown (1983) found that when samples had been proteased, 
banding of LPS was much more diffuse, especially along the upper edges.
Thus although it appeared that clones 5 and 6 possessed a reduced 
amount of LPS compared to the parent strain, this was only demonstrated 
amongst the low molecular weight fractions. Since the full LPS profile 
was not visualised, conclusions about the extent of mutation could not be 
drawn from these SDS-PAGE profiles.
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Figure 4.3 SDS-PAGE analysis of saline extracted antigens.
Antigens were separated on a 11% resolving gel and visualised by LPS- 
silver nitrate staining.
Lanes 1-5 contains clones 2-6. Lane 6 contains 0157:H7 (35150)
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4.2.6 Immunoblotting of Saline-extracted Antigens
It was known that the LPS, notably the O side chains, of clones 5 and 6 no 
longer reacted with either anti-0157 or with antiserum raised against the 
whole organism (0157:H7 ATCC 35150). To investigate this further, the 
saline-extracted antigens of clones 2, 3, 4, 5 and 6 were separated by SDS- 
PAGE as before, alongside the wild-type. The antigens were then 
transferred from the unstained gel to nitrocellulose and immunoblotted 
with antiserum raised against 0157:H7.
The saline-extracted antigens of 0157:H 7 and clones 4, 5 and 6 
reacted with anti-0157:H7 as shown in Figure 4.4. The distinctive LPS 
ladder-like pattern was seen in the lanes containing clone 4 and the 
parent strain. It appeared that clone 4 was not altered with respect to 
antigenicity, neither were clones 2 and 3 which were also tested (not 
shown). Due to difficulties in preparing the antigen extract of clone 1, it 
was not possible to test this mutant. The ladder-like pattern was not seen 
in the lanes containing clones 5 and 6 however, where only two bands of 
32 and 35 kDa which were probably proteins, were visible. Overbeeke & 
Lugtenberg (1980) analysed many human E.coli strains from different 
sources and found that in all cases the fastest moving band in the 30- 
42kDa region was OmpA. All other major outer membrane proteins were 
related to porins OmpC and OmpF. Thus it was thought that the 32kDa 
band was OmpA and the larger band corresponded to the porins, which 
are closely related in size (36-37kDa, Smyth 1985). The identity of OmpA 
could have been confirmed as it is the only outer membrane protein 
which is degraded during incubation of cell envelopes with trypsin. This 
yields a large degradation product with a molecular weight of 
approximately 18kDa associated with the cell envelope. It appeared that
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the major outer membrane proteins of clones 5 and 6 were not 
significantly altered, so further studies were confined to the LPS, which 
did not react with the 0157 antiserum. Saline-extracted heat-stable 
antigens were prepared several times, and the results as descibed above, 
were reproducible each time.
There are two explanations for the lack of reaction between the LPS 
of clones 5 and 6, and anti-0157:H7. One is that the O antigens had been 
altered to the extent that they no longer reacted with anti-0157, but would 
react with antibodies raised against another O antigen. The second 
explanation is that these mutants no longer possessed an O side chain, 
and would therefore be described as rough mutants. Rough LPS consists 
of lipid A and core oligosaccharide, but does not give rise to the ladder­
like pattern in SDS-PAGE gels which results from the separation of a 
mixture of molecules of increasing molecular weight, representing 
additional O-antigen units added to the basic lipid A-core oligosaccharide 
structure.
To assess which explanation was most feasible, two identical 
Western blots were prepared of clones 2, 3, 4, 5 and 6 alongside the parent 
strain. The clinical isolate of 0157 was also included, as well as 026:H11 
and S.dysenteriae type 1. One of the blots was then reacted with antiserum 
against 0157:H7, and the other with anti-026:H ll. The results of these 
blots are shown in Figure 4.5. When antiserum to 0157:H7 was used, the 
characteristic ladder-like banding of LPS was seen in the lanes containing 
clones 2, 3 and 4, the parent strain, and the clinical isolate of 0157. This 
confirmed that these clones were not significantly altered with respect to 
antigenic determinants, and that the antiserum was specific to 0157. 
These bands were not visualised by silver staining, as the stain was 
specific for LPS, and was not effective in the presence of proteins. Only 
two bands from clones 5 and 6, corresponding to the outer membrane
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Figure 4.4 Immunoblot of SDS-PAGE gel (11% acrylamide) of saline-
extracted antigens with anti-0157:H7.
The following strains were tested : wild-type 0157:H 7 (lane 1), clone 6 
(lane 2), clone 5 (lane 3), clone 4 (lane 4)
The 4-chloronaphthol development system was used
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Figure 4.5 Immunoblots of SDS-PAGE gels (11% acrylamide) of saline-
extracted antigens.
Identical gels were immunoblotted with 1) anti-0157:H7 or 2) anti- 
026:H11. Lanes: 1- S.dysenteriae type 1, 2- 026:H11, 3- 0157 clinical isolate, 
4- 0157:H7 parent strain, 5- clone 6, 6- clone 5, 7- clone 4, 8- clone 3
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proteins seen in Figure 4.4, reacted strongly with this antiserum. This 
pattern was similar to that of 026:H11 and S.dysenteriae type 1 and was 
due to antigenic cross-reactivity. This phenomenon has been reported by 
other workers between outer membrane proteins of several serotypes of 
E.coli and other Enterobactericeae (Hofstra & Dankert 1979, Nicolle et al 
1989). When anti-026:H ll was used however, there was a strong reaction 
throughout the LPS profile of clones 5 and 6 (Figure 4.5). Similar reactions 
occurred in the lanes containing the clinical isolate of 0157, clones 2, 3 
and 4, and the 0157:H7 parent strain. The LPS of S.dysenteriae type 1 did 
not bind to anti-026:H ll, however, so this appears to be cross-reactivity 
rather than non-specific binding. Only the outer membrane proteins of 
S.dysenteriae type 1, which also cross-reacted with anti-0157:H7, reacted 
with this antiserum.
Taken together, these results showed that clones 5 and 6 were 
antigenically distinct from 0157:H7, but the fact that the LPS reacted with 
anti-026:H ll means that they are not rough mutants. It was not thought 
that these clones possessed the 026  antigen, however, since the other 
0157 strains also cross-reacted with anti-026:H ll. This antiserum is 
clearly less specific than that raised against 0157:H7. Cross-reaction 
between serotypes and even different species is not uncommon when 
sugar groups and molecular structure are similar. For example, a 
common sugar group is responsible for the antigenic cross-reactivity 
observed between E.coli 0157:H7, Brucella abortus and B.melitensis (Perry 
& Bundle 1990). It is more difficult to explain why the anti-0157:H7 did 
not react with the 026:H11 antigens. Clearly the 0157:H7 antigenic 
determinants are more specific. In support of this hypothesis, the 
presence of unique epitopes for 0157:H7 which could be used to produce 
specific immunological reagents, has been reported (Rice et al 1992). It is 
not known whether 0157:H7 and 026:H11 share similar LPS structures,
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but it seems likely, since in addition to the cross-reaction seen here, anti- 
0157:H 7 was found to inhibit attachment of 026:H11 to HeLa cells by 
>50% (this study).
The immunoblotting indicated that the LPS, but probably not the 
outer membrane proteins of clones 5 and 6 differed from the parent 
strain. Further studies were therefore concentrated on the LPS and not 
the protein moiety of the outer membrane.
4.2.7 Neutral Sugar Analysis
Studies on the heat-extracted antigens of 0157:H7 clones 5 and 6 had 
shown that the LPS was significantly altered in the O side chain and no 
longer reacted with antiserum raised against the parent strain. The neutral 
sugars were therefore extracted from purified LPS and analysed by TLC.
The results of TLC analysis of mutant and wild-type LPS is shown 
in Figure 4.6. LPS was isolated using a phenol /water procedure which 
results in a product containing only around 1% contaminating proteins. 
Most LPS separates into the aqueous phase but occasionally some 
lipophilic LPS remains in the phenol phase. This also occurs with rough 
LPS. To ensure maximum yield of LPS, in this study both phases were kept 
and analysed separately. Both the wild-type and the mutants contained 
glucose and galactose, but fucose in the wild-type was absent in clones 5 
and 6, which instead contained rhamnose. This pattern was seen in both 
the aqueous and phenol phases, although more of the LPS had separated 
into the aqueous phase.
It is hypothesised that the altered sugar profile results from a 
mutation in the LPS synthetic pathway. The O side chain of LPS is made 
up of many repeating tetrasaccharide units which are synthesised on 
carrier lipids and assembled by transfer from one carrier, to a growing
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chain on another carrier molecule. During synthesis, carbohydrates are 
added to the repeat unit from sugar nucleotide intermediates. In the case 
of E.coli 0157:H7, these sugars are mannose, galactose, glucose and fucose 
(Perry et al 1986). These are incorporated into the O chain by membrane- 
bound transferases, in the form of GDP-D-mannose, UDP-D-galactose, 
UDP-D-glucose and GDP-L-fucose. In the mutants however, it appeared 
that rhamnose was incorporated into the repeat units in place of fucose. In 
order to understand this, it is necessary to look at the biosynthetic pathway 
of sugar residues (Figure 4.7). In the wild-type 0157:H7, GDP-L-fucose is 
synthesised from glucose-6-phosphate via a series of intermediates 
including GDP-D-mannose. Glucose, galactose and rhamnose nucleotides 
are synthesised along a different pathway. If the pathway leading to GDP-L- 
fucose was blocked as a result of the mutagenesis procedure, it is 
speculated that the synthesis of dTDP-L-rhamnose is favoured. This would 
also prevent synthesis of GDP-mannose. In this study, mannose was not 
detected in the mutants or the wild-type 0157:H7. This is due to the 
method of analysis, using mineral acid hydrolysis which destroys the 
mannose component in the O chain. It would be necessary to extract the 
mannose using anhydrous hydrofluoric acid to see whether it was present 
in the mutants. Since this was not possible, it can only be speculated that 
mannose would be absent from the mutants. Alternatively the pathway 
could have been blocked after GDP-mannose, that is, at the level of 
production of GDP-4-keto-6-deoxymannose or GDP-L-fucose. Since 
antigenic changes in the LPS were major, and rhamnose was present in 
the mutants, it is hypothesised that the pathway was blocked before GDP- 
mannose, and intermediates were redirected along the rhamnose fork of 
the pathway.
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Figure 4.6 Neutral sugar analysis.
Neutral sugars were extracted from purified LPS by mineral 
acid hydrolysis and separated by thin layer chromatography.
1 2 3
RHAMNOSE
RIBOSE 
FUCOSE
MANNOSE
6L0C0SE 
GALACTOSE
4  5  6  ______ 7
■I
The LPS extraction yielded an aqueous phase and a phenolic phase.
Lanes : 1- Sugar standards. 2 - wild-type (aqueous phase). 3 - clone 5
(aqueous phase). 4 - clone 6 (aqueous phase). 5 - wild-type (phenolic 
phase). 6 - clone 5 (phenolic phase). 7 - clone 6 (phenolic phase).
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4.2.8 Hydrophobicity Studies
Hydrophobic interactions are thought to be important in pathogenesis 
with respect to adhesion of bacterial cells, and in overcoming repulsive 
forces between the bacterial and host cells. Since the LPS of clones 5 and 6 
had been altered, it was possible that the hydrophobicity of these bacteria 
was modified. The hydrophobicity of clone 1 was of interest since when 
grown on solid media this strain produced more mucoid colonies than the 
other 0157:H7 strains. A human E.coli strain, Econl, was included as a 
hydrophobic control. This organism had been isolated from a urine 
sample, found to be hydrophobic in nature, and was routinely used as a 
hydrophobic control at Northwick Park Hospital.
Three methods were chosen to assess hydrophobicity: microbial 
adhesion to hydrocarbons (MATH), hydrophobic interaction 
chromatography (HIC) and a salt aggregation test (SAT). All three methods 
gave an indication of the net hydrophobicity in terms of adhesion. Bacteria 
can have a net hydrophobicity through a small hydrophobic area which 
enables the cell to adhere even though the majority of the cell is more 
hydrophilic (Rosenberg & Doyle 1990). In addition, SAT gives an 
indication of the hydrophobic properties of the cell as a whole. MATH is a 
simple quantitative test, which relies on the fact that hydrophobic 
organisms adhere to liquid hydrocarbons whereas hydrophilic strains do 
not. HIC measures microbial adhesion to octyl- sepharose beads in small 
chromatography columns. The higher the percentage retention in the 
column, the more hydrophobic the organism. SAT works on the principle 
that increasingly hydrophobic bacteria will aggregate at correspondingly 
lower salt concentrations. These three methods were used since a single 
assay does not necessarily indicate the extent of hydrophobicity of the
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microbial cell surface. It should be noted that hydrophobicity is a relative 
term since even organisms described as being hydrophobic disperse 
readily in the bulk aqueous phase.
Each of the three methods used to assess hydrophobicity indicated 
that all the VTEC tested ie 0157:H7 ATCC 35150, clones 1, 5 and 6, and the 
clinical isolate of 0157, were hydrophilic compared to the hydrophobic 
control. Whilst SAT (Table 4.4) and HIC (Table 4.5) were very reproducible, 
MATH (Table 4.3), proved less reliable. One reason for this is that the 
vigorous vortexing of the bacteria in the presence of hydrocarbon often 
leads to cell damage, and hence spurious data. N-hexadecane which was 
used in this study, is less damaging in this respect however, than the 
aromatic hydrocarbons such as xylene which were used in the original 
MATH tests (Rosenberg & Doyle 1990).
Clone 1 appeared slightly more hydrophobic than the wild type, 
although not significantly when compared to the hydrophobic control. 
This could be a consequence of the fact that this mutant was more mucoid 
than the other VTEC tested, which may have affected hydrophobicity, or 
simply meant that the cells had a tendency to clump together. Another 
disadvantage of the MATH assay is that bacteria which clump, will give 
low turbidity readings in the aqueous layer, falsely indicating that the 
organisms have adhered to the hydrocarbon. In a similar way, these 
organisms may have become physically entrapped in the HIC column, 
rather than adhering due to their hydrophobic properties. Non-specific 
clumping would not explain the SAT result however, as no aggregation 
occurred in the control test. It has been reported, however, that SAT is 
only satisfactory for the detection of hydrophobic organisms and HIC is the 
best method for hydrophilic bacteria (Mozes & Rouxhet 1987). Thus, 
although clone 1 appeared to have slightly altered hydrophobicity 
compared to the wild type, it may not be a true reflection of its
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hydrophobic properties. Clones 5 and 6 were not significantly altered 
compared to the parent strain.
The MATH and HIC tests (Tables 4.3 and 4.5) showed that the 
clinical isolate of 0157 was slightly more hydrophobic than the reference 
strain. This may be more significant, since sequential subculturing of 
clinical isolates can result in gradual loss of hydrophobic properties. It may 
be the case therefore, that this strain was originally more hydrophobic 
than it now is. There is evidence that other non-invasive E.coli, EPEC, are 
more hydrophobic than non-pathogenic strains (Smyth et al 1978), so it 
seems possible that prior to sub-culturing, the clinical isolate of 0157  was 
more hydrophobic than shown here.
The overall conclusion is that none of the VTEC tested were 
strongly hydrophobic. This supports the findings of Sherman et al (1987) 
who using HIC, tested several 0157:H7 strains and found that all had a 
high anionic surface charge, but low surface hydrophobicity. The LPS 
mutations in clones 5 and 6 had not affected the hydrophobicity of these 
organisms. It also seemed unlikely that the hydrophobic properties of 
clone 1 had been significantly changed, as slight differences are probably 
explained by the mucoid nature of these bacteria.
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Table 4.3 Microbial Adhesion to Hydrocarbons (MATH)
Strain Volume of Hexadecane added
0.1ml 0.2ml 0.4ml
0157:H7 
Parent strain 
Clone 1
Clone 5
Clone 6
0157
Clinical isolate 
Econl
98.4 ± 3.2
100.3 ±4.1 
99.1 ± 0.9
97.4 ± 2.6 
98.0 ± 2.2
93.3 ± 3.5
97.814.3 90.111.2 
101.517.2 87.212.3 
96.6 1 3.4 93.5 1 3.1 
98.710.8 93.515.7 
93.71 6.2 87.6 14.3 
85.4 1 8.4 64.9 1 3.8
Bacteria were suspended in saline, and a volume of hexadecane ranging 
from 0.1ml to 0.4ml was added and thoroughly mixed. Results are 
expressed as mean percentage retention of organisms in the aqueous layer 
for triplicate tests (1 = range of values).
124
Table 4.4 Salt Aggregation Test (SAT)
Strain Ammonium Sulphate Cone.
0157:H7 Parent strain 2.4M
Clone 1 1.7M
Clone 5 2.3M
Clone 6 2.3M
0157 Clinical isolate 2.3M
Econl 0.6M
A bacterial suspension was mixed with a range of ammonium sulphate 
solutions ranging from 0-4.0M. Figures refer to the highest concentration 
of ammonium sulphate, at which aggregation of organisms was observed. 
This value was reproducible even when performed on separate days.
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Table 4.5 Hydrophobic Interaction Chromatography (HIC)
Strain % Retention by HIC column
0157:H7 Parent strain 48.8 ± 0.5
Clone 1 53.0 ± 3.1
Clone 5 45.5 ± 4.2
Clone 6 45.5 ±1.0
0157 Clinical isolate 50.5 ± 2.6
Econl 75.3 ± 0.3
A suspension of bacteria was applied to an octyl-sepharose
chromatography column. The pre- and post-column optical densities were 
then compared, and the percentage of organisms retained by the column 
was calculated. Mean values of three tests are shown (± = range of results).
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4.2.9. Attachment of Bacteria to Mucus and HeLa cells.
The successful colonization of host mucosal surfaces by pathogenic 
bacteria results from a complex interaction between the bacterial and host 
cells. The initial association involves interaction of the pathogen with 
extracellular host products such as mucus which is secreted by goblet cells 
of the epithelium. Adhesion then involves highly specific interactions 
between bacterial adhesins and receptors on the epithelial surface.
Since the cell envelope of clones 5 and 6 differed from the parent 
strain, the attachment properties of these bacteria were investigated and 
compared. Their ability to attach to mucus and to a human epithelial 
(HeLa) cell line was studied.
4.2.9.1 Attachment to Mucus
Mouse colonic mucus was separated by SDS-PAGE and transferred to 
nitrocellulose. Bacteria which attached to the mucus fractions were 
detected immunologically using mouse antiserum to E.coli, followed by 
goat anti-mouse horseradish peroxidase conjugate. There was no apparent 
difference in the binding capacity of the wild-type and clones 5 and 6, 
which all bound to a -70 kDa protein of mouse mucus (Figure 4.8). An 
E.coli strain expressing K88 fimbrial antigens which are associated with 
attachment to mucus (Laux et al 1986), was included as a positive control. 
Thus although a blot was not done with whole cells to see how reactive 
the serum was, the K88 antigens acted as an indicator that the expected 
reaction had worked. As a negative control, culture medium was added in 
place of bacteria and no band was visualised in this test. This ensured that 
the antibodies themselves did not react with the mucus. In an identical 
experiment none of the strains bound to any component of hamster
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mucus (data not shown), but this may be because hamsters do not appear 
to be colonized by E.coli (S P Borriello, personal communication). A 
parallel study on C.difficile revealed that the bacteria were probably 
binding to glycoprotein (Krishna & Borriello 1992).
Attachment of E.coli to mucus has been studied by other workers 
who concluded that the bacteria bind to fractions in the 50-70-kDa range 
(Cohen et al 1986, Laux et al 1986). Mucin consists of high-molecular- 
weight polymeric glycoproteins and a smaller link glycopeptide. It appears 
that 0157:H7 bind to the 118-kDa link glycopeptide (Sajjan & Forstner 
1990b). In an earlier study, however, it was suggested that mucin samples 
which were prepared from secretions in which there was prolonged 
exposure of the mucus to proteolytic enzymes, may become partially 
degraded during the harvesting procedure. Ferret mucus was found to 
contain a 70-kDa band which was thought to represent partial degradation 
of the 118-kDa component (Roberton et al 1989). Thus it is possible that the 
observed binding of the 0157:H7 strains to a 70-kDa band in this study, is a 
consequence of the mucus preparation, whereby some proteolytic activity 
occurred, and the bacteria attached to a product of degradation of the link 
glycopeptide thought to bind to 0157:H7 (Sajjan & Forstner 1990b).
Binding of E.coli to mucin has in some cases been shown to be 
dependent upon the possession of adhesins such as fimbriae (pili). E.coli 
K12, for example, does not bind to mucus, but if it carries the K88ab 
plasmid which encodes K88 fimbrial antigens, the cells will attach to 
mucus via two glycoproteins of 57- and 64-kDa (Laux et al 1986). 
Adherence by some fimbriae can be blocked by D-mannose, and such 
adhesins, also known as type-1 pili are found on 50-70% of E.coli (Karch et 
al 1985). Sajjan & Forstner (1990a) showed that only a type-1 piliated 
0157:H7 strain was capable of binding to mucus, although this strain was 
more hydrophobic than any of the other type-1 piliated strains
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investigated. Hydrophobicity studies (Section 4.2.8) show that the 0157:H7 
strain used in the present study was less hydrophobic than any of the type- 
1 piliated strains studied by Sajjan & Forstner (1990a), who found it 
necessary to induce the pili by repeated subculturing. It is unlikely 
therefore that the bacteria used in the present study were type-1 piliated. 
Possession of these pili therefore, appears not to be essential to mucus 
binding.
In conclusion it appears that E.coli 0157:H 7 bind to a ~70-kDa 
fraction, of mouse colonic mucus which is possibly a degradation product 
of the 118-kDa link glycopeptide which has been shown to bind 0157:H7 
(Sajjan & Forstner 1990b). Lack of attachment to hamster colonic mucus is 
attributed to lack of receptors, because hamsters are not natural hosts of 
E.coli. The binding capacity of clones 5 and 6 was not affected by the 
alterations to these bacteria, indicating that this binding is not O-type 
specific since clones 5 and 6 no longer possess 0157 antigens.
4.2.9.2 Attachment to HeLa Cells
It is known that VTEC attach to the surface of certain eukaryotic cell lines 
but are non-invasive. 0157:H7 and clones 5 and 6 were allowed to attach 
to HeLa cells to see whether the alterations to the outer membrane of the 
mutants had affected their ability to attach to epithelial cells. The results of 
these assays are shown in Table 4.6. Attachment assays using clone 1 were 
unsuccessful as the bacteria were unable to divide in tissue culture 
medium (even over a shorter time period) so any results would not be 
comparable to the other strains tested. A comparable number of bacterial 
cells ( -  5x107 m l'l) had been added in each case, and since the growth rate 
of clones 5 and 6 was the same as the parent strain, these results indicated
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Figure 4.8 Attachment to mucus
Mouse mucus was separated by PAGE and transferred to nitrocellulose. 
Bacterial cells were allowed to attach and were detected with mouse 
antiserum to E.coli followed by goat anti-mouse peroxidase conjugate. 
Lanes: 1- E.coli K88 (positive control). 2- 0157 (clinical isolate).
3- 0157:H7 ATCC 35150 (parent strain). 4- clone 5. 5- clone 6 
No band was visualised in the negative control (culture medium, no 
bacteria) - not shown.
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that the alterations in the LPS of the mutants had not significantly affected 
their ability to attach to HeLa cells. It is likely that during the 3 hour 
incubation period of the assay (at 37°C) the bacteria reached the 
exponential growth phase, therefore the observation that twice as many 
wild-type cells had attached compared to clone 5, is probably not 
significant. Incubation periods of less than 3 hours were not tested.
In separate assays, 0157:H7 whole cell antiserum was added with 
the bacterial cells to compare the degree of inhibition of attachment of the 
wild-type and mutants. The results of these assays are shown in Table 4.7.
When pre-immune serum was used, there was less than 50% 
inhibition of attachment in each case. The % inhibition of clones 5 and 6 
(31.1% and 35.2% respectively) was slightly less than that of the wild-type 
(45.9%) but this difference is not probably significant since this inhibition, 
by components of the serum (which had not been heated to destroy 
complement), is non-specific. In the presence of 0157:H 7 antiserum, 
however, almost all of the wild-type (95.6%) was unable to attach to the 
HeLa cells (Figure 4.9). In contrast, around 50% of clones 5 and 6 were still 
able to attach to the HeLa cells in the presence of anti-0157:H7. The 
antiserum had some inhibitory effects on attachment of the mutants, but 
this was not comparative to the inhibition of wild-type attachment.
Anti-0157:H7 did not inhibit the attachment of the mutants to the 
HeLa cells to the same extent as the wild-type. Immunoblotting had 
shown that the LPS of clones 5 and 6 did not react with this antiserum so 
the implication was that LPS was involved in attachment. However, other 
studies have shown that LPS is unlikely to be involved in attachment 
(Sherman & Soni 1988). VTEC attach to epithelial cells in an attaching- 
effacing (AE) manner (Sherman et al 1988b), also characteristic of EPEC,
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Table 4.6 Attachment of 0157:H7 and clones 5 and 6 to HeLa cells.
Strain Number of cells
attached ml"*
Wild-type 0157:H7 3.45 xlO6
Clone 5 5.71 x 106
Clone 6 7.03 x 1 0 6
Bacterial cells (5 x 107 m l'1) were allowed to attach to HeLa cells for 3 
hours at 37°C. After washing, the HeLa cells were lysed and attached 
bacteria were serially diluted and cultured. The assays were carried out in 
triplicate, and a mean value is shown in the above table.
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Table 4.7 Attachment of 0157:H7 and clones 5 and 6 to HeLa cells in
the presence of 0157:H7 antiserum.
Strain
Wild-type 0157:H7 
Clone 5
% inhibition by pre- 
immune serum
45.9± 3.6
31.1± 1.5
% inhibition by 
0157:H7 antiserum
95.6± 2.9
51.7± 3.0
Clone 6 35.2± 1.4 45± 1.9
Bacterial cells (5 x 10^ ml-1) were allowed to attach to HeLa cells in the 
presence of either 0157:H 7 antiserum, or pre-immune serum from the 
same rabbit. Assays without serum additions were also carried out. 
Attached cells were enumerated as described in Table 4.6.
The number of cells attaching in the presence of serum is expressed as a 
percentage of the number which attached in the absence of serum. Assays 
were carried out in triplicate and the figure in the above table is the mean 
value (± = range of values)
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Figure 4.9 Attachment of 0157:H7 to HeLa cells in the presence and
absence of 0157:H7 antiserum.
Bacteria were allowed to attach to HeLa cell monolayers which had been 
cultured on 13mm round glass coverslips. After several washes to remove 
unattached bacteria, the HeLa cells were stained with Giemsa stain and 
photographed. Assays were carried out in the presence (1) and absence (2) 
of anti-0157:H7.
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which are thought to attach via a 94-kDa membrane protein encoded by 
the chromosomal eae gene (Jerse & Kaper 1991). Homologous sequences in 
VTEC strains indicate that a chromosomal gene may be responsible for 
VTEC adherence (Jerse et al 1991). A possible adhesin is therefore a 94-kDa 
outer membrane protein which competitively inhibits adherence of VTEC 
(Sherman et al 1991). It is speculated that to inhibit attachment of the wild- 
type, the antiserum either attached directly to the adhesin(s), or antibody- 
antigen complexes masked the adhesin(s), blocking attachment. It follows 
therefore that the antiserum was less effective at inhibiting attachment of 
the mutants either because the adhesin itself was altered antigenically, or 
because the adhesin was not masked by antibodies attaching to the LPS. To 
investigate this further, outer membrane preparations were separated by 
SDS-PAGE, transferred to nitrocellulose and immunoblotted with anti- 
0157:H7. This showed that unlike the parent strain and a clinical isolate of 
0157, outer membrane components from clones 5 and 6, in the 94-kDa 
region, did not react with the antiserum (Figure 4.10). This could indicate 
that a protein of 94-kDa is involved in attachment of VTEC to epithelial 
cells, and that in these mutants this protein is antigenically distinct from 
the parent strain. Such an alteration would not necessarily affect the 
function of the protein, since it appears that the Eae protein of EPEC, 
which is involved in attachment, is antigenically distinct from the 
putative homologue in VTEC (Jerse et al 1991). In the absence of anti- 
0157:H7 the adhesion of the mutants was not different to that of the wild- 
type, therefore it is concluded that the components(s) of the outer 
membrane responsible for attachment had probably been altered 
antigenically but not functionally.
In a study on the adhesion of E.coli, from various sources, to 
mammalian cells, it was concluded that binding was associated with the 
presence of fimbriae (Jann et al 1981). The role of fimbriae in attachment of
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Figure 4.10 Immunoblotting of outer membrane preparations with anti-
0157:H7.
Outer membranes were separated on 11 % SDS-PAGE gels, transferred to 
nitrocellulose and immunoblotted with anti-0157:H7.
Lanes: 1- 0157 (clinical isolate). 2- clone 5. 3- clone 6. 4- 0157:H7 ATCC 
35150 (parent strain).
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0157:H7 to mammalian cells is controversial. Most strains possess a 60- 
MDa plasmid which encodes fimbriae which were thought to be required 
for adhesion to epithelial cells (Karch et al 1987). Subsequent studies have 
shown that possession of this plasmid is not essential for either adherence 
to epithelial cells or virulence (Junkins & Doyle 1989, Tzipori et al 1987, 
Hall et al 1990). A recent study indicated that the plasmid is not necessarily 
associated with possession of fimbriae (Ashkenazi et al 1992). The present 
study supports the theory that the 60-MDa plasmid is not essential for 
adherence of 0157:H7, since both the wild-type, and the mutants, which 
had lost the plasmid, attached to HeLa cells to the same degree.
4.2.10 Toxin Production
All six clones were screened for toxin production using immunological 
and biological techniques. The initial screen was a colony ELISA which 
detected the presence of the toxin antigens. Following this, Vero cell assays 
were carried out to see whether the toxin detected antigenically was 
biologically active. The distribution of toxin between the inside and 
outside of the cell was then determined by a standard plate ELISA.
4.2.10.1 Colony ELISA
The results of the colony ELISA are shown in Figure 4.11. It had 
been established that the wild-type produced both VT1 and VT2 (Section 
3.1.3), so assays were carried out in duplicate to assess the relative amount 
of each toxin produced by the clones. Clones 2, 3, 4, 5 and 6 seemed to 
produce comparable amounts of VT1 and VT2 to the wild-type, but clone 1 
appeared to produce more of each toxin than any of the other strains. This 
clone however had been more severely altered by the mutagenesis
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Figure 4.11 Colony ELISA of Q157:H7 (WT) and clones 1-6.
Strains were grown overnight on Penassay agar plates then transferred to 
nitrocellulose membrane in the presence of polymyxin B, and 
immunoblotted with MAb against 1) VT1 and 2) VT2.
The DAB/nickel horseradish peroxidase development system was used. 
Controls :VT1- C600 933J. VT2- C600 933W.
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procedure than the others. Evidence of this included the inability of these 
organisms to grow in the Api 20E biochemical assay or to survive in the 
tissue culture attachment assays. In addition, all attempts to extract heat- 
stable antigens from this mutant were unsuccessful. It appeared that this 
strain, which when grown on solid media had more mucoid colonies than 
the wild-type or the other clones, had an altered cell wall. Thus the 
apparent increase in toxin production seen in the colony ELISA may have 
been due to a more permeable cell wall which allowed more efficient 
extraction of toxin by polymyxin B treatment.
4.2.10.2 Vero Cell Assays
A preliminary Vero cell assay was carried out to determine whether the 
toxin detected by colony ELISA was biologically active. Undiluted 
supernatant filtrate from an overnight culture of clones 1, 5 and 6 and the 
parent strain, was added to Vero cell monolayers. Clones 5 and 6 were of 
interest since it had already been determined that the LPS of these strains 
differed from the wild-type. Clone 1 was tested to see whether this strain 
produced more toxin than the wild-type, or whether the apparent 
increased toxin levels detected by colony ELISA reflected differences in the 
permeability of the cell wall which increased the efficiency of toxin 
extraction by polymyxin B.
The assay revealed that none of the mutants produced active 
extracellular toxin even if toxin production was induced by mitomycin C 
(Table 4.8). Intracellular toxin levels were therefore examined, by breaking 
open cells through sonication and adding filtered sonicate to Vero cells. 
This showed that clones 1, 5 and 6 were able to produce some biologically 
active toxin, although intracellular levels were much lower than the 
parent strain and in some cases induction by mitomycin C was essential.
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This indicated that most of the toxin detected by colony ELISA was not 
biologically active.
If these crude toxin preparations from the mutants were kept at 4°C 
overnight, all toxic activity was lost. This could either be due to increased 
protease activity in these preparations or an increased susceptibility of 
mutant toxin to proteolytic activity. To assess whether there was increased 
protease activity in the mutant filtrates, wild-type toxin was added to an 
equal volume of the non-active mutant toxin preparation. After 48 hours 
at 4°C the activity of the normal toxin was compared to a control sample 
which had been incubated in PBS. Both toxin samples were still active, 
indicating that the loss of activity of the mutant toxin was not due to 
increased protease activity, but resulted from the instability of the protein.
The quantity of toxin required to elicit detectable immunoreactivity 
in a colony ELISA is much greater than the amount which can be detected 
by a cytotoxicity assay. The lack of detectable extracellular active toxin from 
clones 1, 5 and 6 is therefore probably due to attenuation of cytotoxic 
activity rather than the instability of the mutant polypeptides.
4.2.10.3 Plate ELISA
The results of the colony ELISA indicated that the clones of most interest, 
5 and 6, produced comparable levels of VT1 and VT2 to the wild-type 
(Figure 4.11). Also of interest was the fact that clone 1 appeared to over­
produce both toxins. Vero cell assays detected very little active toxin in any 
of these mutants however, and no activity was detected extracellularly. 
This raised the possibility that in addition to a reduction in toxin activity 
in these mutants, the secretion of the toxin was affected.
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Table 4.8 Vero cell assay.
Intracellular Extracellular
Induced Normal Induced Normal
Wild-type +++ (+++) +++ (+++) +++ (+++) +++ (+++)
Clone 1 +/- (-) (-) (-) (-)
Clone 5 + (-) +/- (-) (-) (-)
Clone 6 + (-) +/- (-) (-) (-)
+++ = 100%. + =25-50%. +/- =10-25%. - = 0%.
Figures correspond to % cell death
The cytotoxicity of culture supernatant (extracellular) and sonicated cells 
(intracellular) of 0157:H7 and clones 1, 5 and 6 was investigated. Cultures 
had been grown in the presence (induced) or absence (normal) of 
O.lpgml‘ 1 mitomycin C. Results were recorded after 3 days (day 1 results in 
parentheses).
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Figure 4.12 Piate ELISA to demonstrate distribution of VT1 and VT2 of
0157:H7 (wild-type) & clones 1,5 and 6 . 
1) Distribution of VT1
w ild -ty p e Clone 1 Clone 5 Clone 6
■  Intracellular* 
H  Intracellular -
■  Extracellular* 
□  Extracellular -
2) Distribution of VT2
■  Intracellular* 
H  Intracellular - 
H  Extracellular* 
E  Extracellular -
MAb against 1)VT1 and 2)VT2 were used to detect toxin in intracellular 
(sonicate) and extracellular (supernatant) fractions of overnight cultures 
grown with (+) and without (-) mitomycin C.
Cultures were standardised spectrophotometrically before fractionating.
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The distribution of toxin between the inside and outside of the cell 
was therefore examined using a standard plate ELISA. MAb against VT1 or 
VT2 were used as capture antibodies to coat an ELISA plate. Toxin which 
bound to these antibodies was detected by rabbit polyclonal VT antibodies 
followed by anti-rabbit peroxidase conjugate.
The results of the ELISA are shown in Figure 4.12. It is immediately 
obvious that not all toxin is located intracellularly, which combined with 
the results of the Vero cell assay indicates that the extracellular toxin and 
most of the intracellular toxin must be biologically inactive. In general, 
levels of VT1 and VT2 detected in all three mutants were lower than wild- 
type levels and extracellular levels were more greatly reduced. The toxin­
converting phages did not appear to be affected as mitomycin C still caused 
an increase in VT production by phage induction. The increase in 
intracellular toxin levels of clones 5 and 6 was comparable to the wild- 
type, but extracellular increases were significantly lower. This implies that 
secretion is impaired.
4.2.10.4 Immunogold Labelling
Immunogold labelling studies were carried out in an attempt to explain 
the reduced level of secreted toxin by the mutants. MAb tagged with 
colloidal gold were used to visualise toxin in thin sections of bacterial 
cells, which were viewed by transmission electron microscopy.
The results of the immunogold labelling are shown in Figure 4.13. 
The technique was only partially successful as only 2-6 gold particles were 
seen per cell, and most cells were unlabelled. This is thought to be a 
reflection of the fixation regime used. There was no discernible difference 
between cells which had been grown in the presence or absence of 
mitomycin C. The labelling of anti-VT2 was not successful even when the
143
Figure 4.13 Immunogold labelling of VT1
0 5^ J M
Bacterial thin sections were treated with MAb to VT1 followed by rabbit 
anti-mouse then Protein A-gold. Sections were washed before each 
addition. After the final step the sections were allowed to dry before post- 
staining, and viewed by transmission electron microscopy.
continued overleaf
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concentration of MAb was increased from 1:1000 to 1:100, so the following 
results refer to detection of VT1 only. Unfortunately it was not possible to 
repeat this work.
In the wild-type, the toxin was located either outside of the cell, in 
the periplasmic space, or in the cell periphery. Similar observations were 
made of VT1 in clone 5. In clone 6 however the toxin tended to be located 
more towards the centre of the cell, and in several cells a clumping of 5-6 
gold particles was observed. This observation was made in >20 cells 
studied. It is not known whether this reflects a discrete localization of VT1 
or passive clumping of the gold. No toxin was observed in the periplasm. 
Naturally these observations are limited and may not be significant, 
however they support the hypothesis that secretion is affected, possibly 
because the release of toxin from the cytoplasm is impeded.
It appears from these results that clones 5 and 6 produce slightly less 
toxin than the wild-type and activity is greatly reduced. No toxin activity 
was detected outside of the cell and this may reflect the fact that the 
mutant toxin was unstable. It is hypothesized therefore, that when the 
mutant toxin is synthesized it possesses low activity, but, during passage 
across the outer membrane this activity is lost, so no active toxin is 
detected outside the cell. The toxin is thus affected biologically but still 
cross-reacts antigenically with the wild-type.
VT are composed of a single A subunit non-covalently associated 
with a pentamer of B subunits. To be functionally active, the B subunit 
must possess the ability to bind to Gb3  and to oligomerize correctly with 
the A subunit. The A subunit, in addition to assembling correctly with B 
subunits must possess RNA N-glycosidase activity. If any of these 
characteristics are altered, toxin activity will be affected. Several workers 
have reported that changes to a few amino acid residues can reduce toxin 
activity. A critical site for enzymatic activity of the A subunit of VT1 is
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glutamic acid residue 167. If this residue is replaced with aspartic acid, 
specific activity is decreased 1000-fold, although the change does not affect 
the polypeptide conformation, and full-length proteins are produced 
which are correctly processed by signal peptidase (Hovde et al 1988). The 
corresponding amino acid residue, glutamic acid 166, is essential for VT2 
activity (Jackson et al 1990). Deletion of amino acids 3-18 of the VT2 A 
subunit results in loss of cytotoxicity and enzymatic activity (Perera et al 
1991b). Mutations in the B subunit have also been shown to be essential to 
toxin activity. Perera et al (1991a) identified 3 amino acid residues in Shiga 
toxin and VT2 B subunits which were essential for holotoxin activity. 
These mutants were immunogenic but not cytotoxic, much like the 
mutant toxins produced in the present study. It would have been of great 
interest to sequence the toxin genes from clones 5 and 6 to investigate the 
reduced activity.
It is possible that toxin activity was affected at the level of toxin 
binding. This could have been investigated using a receptor analogue 
ELISA such as that described by Weinstein et al (1988a). The receptor 
analogue used was Gal-Gal-BSA, which is commercially available. This 
was attached to an ELISA plate and toxin allowed to bind. The extent of 
binding was detected by specific MAb to the toxins. Reduced binding, or 
the inability of the mutant toxins to bind to the VT receptor would explain 
the observed loss of cytotoxicity.
As mentioned above, it has been established that minor changes in 
the amino acid sequence of VT can dramatically affect their activity. It 
would have been of great interest therefore to sequence the toxins from 
the mutants and possibly relate alterations at the nucleotide level to 
reduced activity. Since the nucleotide sequences of VT1 and VT2 are 
known (Calderwood et al 1987, Newland et al 1987) it would be possible to 
utilise the polymerase chain reaction (PCR) in sequencing the mutant
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toxins. Primers could be synthesized to amplify the entire toxin gene, or 
shorter sequences could be amplified, and readily cloned into suitable 
vectors and sequenced. Perera et al (1991a,1991b) have demonstrated that 
both 5' and 3' terminal coding sequences are essential for functional VT 
operons, so these areas could be concentrated on initially. Although 
glutamic acid residue 167 (VT1) or 166 (VT2) has been shown to be 
essential for toxin activity, it is probably not affected in these mutants since 
there is some activity, albeit greatly reduced.
In addition to reduced biological activity, there is some evidence 
that toxin secretion is also impaired. VT are periplasmic proteins which 
are secreted from the cell via a 'leaky membrane', that is, there is no active 
secretion. Proteins destined for an extracytoplasmic location are 
synthesized with an additional hydrophobic amino-terminal extension 
(approximately 20 residues) known as the signal sequence. Single amino 
acid substitutions in the signal sequence can affect the export of a protein. 
Maltose binding protein (MBP), for example, accumulates in a precursor 
form in the cytoplasm if a single hydrophobic or uncharged amino acid is 
replaced with a charged residue (Bedouelle et al 1980). This suggests that 
the hydrophobicity of the signal sequence is important in localisation of an 
exported protein. In the present study the results of the plate ELISA 
indicated that secretion of VT by the mutants was not as efficient as the 
wild-type. It may be the case that toxin secretion is reduced due to an 
altered signal sequence. This could be confirmed by sequencing the signal 
sequence.
An alternative explanation to reduced secretion of toxin is that 
other molecules which are essential to secretion are affected. In order to 
translocate across biological membranes, proteins assume a loosely folded 
structure, the 'pre-folded confirmation' (Kumamoto 1991). This is thought 
to be maintained by soluble protein factors known as molecular
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chaperones. One of the better characterised of these agents is SecB. Mutants 
in SecB exhibit severe defects in some proteins for example MBP. In SecB" 
mutants 70% of intracellular pre-MBP was found to be in an export- 
competent conformation but was exported extremely slowly, showing that 
SecB also accelerates the export process (Kumamoto 1991). It may be 
possible to test this theory because only a subset of exported proteins are 
affected by a mutation in SecB. Mutants in SecB are inhibited in MBP 
secretion but export normal levels of alkaline phosphatase (Kumamoto & 
Beckwith 1985). These proteins can be assayed, and reduced levels of 
extracellular MBP but not alkaline phosphatase, compared to wild-type 
levels, could be indicative of SecB mutations.
The observed reduction in secreted toxin could be a function of the 
toxin itself, either by alterations in the signal sequence or the tertiary 
structure of the molecule. The latter may be less likely since antigenic 
determinants seemed to be unaffected in the mutants. Molecular 
chaperones may have been altered by the mutagenesis, in which case it is 
likely that other secreted proteins would also be affected. Alternatively, the 
export of toxin across the membrane may have been affected by the 
changes in the outer membrane itself. Since secretion is not active, it could 
simply be that the mutated membrane is less 'leaky' than the wild-type 
membrane. It should be possible to test this hypothesis by inducing the 
phages from the mutants and the wild-type, and lysogenising another 
E.coli strain such as K12. The amount of extracellular toxin produced by 
the K12 lysogens could then be compared, and reduction in mutant levels 
would be a function of the toxin or phage genes and not a property of the 
cell membrane.
In summary, mutants of 0157:H7 ATCC 35150 have been created by 
chemical mutagenesis. Six clones were analysed, and clones 1, 5 and 6 were
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found to be altered with respect to plasmid content. Clones 5 and 6 were 
altered with respect to outer membrane components, and all three 
mutants showed a reduced capacity to produce toxin, compared to the 
wild-type. The O chain of the LPS of mutants 5 and 6, failed to react with 
anti-0157:H7 although the major outer membrane proteins, Omp F, C, 
and A, appeared to be unaffected antigenically. Neutral sugar profiles of 
clones 5 and 6 revealed that the LPS contained rhamnose instead of fucose, 
which was present in the wild-type. The hydrophobicity of these mutants, 
and their ability to attach to colonic mucus and epithelial cells was not 
affected. However, it appeared that a protein responsible for binding of the 
bacteria to epithelial cells may have been altered antigenically since it no 
longer reacted with anti-0157:H7, and this antiserum was not effective at 
blocking attachment. Clones 5 and 6 produced very little active toxin, and 
secretion may have been impaired. Immunological toxin screening 
revealed that the mutants produced only slightly less toxin than the wild- 
type.
Attempts to extract outer membrane components from clone 1 were 
unsuccessful, so LPS analysis and attachment studies were not carried out 
on this mutant. However, toxin secretion and activity were affected. 
Clones 2, 3 and 4 were not significantly altered by the mutagenesis, and 
were included in studies only for comparative purposes.
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Chapter 5 Mechanism of Internalisation and Intracellular Processing of 
Verotoxins
5.1 Receptor-Mediated Endocytosis
5.1.1 Introduction
As VT act on an intracellular target, namely the 60s ribosomal subunit 
(Endo et al 1988), the process of internalisation is crucial to the action of 
these toxins. It is known that several toxins with intracellular targets enter 
cells via receptor-mediated endocytosis (RME) (Willingham & Pastan 
1984), therefore this process was investigated as a potential mechanism for 
entry of VT1 and VT2.
RME involves the internalisation of toxin-receptor complexes into 
coated vesicles, via specialised regions of the cell membrane known as 
coated pits. Upon loss of the vesicle coat, the vesicles, now known as 
endosomes, fuse with either the trans Golgi complex or primary 
lysosomes, from where the toxin is able to translocate to the cytosol, and 
hence reach the intracellular target. In some cases for example diphtheria 
toxin, the toxin is able to enter the cytosol directly from the endosome, but 
commonly a fusion step between endosomes and lysosomes is necessary.
The approach taken to investigate the relevance of RME to VT 
internalisation, was to use inhibitors which block various steps of the 
process and to see the effects of these agents on the cytotoxicity of VT1 and 
VT2 towards Vero cells (Figure 5.1). A key weakness in studying the 
cellular pathogenesis of toxins is that cultured cell lines are not necessarily 
the appropriate target cells, therefore in vitro studies may not give a true 
picture of intracellular events. It has been shown, however, that the effect 
of Shiga toxin on cultured epithelial cells from human colon and ileum
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Figure 5.1
Schematic Representation of Receptor-Mediated Endocytosis
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The points of action of the inhibitors used in this study are indicated.
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was similar to that on Vero and HeLa cells (Moyer et al 1987). It would 
appear that for Shiga toxin , Vero cells are an appropriate model for toxic 
action. Since VT and Shiga toxin are related both in amino acid sequence 
and in mode of action, it is thought that the activity of VT1 and VT2 in 
Vero cells will also be representative of the in vivo situation.
Endocytosis is an energy-dependent process, so initially metabolic 
inhibitors were added to Vero cells, along with either VT1 or VT2. The 
cytotoxic activity of both toxins was reduced by a metabolic inhibitor, 
indicating that energy was required for intoxication to take place. Two 
features of RME which are essential to the internalisation of other toxins, 
are the fusion of endosomes with lysosomes, and the requirement for 
exposure to an acidic intravesicular compartment. This study showed that 
intoxication of Vero cells by either VT1 or VT2 was prevented when 
fusion between endosomes and lysosomes was blocked. There was no 
requirement for exposure to an acidic environment, as agents which 
increased intravesicular pH did not inhibit the cytotoxicity of either VT1 
or VT2.
Two VTEC strains were used: E3787, a VT1 producer, and E32511, 
which produces only VT2. The titres of VT2 were consistently higher than 
those of VT1, probably because VT2 tends to be more evenly distributed 
between the inside and outside of the cell, whereas VT1 is almost 
completely cell-associated (Strockbine et al 1986).
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5.1.2 Results and Discussion
The effects of various inhibitors of RME were assessed to determine the 
pathway of entry and any intracellular processing of VT1 and VT2. The 
points of action of these agents and conditions are shown in Figure 5.1. In 
order to determine the concentration of inhibitor to use, all drugs were 
titrated across monolayers of Vero cells to assess their toxicity to the cell. 
The highest concentration of each drug, which caused no visible effects on 
the cell line, was then chosen to be used in this study.
5.1.2.1 The Effect of Metabolic Inhibitors
Metabolic inhibitors affect energy-dependent processes such as endocytosis 
by reducing intracellular levels of ATP. The endpoint effect of metabolic 
inhibitors on intoxication of Vero cells by VT1 and VT2 is shown in Table 
5.1. Of the three inhibitors tested: sodium fluoride, 2-deoxyglucose and 2,4- 
dinitrophenol, only 2-deoxyglucose reduced the cytotoxic effect of the 
toxins. This is consistent with other reports, where some metabolic 
inhibitors were unable to reduce intracellular ATP significantly to affect 
endocytosis. In order to reduce the activity of ricin and diphtheria toxin for 
example, it was necessary to add sodium fluoride in conjunction with 
sodium azide, an inhibitor of oxidative phosphorylation (Sandvig & 
Olsnes 1982b). In the present study however, even the use of these two 
drugs together failed to affect the intoxication of cells by either VT1 or VT2 
(Table 5.1). Sodium fluoride alone has been effective in reducing the 
cytotoxic effects of Shiga toxin, but did not inactivate the toxin as such, and 
had no effect on binding of the toxin to the receptor cell (Eiklid & Olsnes 
1983).
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Table 5.1 Endpoint effect of metabolic inhibitors on cytotoxicity of VT1
and VT2.
Inhibitor VT1 VT2
None 256 65,536
2-deoxyglucose 4 <256
Sodium fluoride 256 65,536
2.4-dinitrophenol 256 65,536
Sodium fluoride + 
sodium azide
256 65,536
Culture filtrate of either a VTl-producer (E3787) or a VT2-producer 
(E32511) was titrated across monolayers of Vero cells.
A constant volume (25(0.1) of inhibitor was added to give a final 
concentration of 5mM. The endpoint was determined after 20-24 
hours at 37°C in 5% CO2 , as the reciprocal toxin concentration 
which killed 50% cells.
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Metabolic inhibitors have successfully been used to protect against 
toxins which are known to enter mammalian cells by RME, for example, 
ricin, diphtheria toxin, Clostridium difficile toxin A and Shiga toxin 
(Sandvig & Olsnes 1982b, Henriques et al 1987, Eiklid & Olsnes 1983). Since 
cytotoxicity of VT1 and VT2 towards Vero cells was reduced by 2- 
deoxyglucose, it seemed likely that the internalisation mechanism of these 
toxins is an energy-dependent process, such as RME.
5.1.2.2 The Effect of preventing Fusion between Endosomes and
Lysosomes
Fusion between endosomes and lysosomes is selectively and reversibly 
inhibited at temperatures below 20°C, and in the presence of 200mM 
potassium chloride. Cellular intoxication by VT1 and VT2 was prevented 
at 18°C suggesting that a fusion is required for activity of the toxins (Table 
5.2). This was confirmed by transferring cells to 37°C which overcame the 
protective effect. Vero cells which were kept at 18°C in the presence of 
toxin showed no cytopathic effects even after 48 hours. Other workers 
have reported similar protection at 18°C from intoxication by C.difficile 
toxins A and B, and Shiga toxin (Henriques et al 1987, Florin & Thelestam 
1986, Eiklid & Olsnes 1983). The action of the toxins appears to be blocked 
at the fusion between endosomes and lysosomes since it has been 
demonstrated using ricin-peroxidase conjugates that transport of toxin to 
the Golgi complex is a temperature-dependent process (van Deurs et al 
1987).
Binding of the toxin may also be reduced at lower temperatures as 
Sandvig et al (1989) have demonstrated that at low toxin concentrations 
approximately twice as much Shiga toxin binds at 37°C as at 18°C. An 
earlier study however showed that toxin binding was the same at 25°C
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when toxin was active, as at the lower inhibitory temperature of 20°C 
(Eiklid & Olsnes 1983). In this study, cells which had been incubated at 
18°C with VT, were washed to remove unbound toxin and then 
reincubated at 37°C. Toxin titres were then comparable to the control 
experiment where cells were incubated at 37°C directly after adding the 
toxin. Thus it appeared that for both VT1 and VT2, even if binding is 
reduced at 18°C, it has no significant effect on the titres of these toxins 
(Table 5.2).
Fusion between intracellular vesicles is also reported to be inhibited 
at high potassium chloride concentrations, therefore cells were incubated 
with toxin in the presence of 200mM potassium chloride (Table 5.2). Cells 
were protected from the activity of both VT1 and VT2 by this agent, which 
further demonstrated that a fusion is needed for cellular intoxication to 
occur. Other toxins which are inhibited by high levels of potassium 
chloride include C.difficile toxins A and B, and Shiga toxin (Henriques et 
al 1987, Florin & Thelestam 1986, Eiklid & Olsnes 1983).
These findings show that when the toxins are trapped in the 
endosomes, either by low incubation temperature or high potassium 
chloride levels, no cytopathic effects will be seen. This suggests that VT1 
and VT2 cannot be transferred to the cytosol directly from the endosomes, 
at least not in an active form, but must first pass into either primary 
lysosomes or the trans Golgi complex. This is probably due to a 
requirement for further processing of the toxins by enzymes not present in 
the endosomes to release the active fragment.
Endosomes are generated from coated pits which are known to 
exclude a number of membrane proteins, for example some proteases, 
which are found in lysosomes and the trans Golgi complex. Further 
studies using inhibitors of lysosomal proteases may have confirmed that
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Table 5.2 Endpoint effect of prevention of fusion between
endosomes and lysosomes on the cytotoxicity of VT1
and VT2
VT1 VT2
No inhibitor 256 65,536
a Potassium chloride 
200mM
No CPE No CPE
b Incubation 18°C No CPE No CPE
c Incubation 18°C 
Reincubation 37°C
256 65,536
Culture filtrate of either a VTl-producer (E3787) or a VT2- 
producer (E32511) was titrated across monolayers of Vero cells.
(a) 25pl potassium chloride was added to each well to a final 
concentration of 200mM. Cells were incubated at 37°C.
(b) Cells were incubated at 18°C.
(c) Cells were incubated at 18°C for 24 hours then transferred to 
37°C. CPE only appeared after incubation at 37°C.
The toxin titre is the reciprocal toxin dilution which killed 
50% of cells after 20-24 hours incubation in 5% C02-
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VT require lysosomal processing. For example, the activity of C.difficile 
toxin B is reduced in the presence of chymostatin, leupeptin and antipain, 
indicating that this toxin requires processing by lysosomal proteases 
(Florin & Thelestam 1986). C.difficile toxin A however, is not inhibited by 
these agents, although there is still a requirement for fusion between 
endosomes and lysosomes (Henriques et al 1987). It seems, therefore, that 
if further processing of toxins occurs in lysosomes or the Golgi complex it 
may not necessarily involve common lysosomal proteases.
5.1.2.3 The Effect of Lysosomotropic Agents
Amines such as ammonium chloride, chloroquine and methylamine are 
able to penetrate membranes in their unprotonised form. Inside acidic 
vesicles they become protonised and thereby increase the internal pH. 
Protection by lysosomotropic agents implies a requirement for exposure to 
an acidic environment, possibly for enzymatic activation and/or transfer 
of toxin to the cytosol. Such compounds have been successfully used to 
protect against C.difficile toxins A and B, and diphtheria toxin (Henriques 
et al 1987, Florin & Thelestam 1986, Mekada et al 1981). In the present 
study however, all the agents tested: ammonium chloride, chloroquine 
and methylamine, failed to inhibit VT1 and VT2 activity (Table 5.3). 
Mutant Chinese Hamster Ovary (CHO) cells which have a defect in ATP- 
dependent acidification of endosomes were available to confirm this 
observation. The ability of VT1 and VT2 to intoxicate both wild-type CHO 
cells and the mutants would have confirmed that acidification of 
endosomes is not essential for toxin activity. Unfortunately this 
experiment could not be carried out as CHO are resistant to VT 
(Konowalchuk et al 1977).
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In addition to raising the intracellular pH, lysosomotropic agents 
inhibit transglutaminase which may be involved in the clustering and 
internalisation of ligands. This seems to be the mechanism of protection 
against Pseudomonas exotoxin A (Middlebrook & Dorland 1984). Since 
VT1 and VT2 remain cytotoxic in the presence of these agents they must 
be able to enter cells even if this enzyme is inactivated. The implication of 
these results is that VT can, under certain circumstances, enter cells by an 
alternative mechanism that does not involve coated vesicle formation.
Trifluoperazine inhibits the clustering process of endocytosis and 
also blocks an alternative endocytotic pathway which is independent of 
the coated pit mechanism. In the presence of this drug, the action of both 
VT1 and VT2 is blocked (Table 5.3). This observation supports the 
hypothesis that VT1 and VT2 under normal circumstances enter cells by 
RME although do not require exposure to an acidic environment. If 
clustering of the toxin-receptor complexes is blocked however the toxins 
are still able to enter cells, probably via an alternative pathway which does 
not involve coated pits.
5.1.2.4 The Effect of Monensin
Monensin is a proton ionophore which induces electroneutral exchange 
of H+ for monovalent cations, for example K+ and Na+. This disruption 
of the proton gradient has the effect of raising intravesicular pH. 
Protection by such an agent implies that exposure to an acidic 
environment is essential for cellular intoxication.
Monensin gave significant protection against VT1 and VT2 (Table 
5.3) which may indicate a requirement for intravesicular acidification. 
However since other lysosomotropic agents failed to protect against VT1 
and VT2 (Table 5.3), the protective effect of monensin can probably be
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Inhibitor VT1 VT2
No Inhibitor 256 65,536
Ammonium chloride 256 65,536
20mM
Chloroquine 256 65,536
lOOpM
Methylamine 256 65,536
20mM
Trifluoperazine <4 <256
25|iM
Monensin lOpM 4 <256
Culture filtrate of either a VTl-producer (E3787) or a VT2-producer 
(E32511) was titrated across monolayers of Vero cells.
A constant volume (25(0.1) of each inhibitor was added to each well (final 
concentration as shown above).
The toxin titre is the reciprocal toxin dilution to give 50% cell death after 
20-24 hours incubation at 37°C in 5% CC>2.
Table 5.3 Endpoint effect of lysosomotropic agents and trifluoperazine
on cytotoxicity of VT1 and VT2
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attributed to other properties of the compound. In addition to increasing 
vesicular pH, monensin interferes with the transport of protein between 
different vesicular compartments, especially the fusion of endosomes with 
the Golgi region. Since VT1 and VT2 were both inhibited under 
conditions which prevented such a fusion (Table 5.2), it is likely that the 
protection afforded by monensin is due to interruption of protein 
transport. In addition, it has been shown that the endocytosis of low 
density lipoprotein (LDL) can be interrupted by monensin as the drug 
blocks the return of receptors for recycling (Basu et al 1981). It is probably a 
combination of these effects which made monensin an effective inhibitor 
of VT1 and VT2. The effectiveness of monensin as a toxin inhibitor has 
also been reported for C.difficile toxins A and B, Shiga toxin and 
diphtheria toxin (Henriques et al 1987, Caspar et al 1987, Sandvig & Brown 
1987, Sandvig & Olsnes 1980).
The above data indicates that the internalisation of VT1 and VT2 is 
an energy-dependent process which can be prevented by metabolic 
inhibitors. Most glycolipid-binding toxins, for example cholera and tetanus 
toxins, are endocytosed from uncoated areas of the plasma membrane. The 
first reported example of a lipid-binding ligand to be endocytosed from 
coated pits was Shiga toxin (Sandvig et al 1989). Since then it has been 
shown that glycolipids can enter cells by RME without being cross-linked 
with a ligand (Kok et al 1989). Internalisation of VT1 and VT2 is an energy- 
dependent process which has no requirement for exposure to a low pH, 
but fusion between endosomes and lysosomes is essential. It is proposed 
therefore that VT1 and VT2 are also endocytosed via coated pits, but that if 
the clustering of toxin-receptor complexes is blocked, an alternative 
pathway becomes apparent.
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5.2 The Role of Calcium Uptake in Cellular Internalisation of 
VT1 and VT2
5.2.1 Introduction
The activity of several toxins including Shiga toxin and C.difficile toxin B 
is affected in the presence of drugs which block calcium transport across 
membranes (Sandvig & Brown 1987, Caspar et al 1987). To investigate the 
potential role of the calcium uptake system in VT internalisation, several 
drugs were chosen which inhibit the pathway at different stages (Figure 
5.2)
Verapamil is a potent calcium channel blocker. Lanthanum 
chloride can also prevent entry of calcium, but has in addition a more 
general inhibitory effect on membrane fluidity. Chlorpromazine and 
trifluoperazine are able to prevent the formation of the calcium- 
calmodulin complex. Indomethacin is an inhibitor of the synthesis of 
prostaglandins, and is known to inhibit the action of some toxins 
(Giugliano & Drasar 1984).
5.2.2 Results and Discussion
The effect of these various inhibitors of the calcium pathway are described 
below. The points of action of the agents are shown schematically in 
Figure 5.2.
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5.2.2.1 The Effect of Calcium Channel Blockers
Verapamil protected Vero cells effectively against both VT1 and VT2 
(Table 5.4), suggesting that functioning physiological calcium channels are 
necessary for cellular intoxication. This protection is probably at the level 
of toxin entry, as it has been shown that no protection occurred if 
verapamil was added after internalisation of C.difficile toxin B (Caspar et 
al 1987). Sandvig & Brown (1987) reported that Shiga toxin binding is not 
affected if calcium uptake is interrupted, and the slight decrease in binding 
of C.difficile toxin B in the presence of verapamil was insufficient to 
account for the protective effects of this drug (Caspar et al 1987). It is 
proposed therefore that verapamil is able to reduce the cytotoxic effect of 
VT1 and VT2 on Vero cells by blocking transport of the A subunit across 
the cell membrane. It has been suggested that verapamil may act at 
vesicular membranes, blocking toxin entry into the cytosol, rather than, or 
in addition to, at the plasma membrane, which would prevent toxin entry 
into the cell (Sandvig & Olsnes 1982a). This appears not to be the case for 
Shiga toxin however (Sandvig & Brown 1987), and since VT1 is closely 
related to Shiga toxin it is proposed that protection by verapamil against 
VT1 and VT2, is at the level of toxin entry into the cell.
Lanthanum chloride (LaCl3 ) is a calcium antagonist, which protects 
cells against the toxic effects of abrin, modeccin, ricin, diphtheria toxin and 
C.difficile toxin B (Sandvig & Olsnes 1982a, Giugliano & Drasar 1984). No 
protection was seen against VT1 and VT2 however, either in this study or 
in a previous study (Giugliano & Drasar 1984). This can be explained by 
considering the fact that La^+ ions interfere with processes other than 
those dependent on Ca2+, and may have a more general inhibitory effect 
on membrane permeability. Thus lanthanides protect against ricin and
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diphtheria toxin, whereas verapamil has no effect (Sandvig & Olsnes 
1982a), indicating that the main protective mechanism of La3+ is not at 
the level of the calcium uptake system. This hypothesis is supported by an 
observation made by Sandvig & Olsnes (1982a) that similar protection was 
afforded by Fe3+, although this trivalent cation has no effect on the uptake 
of calcium. Both verapamil and La3+ protected against C.difficile toxin B 
but in the latter case protection was only afforded if the cells were pre­
incubated with the drug before addition of the toxin (Caspar et al 1987). 
When these observations are considered, the fact that lanthanum chloride 
did not protect Vero cells from VT1 and VT2, does not contradict the 
initial conclusion that internalisation of VT1 and VT2 is linked to calcium 
uptake.
5.2.2.2 The Effect of Inhibitors of the Secretory Mechanism of Cells
Chlorpromazine and indomethacin inhibit the action of several toxins 
including E.coli heat-stable toxin (ST), cholera toxin and C.difficile toxin 
(Greenberg et al 1980, Giugliano & Drasar 1984). In this study, neither agent 
had any effect on cellular intoxication by either VT1 or VT2 (Table 5.4).
E.coli ST and cholera toxin cause disease by stimulation of the 
secretory mechanism of cells. Indomethacin blocks this activation, and so 
protects against the toxin. The action of VT is to inhibit protein synthesis, 
and no activation of the secretory pathway of the cell is involved 
(Konowalchuk et al 1977). Therefore it is not surprising that indomethacin 
had no effect on the toxicity of VT1 or VT2.
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Figure 5.2 The Calcium-Calmodulin Pathway: Points of Action of 
Inhibitors
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LaCIs
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In addition to blocking the secretory mechanism of mammalian cells, 
chlorpromazine is able to bind the calcium-binding protein calmodulin. 
The apparent requirement for functioning calcium channels indicates that 
the calcium pathway is important in VT uptake, so it was logical to 
assume that calmodulin may be involved. It was shown however that 
there was no protection given by chlorpromazine against VT1 or VT2 
(Table 5.4). This result, and a similar finding by Giugliano & Drasar (1984) 
indicated that calmodulin is not involved in toxin activity. Another 
inhibitor of the calcium-calmodulin complex, trifluoperazine, did inhibit 
VT activity (Table 5.4), which apparently contradicts the previous 
observation. Protection by this compound however, is not always related 
to a requirement for calcium (Sandvig & Olsnes 1982a). Thus, it appears 
that protection by trifluoperazine is accounted for by the prevention of the 
clustering of toxin-receptor complexes during endocytosis (Section 5.1.2.3). 
Resistance to the effects of trifluoperazine can be explained, not in terms of 
the calcium pathway, but as to whether the toxin is able to bypass the 
endocytotic pathways blocked by the drug. It appears that the study by 
Sandvig & Olsnes (1982a), showing no correlation between calcium 
requirement and protection by trifluoperazine, coupled with the lack of 
protection by chlorpromazine seen in this study, indicates that calmodulin 
is not greatly involved in cellular intoxication by VT1 or VT2.
5.2.2.3 The Effect of Inhibition of the Calcium-Calmodulin Complex
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5.2.2A The Significance of Extracellular Calcium Levels
Some toxins, such as Pseudomonas aeruginosa toxin, are unable to 
intoxicate cells which are deprived of calcium (Fitzgerald et al 1980). Both 
VT1 and VT2 remained active however, in the presence of ImM EGTA, a 
divalent ion chelator (Table 5.4). It is possible that this concentration of 
EGTA was insufficient to deprive the cells of calcium, but it did show that 
the toxins were able to intoxicate cells which were depleted of normal 
levels of calcium. This could either mean that there is sufficient 
intracellular Ca2+ to support entry of the toxins, or that only low levels of 
Ca2+ are necessary for maximum toxic effect.
It was concluded that physiologically functioning calcium channels 
are necessary for entry of both VT1 and VT2 into Vero cells, and 
internalisation still occurs if extracellular calcium levels are depleted. 
There does not seem to be a major role for calmodulin in VT intoxication 
of Vero cells.
To summarise the findings of this study, it appears that VT are 
endocytosed via coated pits, but can by-pass this pathway. There is no 
requirement for exposure to a low pH for toxin activation, but fusion 
between endosomes and lysosomes is essential. In order for VT to 
intoxicate cells, however, physiologically functioning calcium channels 
are necessary. Activity is independent of physiological levels of calcium, 
however, and the calmodulin complex is not involved.
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Table 5.4 Endpoint effect of Inhibitors of the Calcium Pathway on the 
toxicity of VT1 and VT2 on Vero cells
Inhibitor VT1 VT2
No Inhibitor 256 65,536
Verapamil 160pM 4 1024
Lanthanum chloride 462pM 256 65,536
Chlorpromazine 128pM 256 65,536
Indomethacin 128pM 256 65,536
Trifluoperazine 25pM <4 <256
EGTA lOOpM 256 65,536
Culture filtrate of either a VT1-producer (E3787) or a VT2-producer 
(E32511) was titrated across monolayers of Vero cells. A constant volume 
(25|il) of each inhibitor was added to each well and after 20-24 hours 
incubation at 37 °C in 5% C 02, the endpoint was determined as the 
reciprocal toxin dilution to kill 50% cells.
169
Chapter 6 Overall Conclusions
In order to investigate the pathogenic mechanisms of VTEC, toxin 
production, toxin internalisation and intracellular processing, and 
bacterial attachment were studied.
It was necessary to develop a reliable assay for VT, and three 
methods were chosen. The Vero cell assay measured toxin activity, 
whereas the latex agglutination assay and colony ELISA detected the 
presence of VT antigenically. It was found that the most efficient 
immunological assay for VT was a colony ELISA, since many strains could 
be screened on a single agar plate, and it was possible to distinguish 
between production of VT1 and VT2. Latex agglutination required each 
organism to be grown separately in liquid culture, and although VT could 
be detected, it was not possible to distinguish between VT1 and VT2. For 
these reasons, this assay was not considered suitable for further studies.
The use of two assay systems was beneficial in the characterization 
of 0157:H 7 mutants, since the toxin they produced was not altered 
antigenically, but had little biological activity. The Vero cell assay was also 
modified to allow toxin internalization to be studied.
VT1 and VT2 are both encoded by lysogenic phages, so a study was 
made of the effect of mitomycin C, a phage inducer, on toxin production. It 
was found that production of both VT1 and VT2 appeared to be increased 
when bacteria were exposed to mitomycin C for at least two hours. At high 
concentrations, the drug also caused cell lysis, and extracellular phage 
particles were demonstrated by plaque assay. The specific activity of toxin 
inside the cells increased in the presence of mitomycin C, although 
extracellular specific activity levels were lower in mitomycin C-treated 
cells as a result of bacterial proteins released during cell lysis.
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Both toxin production and bacterial attachment to mammalian 
cells, were investigated through the production of mutants, by chemical 
mutagenesis, of E.coli 0157:H 7 ATCC 35150, the most common VTEC 
isolate. It was found that the mutants did not possess the plasmids found 
in the wild-type, including a 60-MDa plasmid which has been associated 
with attachment. They also had an altered biochemical profile, and did not 
react with 0157:H7 antiserum in a passive haemagglutination assay. A 
negative reaction in a latex agglutination assay with anti-0157 revealed 
that the alteration was in the O side chain of the LPS. Immunoblotting 
revealed that major outer membrane proteins, but not the LPS, of these 
mutants reacted with anti-0157:H7, but the LPS did cross-react with 
antiserum raised against an enteropathogenic E.coli, showing that these 
were not rough mutants. The LPS was therefore purified, and analysis of 
the neutral sugars showed that the mutants contained rhamnose instead 
of fucose, which was present in the wild-type. These LPS mutations did 
not affect the hydrophobicity of these organisms, or their ability to attach 
to mouse colonic mucus or HeLa cells. This indicates that the 60-MDa 
plasmid is not significantly involved in attachment.
Toxin levels produced by the mutants were reduced compared to 
the wild-type, and toxin detected immunologically, showed little cytotoxic 
activity. No active toxin was detected outside the bacterial cells, and the 
intracellular toxin activity appeared unstable. In addition to toxin activity, 
secretion of toxins seemed affected, possibly as a result of the LPS 
mutations. It was concluded that the toxin genes had been mutated in 
areas essential for full activity. Sequence analysis of these genes would 
have provided valuable insight into toxin activity.
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This study has indicated that VT enter cells by receptor-mediated 
endocytosis. Both VT1 and VT2 were inhibited by a metabolic inhibitor of 
glycolysis (2-deoxyglucose) that prevents endocytosis, but not by two other 
similar inhibitors (sodium fluoride and 2,4 dinitrophenol) indicating that 
VT can use an alternative internalization mechanism independent of 
coated pit formation. This theory is supported by the inhibition of VT by 
trifluoperazine, which also inhibits both the clustering process of 
endocytosis and an alternative coated-pit independent mechanism.
Inhibitors of fusion of intracellular vesicles (incubation at 18°C) and 
transfer of material from endosomes to lysosomes (calcium chloride) 
inhibited VT showing a requirement for such fusion and an inability of 
the toxin to pass directly from the endosome into the cytosol.
Cells were protected from VT activity by verapamil, indicating a 
role for functioning physiological calcium channels. Neither 
indomethacin nor chlorpromazine protected cells from the toxic effects of 
VT, although trifluoperazine which acts in a sim ilar way to 
chlorpromazine was inhibitory. This is probably due to prevention of 
endocytosis which is also caused by this drug. VT were still able to 
intoxicate calcium-deprived cells. These findings indicate that 
physiologically functioning calcium channels are necessary for activity of 
both VT1 and VT2, but the calmodulin complex is not involved.
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